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Abstract
The incidence of sexually transmitted infections has increased due to changes in
lifestyle and contraceptive practices. The female reproductive tract is therefore
increasingly being exposed to potential infection, thus the mechanisms involved in
its defence are important. The first line of defence is provided via the mucosal
epithelial surface that lines the reproductive tract and the innate immune system.
The innate immune response is fundamental to the recognition of infectious agents
and the implementation of further defence mechanisms. Natural antimicrobial
peptides have been described as being central to the function of the innate immune
response. These peptides have been found to be expressed across a wide range of
mucosal surfaces, including the reproductive tract. It has been shown that these
molecules have cyclical variation providing protective coverage across the menstrual
cycle. Their expression appears to be governed by a variety of different effector
mechanisms which involve cytokines, sex steroids and cell-cell interactions.
The aims of this thesis are (1) to characterise the expression and regulation of a range
of natural antimicrobials within the human endometrium using representative cell
lines. (2) To investigate the role(s) played by the interaction between epithelial and
stromal cells in the expression of these molecules. (3) To assess the effects of
different inflammatory mediators on the production of antimicrobials and the
elucidation of the underlying mechanisms. (4) To identify the interactions between
antimicrobials and with other innate immune effector molecules. (5) To elucidate the
role of sex steroids in the regulation of natural antimicrobials. (6) To examine the
expression patterns of these molecules over time in response to infection. (7) To
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describe the expression of antimicrobials in human Fallopian tubes with and without
an ectopic gestation. (8) To examine the expression of natural antimicrobials in the
uterine decidua of ectopic and failed intra-uterine pregnancy.
Mimics of infection such as lipopolysaccharide (LPS - representative of G -ve
infection), lipoteichoic acid (LTA - representative of G +ve infection) and cytokines
such as 1L-1 p and TNFa; were demonstrated to alter the mRNA expression of natural
antimicrobial molecules in the endometrial cell line Hec-IA (human endometrial
carcinoma). The expression of natural antimicrobials was further identified to be
both phasic and temporal over time. Changes in expression levels were also observed
in primary endometrial stromal cell lines. The interaction between the epithelial and
stromal cells concurrently with the addition of mediators of inflammation also
yielded a change in mRNA expression. The presence of stromal derived media and
mimics of infection caused an increase and earlier expression of molecules such as
elafin in the Flec-IA cell line. Flowever, with the addition of progesterone treated
stromal derived media, a downregulation of elafin was observed. Further
investigation suggested a role for progesterone either directly upon the epithelial
cells, which proved to have high levels of genomic progesterone receptors (PR-A and
PR-B) or via stromal mediated factor(s). Two such factors were identified and
investigated further, TGFp-1 and MMP-7 (matrilysin). Hec-IA cells treated
directly with progesterone demonstrated increased levels of elafin mRNA, however,
the presence of stromal cells inhibited this effect. The treatment of Hec-IA cells
with TGF|3-1 concurrently with inflammatory stimuli decreased the expression of
elafin. However, the addition of MMP-7 increased the expression of elafin mRNA.
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In the presence of progesterone endometrial stromal cells up-regulate the level of
TGFp-1 and this has been shown to decrease the epithelial expression of both MMP-
7 and elafin.
Antimicrobials are differentially expressed within the Fallopian tube collected during
different stages of the ovarian cycle and this appeared to be governed by the
circulating levels of the exogenous sex steroids. Many of these molecules were also
observed to be increased in response to an ectopic pregnancy. The uterine decidua
from an ectopic gestation was also demonstrated to show differential expression to
that observed in the decidua of both surgically managed miscarriage and from
termination.
This work furthers our understanding in the expression and regulation of
antimicrobials in the upper reproductive tract, including the role of paracrine
mediated factors. The altered expression in the presence of an ectopic gestation both
in the Fallopian tube and uterine decidua indicates that further research may offer
preventive, diagnostic and treatment opportunities in adverse pregnancy outcomes.
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Chapter 1: General Literature Review
1.1 The Female Reproductive Tract
1.1.1 The human uterus and the menstrual cycle
The uterus is the organ responsible for maintaining the viability of the fetus and
providing support for the duration of pregnancy. Within the uterus there is a lining
of glandular tissue, the endometrium, which is made up of a basal and functional
layer. In the absence of pregnancy the human endometrium responds to cyclical
changes involving the sequential degeneration and regeneration of the functional
layer. These changes occur over an average 28 day period and are responsive to the
sequential exposure of the ovarian hormones, oestrogen and progesterone. The
maturation of the endometrium is essential in the preparation for the implantation of
the blastocyst. The uterine cycle consists of three phases consisting of menstrual
flow, proliferation and the secretory phase (figure 1.1.1 depicting the cyclical
changes of the endometrium). The classic histological features are described by
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Figure 1.1.1 (A) Concentrations of pituitary gonadotrophins, follicle-stimulating
hormone (FSH) and luteinising hormone (LH). (B) Events in the ovary related to the
ovarian cycle with follicle selection, maturation and ovulation. This is followed by
formation of the corpus luteum, which then regresses. (C) The levels of ovarian
hormones, oestrogen (blue) and progesterone (purple) in the circulation across the
menstrual cycle. (D) The cyclical changes within the endometrium showing the





1.1.2 Regulation of the menstrual cycle
The process of menstruation occurs when implantation fails to occur and there is
luteal regression, progesterone withdrawal and thus the functional layer of the
endometrium is shed. This occurs in response to the demise of the corpus luteum
and the resultant decrease in the levels of progesterone. Much of our current
understanding of the vascular changes during menstruation comes from the work of
Markee on the rhesus monkey in 1940 (Markee 1940). This work also determined
that the steroid hormones are the major factors in the control of these structural
changes. There are also vasoactive substances in the menstrual fluid in the form of
prostaglandins, PGE2 and PGF2a (Lumsden, Kelly et al. 1983). PGF2« is a
vasoconstrictive substance and it has been suggested that this agent is pivotal to the
start of menstruation (Baird, Cameron et al. 1996). Explant studies have implicated
hormones in the regulation and production of these prostaglandins (Abel and Baird
1980; Abel and Kelly 1983). There is also an increase in prostaglandin
dehydrogenase (PGDH), the enzyme that mediates the metabolism of PGE2 and
PGF2a, indicating progesterone dependence of this enzyme (Casey, Hemsell et al.
1980; Critchley, Wang et al. 1998; Hapangama, Critchley et al. 2002).
The menstrual phase is also considered to be an inflammatory event (Finn 1986;
Kelly, Illingworth et al. 1994). In the pre-menstrual phase, leukocytes increase in
number in the endometrium; this provides a level of immune defence as well as
mediating the breakdown of tissue. In addition, a subset of NK cells, characterised
by the expression of the CD56 surface marker, increase in number from mid-cycle
onwards. Leukocytes release proteases and stimulate the release of cytokines and
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chemokines, the key mediators of the inflammatory response. The leukocytes
include macrophages, neutrophils and uterine natural killer (uNK) cells, most of
which lack classic oestrogen receptor a (ERa) and progesterone receptors (PR)
(Poropatich, Rojas et al. 1987; Henderson, Saunders et al. 2003). The uterine natural
killer cells have been shown to express oestrogen receptor p (ERp) and the
glucocorticoid receptor (GR) (Henderson, Saunders et al. 2003). This lack of ERa
and PR is indicative of a degree of paracrine mechanism of control over these cells;
oestrogen could act directly via ERa and Cortisol via GR. Neutrophils are present
throughout the cycle at a basal level, with a dramatic increase observed in the
premenstrual phase at regions of uterine inflammation (Noyes, Hertig et al. 1950;
Kamat and Isaacson 1987; Poropatich, Rojas et al. 1987). This migration of
neutrophils may be mediated via the chemotactic factor interleukin - 8 (IL-8)
(Rampart, Van Damme et al. 1989; Colditz, Zwahlen et al. 1990).
1.1.3 Oestrogen and Progesterone
The co-ordinated actions of the steroid hormones oestrogen and progesterone are
central to the regulation of the female reproductive system. Oestrogen and
progesterone have significant roles throughout the reproductive tract, however their
actions have also been observed in other systems, such as bone remodelling and
peripheral vasoreactivity (Prior 1990; Hashimoto, Akishita et al. 1995). There have
also been many reports supporting a role for steroid hormones and their receptors in
immunomodulation. Monocytes and macrophages have been shown to express
nuclear ERs by a number of independent groups (Ashcroft, Mills et al. 2003;
Carruba, D'Agostino et al. 2003). The presence of these receptors may allow sex
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steroids to directly or indirectly participate in immune regulation; such as the
differentiation of monocytes and cytokine release from the macrophages (Ashcroft,
Mills et al. 2003; Carruba, D'Agostino et al. 2003; Capellino, Montagna et al. 2006).
Whilst other studies have shown that there is a role for oestrogens in chronic
inflammatory conditions such as rheumatoid arthritis (Cutolo, Sulli et al. 1995) and
endometriosis (Giudice and Kao 2004). Gender-based differences in response to
inflammatory conditions have also been attributed to immuno-modulation by the sex
steroids (Wira, Fahey et al. 2005). The immune system of the female reproductive
tract is hormonally influenced and provides protection from infection throughout the
menstrual cycle. The modulation of cytokines, leukocytes and the interactions
between the innate and adaptive immune systems are critical to the maintenance of
an infection free environment and for the support of conception (Wira, Fahey et al.
2005).
Oestrogen acts specifically on the uterus during the proliferative phase, bringing
about both the proliferation and importantly the priming of progesterone receptors
(PRs). Oestrogen and progesterone are ligands and both act upon the nucleus and
whilst the receptor controls the action of the hormones, the hormones are also able to
mediate the level of receptor expression. When the receptors bind their hormone,
gene transcription is modulated to bring about a change in function. The oestrogen
receptor (ER) has two transcribed forms, ERa (Greene, Gilna et al. 1986) and
described a decade later, ERP (Kuiper, Enmark et al. 1996; Mosselman, Polman et al.
1996). Currently, there are also three main isoforms of the progesterone receptor
(PR), designated simply as PR-A, PR-B and PR-C. Both of the PR-A and PR-B
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isoforms are expressed from different promoters on the same gene (Kastner, Bocquel
et al. 1990; Mote, Arnett-Mansfield et al. 2006). The isoforms are virtually identical,
with PR-B exhibiting an additional 164 amino acids, at the N-terminal end. When
the receptor binds with progesterone, it undergoes a conformational change and
undergoes dimerisation. The third isoform is PR-C, which is believed to have a role
in the regulation of the transcriptional activity of PR-A and PR-B (Wei, Gonzalez-
Aller et al. 1990; Wei, Hawkins et al. 1996). Recently, it has also been demonstrated
that the PR-C isoform is upregulated at term and in labouring myometrial cells and
may serve to inhibit endogenous levels of PR-B transcriptional activity (Condon,
Hardy et al. 2006). PR-C does not have DNA binding capacity, but, can bind to
progesterone (Wei, Norris et al. 1997) and render it unavailable for PR-B. There is
also a fourth PR (PR-M), which has only been identified recently and is still to be
further characterised. It has been described as a truncated form and was cloned from
human adipose and aortic cDNA (Saner, Welter et al. 2003).
There is crosstalk between the ER and PR, with oestrogen having control over the PR
as well as its natural progesterone ligand. A number of experiments utilising rat
uterine cells have demonstrated that when progesterone receptors are bound with
progestin or anti-progestin, the result is an inhibition in oestradiol stimulation of the
ER (Katzenellenbogen 2000). It has also been shown that the use of the intra-uterine
contraceptive device, levonorgestrel-releasing intrauterine system (LNG-IUS), which
releases a high dose of progestin, downregulates the ER, PR-A and PR-B. This
downregulation is observed in both the glands and the stroma of the endometrium,
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thus further indicating the requirement for progesterone and its receptors for the
maintenance of ER levels (Critchley, Wang et al. 1998).
1.1.4 The proliferative phase and secretory phase of the menstrual cycle
Proliferation occurs from day 4 to day 14 in the menstrual cycle and is regulated by
oestrogen. Both oestrogen and progesterone receptors are expressed within the
stromal and glandular compartments (Lessey, Killam et al. 1988; Snijders, de Goeij
et al. 1992; Wang, Critchley et al. 1998). Oestradiol is a product of the developing
Graaffian follicle. The pituitary hormone FSH mediates the maturation of at least
one of these follicles, stimulating the release of oestrogen (oestradiol), which in turn
stimulates the proliferation of the endometrium. Oestrogen stimulation of the
endometrium gives rise to a number of different changes, such as the formation of
new glands and stromal regeneration from the residual basal layer. The formation of
new glands is characterised with the increased prominence of the nuclei which are
undergoing mitosis. There is also an increase in mitosis within the compact stromal
compartment. At the end of this phase, "day 14", there is a huge increase in the
levels of the pituitary hormone LH, consequent upon increasing oestradiol levels
from the developing follicle prior to ovulation.
The secretory phase occurs conventionally from day 16 to 25 and is mediated via the
steroid progesterone. LH also continues to be released from the pituitary and is
responsible for the luteinisation of both the theca and the granlulosa cells of the
corpus luteum. The granulosa lutein cells are responsible for the secretion of
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progesterone. These events combine in maintaining the secretory transformation of
the endometrium.
During the early secretory phase the glands develop sub-nuclear vacuoles of
glycogen and become convoluted in appearance. The level of mitosis within the
glands begins to decrease and ceases around day 18. Also at this time the glycogen
deposits can be observed on the apical side of the cells and are maximally released
around days 20-21, until depleted. At the mid to late secretory phase, the tortuosity
of the glands is increased, whilst the stromal oedema increases for the duration of the
secretory phase, there is a peak in the mid-secretory phase. The stromal cells change
both structurally and functionally during this mid to late secretory phase. These pre-
decidual changes begin at the spiral arterioles and occur across the whole of the
stromal region. Decidualisation of the stromal cells occurs in preparation for
blastocyst implantation and progressively forms the decidua during pregnancy
(Noyes, Hertig et al. 1950). Pinopodes are expressed between days 19 to 21 on the
apical surface of the luminal uterine epithelium. This process is progesterone
dependent and their appearance corresponds with the likely time of implantation
(Martel, Monier et al. 1991; Nikas, Drakakis et al. 1995; Nikas and Psychoyos 1997).
In the late secretory phase, leukocytes infiltrate the endometrium with both
macrophages and lymphocytes being represented (Bulmer, Longfellow et al. 1991).
However, the predominant leukocyte is the uterine natural killer (uNK) cell. These
cells are abundant during this phase and remain through the first trimester of
pregnancy (King, Wellings et al. 1989; Bulmer, Longfellow et al. 1991). The
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significance of this, and particularly with relevance to the immuno-modulation of the
female reproductive tract, will be discussed in more detail throughout this thesis.
1.1.5 Sex steroid receptor expression across the menstrual cycle
There has been extensive immunohistochemical investigation of the human
endometrium in the elucidation of cyclical variation of ER and PR levels and their
occurrence within both the basal and functional regions, within both the epithelial
and stromal compartments of the endometrium (Garcia, Bouchard et al. 1988;
Lessey, Killam et al. 1988; Critchley, Bailey et al. 1993; Snijders, de Goeij et al.
1996; Wang, Critchley et al. 1998). All of these studies have demonstrated the
nuclear localisation of both receptors. PR-A and PR-B have been located within the
glands and the stroma in the proliferative phase. However, during the secretory
phase onto early pregnancy, it is only the PR-A isoform that is observed and this is
restricted to the nuclei of the stromal cells. This indicates that the PR-A is likely
responsible for the action of progesterone in the luteal phase within the stroma and
specifically decidualisation. The immuno-expression of ERa has been shown to
increase in the endometrial functional layer during the proliferative phase peaking
late on in the phase. However, the ER in the glands is downregulated during the
secretory phase, and this is in response to the increasing levels of progesterone. This
effect can be inhibited with the administration of the anti-progestin, mifepristone
(RU486), early in the secretory phase (Maentausta, Svalander et al. 1993; Kumar,
Zhu et al. 1998). There is a decline in the levels of ERa in both the glandular and
stromal compartments throughout the secretory phase. ERp mRNA was detected in
both the glands and the stroma, however, there was a decrease in expression within
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the glands in the late secretory phase (Critchley, Brenner et al. 2001; Lecce, Meduri
et al. 2001). ER|3 has also been shown to be expressed in endothelial cells, which
may imply an influence on the regulation of vascularisation. Women with
compromised fertility treated with clomiphene citrate, which is an anti-oestrogen,
demonstrated lower pregnancy rates. This correlated with the low levels of
oestrogen receptors within the pre-ovulatory endometrium (Ohno and Fujimoto
1998).
In-vitro it has been shown that PR-A is more prevalent than the PR-B isoforms
during decidualisation. However, there is marked reduction in the availability of PR-
A as decidualisation progresses. This reduction is further accelerated with the
addition of a synthetic progestin (Brosens, Hayashi et al. 1999). Also, the transient
transfection of either of the PR isoforms brought about an inhibition of decidual
prolactin (PRL) promoter-reporter construct in response to cAMP. The insertion of
an LNG-IUS brings about a downregulation of the PR isoforms within both the
glands and the stroma (Critchley, Wang et al. 1998). This suggests that the
regulation of both receptor isoforms is mediated by their ligand. However, it is
suggested from murine models, that it is PR-A which is essential to the function of
the uterus and the ovaries (Mote, Arnett-Mansfield et al. 2006). It was ascertained
that in the chick oviduct PR-A and PR-B are translated from two separate start
codons within the same gene. This provided the opportunity to knock out either one
of the isoforms in order to determine the roles of the respective isoforms. The
importance of functioning PRs was demonstrated to be crucial to fertility with the
use of knockout mice. These mice were rendered infertile, with specific dysfunction
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in ovulation, implantation and the decidualisation of stromal cells (Mote, Arnett-
Mansfield et al. 2006). In the mouse PR-A knockout, there was infertility, whilst the
PR-B knockouts proved to be essential to the morphology of the mammary glands
(Mote, Arnett-Mansfield et al. 2006). In contrast to the human where the activities of
the two isoforms are mediated by their co-localisation, the expression of PR-A and
PR-B in the mouse may be separate (Mote, Arnett-Mansfield et al. 2006).
1.2 Immunity
The human body is constantly exposed to a myriad of infectious agents, and due to
the effectiveness of our immune systems this rarely manifests as an infection. The
mammalian immune system has been classically divided into two distinct parts; the
innate immune response and the adaptive immune response. The innate immune
system is the first line of defence, and has been described as primitive by some.
Whilst the adaptive immune response acts in synergy and in response to signals that
are received from the innate effectors, and is second in line, but, serves as the more
'experienced' component.
1.2.1 Adaptive immunity
The adaptive immune response is acquired and is distinct from that of the innate
immune response because of its specificity. A number of different molecules and
effectors are involved which interact directly with specific antigens. Adaptive
immunity can be further divided into that of a humoral or cellular mediated response.
12
Humoral immunity is directed towards extracellular antigens and the B-cells are the
main components. B-cells are stimulated upon the recognition of an antigen or they
can be activated by dendritic cells. This activation brings about a differentiation into
a plasma cell, and this begins to produce an antibody which is specific against the
target antigen (Veeraswamy, Cella et al. 2003).
Dendritic cells (DCs) are members of the innate immune system; however, they are
pivotal to the function of the adaptive response. Dendritic cells have often been
described as the 'bridge' between the two components of immune defense (Clark and
Kupper 2005) (figure 1.2.1.1). DCs serve as antigen presenting cells (APCs), and
control and initiate the immune response through the activation of naive T cells
(Banchereau and Steinman 1998). Immature DCs are localised within peripheral
non-lymphoid tissues and upon inflammation or infection, they become mature with
an upregulation of MHC class II molecules (Banchereau and Steinman 1998;
Pulendran, Palucka et al. 2001; Banchereau 2002). The DCs migrate to secondary
lymphoid tissues and become terminally differentiated in the T-cell areas (Cella,
Scheidegger et al. 1996; Cella, Sallusto et al. 1997). Mature DCs (mDCs) produce
cytokines including IL-12 which is involved with the production of IFN-y-producing
T-helper 1 (Thl) cells (Macatonia, Hosken et al. 1995). The culture of peripheral
blood monocytes with IL-4 and GM-CSF (granulocyte-macrophage colony
stimulating factor) can be differentiated into immature DCs (Banchereau and
Steinman 1998).
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Cellular immunity is directed towards intracellular antigens such as that of viral
particles. The key mediators of cellular immunity are the T-cells, which utilise the
T-cell receptor (TCR) in the recognition of pathogens. The TCRs recognise foreign
peptides on the surface of cells by the major histocompatibilty complex (MHC).
When a foreign antigen is presented and recoginised by the T-cell, a subset of T-cells
are capable of directly killing that cell. After activation both B- and T- cells
undergo clonal expansion which serves to increase the response (Janeway, Travers et
al. 2001).
The adaptive immune response is responsible for the memory of the encountered
pathogens ensuring a rapid response in the event of re-infection. The adaptive
immune response typically takes 3-4 days to gain the upper hand over a microbial
infection. This delay in response would provide the average microbe with a doubling
time of approximately 20 minutes, a huge advantage over the advancing immune
defence molecules (Janeway, Travers et al. 2001). Thus, it would be unlikely that we
would survive with the reliance solely upon the adaptive immune response; hence the
more rapid response of the innate response has a crucial role to play in host defence.
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Figure 1.2.1.1 A simplified representation of some of the interactions of dendritic
cells at the interface between the innate and adaptive immune response.
1.2.2 Innate immunity
The innate immune system serves as the first line of defence and as such is in a state
of constant activation. The main cell components of the innate immune system are
that of the epithelium and phagocytes. The epithelium represents the outer barrier or
first line of defence from the environment (Janeway, Travers et al. 2001). This outer
layer of epithelium functions as a mechanical barrier and is responsible for the
production of a host of effector molecules of the immune response (Boman 2000).
Amongst these molecules are the microbicidal small peptides - natural
antimicrobials. Natural antimicrobial peptides are secreted by epithelial cells both in
response to infection and/or constitutively (Ganz 1987). They are also produced by
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phagocytic cells such as the neutrophilic granulocyte cells, which function to engulf
any invading microbe and are amongst the first cells to arrive at the site of infection.
Some antimicrobials also function as antiproteases or are chemotactic for other
immune effector cells, thereby enhancing the response (Territo, Ganz et al. 1989;
Chertov, Michiel et al. 1996).
The innate immune response was previously thought not to be as specific as the
adaptive, and there are no memory cells, nor is clonal expansion involved. However,
it has become increasingly apparent that there is more specificity than has
traditionally been realised. The innate immune response is triggered in response to
common structural patterns exhibited by microbes, known as pathogen-associated
molecular patterns (PAMPS) (Medzhitov and Janeway 2000). Innate immune cells
express pattern recognition receptors (PRRs), which enable the recognition of
pathogens. Among these receptors are a family known as the toll like receptors
(TLRs) (Akira and Sato 2003; Zhang, Zhang et al. 2004). These receptors are
responsible for the recognition of different pathogens; such as proteoglycans (TLR2)
(Takeuchi, Hoshino et al. 1999), single stranded RNA (TLR7) (Lund, Alexopoulou
et al. 2004; Yang, Puel et al. 2005; Hoshino, Sugiyama et al. 2006), bacterial DNA
(TLR9) (Hemmi, Takeuchi et al. 2000), LPS (TLR4) (da Silva Correia, Soldau et al.
2001), Flagellin (TLR5) (Hayashi, Smith et al. 2001), double stranded RNA (TLR3)
(Alexopoulou, Holt et al. 2001). A microbe approaching a cell exhibiting one or
more of these patterns will result in a signalling cascade via MyD88 (myeloid
differentiation factor 88) and TIR domain containing adapter inducing IFN-P (TRIF)
(Yamamoto, Sato et al. 2002; Akira and Sato 2003; Yamamoto, Sato et al. 2003), a
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schematic summary of some of the signalling mechanisms is depicted in figure
1.2.2.1. The response that follows will be specific to the type of pattern and thus the
microbe and this could mean the induction of immune effector molecules including
the natural antimicrobials (Underhill and Ozinsky 2002; Chalifour, Jeannin et al.
2004; Vora, Youdim et al. 2004). MyD88 is an adapter of signal transduction
Toll/IL-IR homology (TIR) domain and is recruited following ligation to TLRs
(O'Neill 2002). The recruitment of MyD88 results in a signalling cascade which
culminates in the nuclear translocation of NF-kB and the activation of the AP-1
transcription factor family (Muzio, Natoli et al. 1998; Kopp and Medzhitov 1999;
Cario, Rosenberg et al. 2000; Faure, Equils et al. 2000).
The patterns associated with pathogenic microbes are similar to those associated with
commensal organisms. The mechanisms by which the innate immune effectors
differentiate between these modalities are hitherto not understood (Kopp and
Medzhitov 2003; Chung and Dale 2004). However, it has been demonstrated in the
oral cavity that such a distinction is in fact made. Both commensals and pathogens
of the mouth have been demonstrated to upregulate the expression of natural
antimicrobials; however, this is mediated by different signalling pathways (Chung
and Dale 2004; Chung, Hansen et al. 2004).
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Figure 1.2.2.1 Diagram showing some of the signalling pathways involved in the
recognition of pathogens or inflammation. Adapted from Wagner and Bauer
(Wagner and Bauer 2006).
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1.2.3 Immunity of the female reproductive tract
The role of the immune system as an integrated system has been well documented.
The immune system has a pivotal role in the interaction with all other systems of the
body, and can no longer be regarded as a 'stand alone' module. Perhaps one of the
most complex interactions is that between the immune and reproductive systems.
The interplay between the steroid hormones and cytokines has been implicated to be
at the heart of these multiple levels of interaction (Wira, Fahey et al. 2005).
Although, the interest in these interactions has been relatively recent, the first report
of such an interaction is from as early as 1898, where the changes in the thymus after
castration were described (Kayisli, Guzeloglu-Kayisli et al. 2004). This has been
followed by the evidence that oestrogen treatment enhances extrathymic T - cell
maturation (Okuyama, Abo et al. 1992). Further studies on the oestrogen receptor,
where both ERa and ER(3 knockout mice demonstrated lower levels of thymic
cellularity and altered T - cell phenotypes (Staples, Gasiewicz et al. 1999). This was
suggestive of interactions between the immune cells and that of the steroid sex
hormones (Erlandsson, Ohlsson et al. 2001). The ovarian steroids are responsible for
the modulation of a number of immune mediators within the female reproductive
tract. The process of menstruation involves the breakdown and repair of tissues and
requires the coordination of cellular processes such as apoptosis, angiogenesis, cell
proliferation, tissue repair and control of leukocyte populations (Harada, Kaponis et
al. 2004). Much of this regulation is mediated via autocrine and paracrine factors
from both the non-resident immune cells and resident epithelial and stromal cells of
the endometrium (Kayisli, Mahutte et al. 2002).
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1.3 Natural antimicrobial peptides
Antimicrobial peptides have been identified in the archea, eubacteria, prokaryotes,
protists, plants and invertebrates which suggest that these molecules have been
around from early evolution (Hoffmann 1995). The antimicrobial peptides have also
been identified within all higher eukaryotes (Boman 1995; Martin, Ganz et al. 1995;
Ganz and Lehrer 1999), thus suggesting that they are still an important component of
the immune defence. Mammalian natural antimicrobial peptides (NAPs) are
expressed mainly within the mucosal epithelia and in the blood, having a pivotal role
in the defensive barriers that these structures present. NAPs are small molecules
typically around 50 amino acids in length, and have been demonstrated to act directly
against bacteria, enveloped viruses and fungi (Aley, Zimmerman et al. 1994; Kragol,
Hoffmann et al. 2002). The net charge for the majority of these peptides is positive,
which gives rise to the designation as cationic antimicrobial peptides. It has been
demonstrated that single amino acid substitutions can greatly affect the function of
these peptides (Kragol, Hoffmann et al. 2002). The tertiary structures are diverse
with the commonality of their amphipathic nature.
1.3.1 Mechanism of action
Antimicrobial peptides function by means of membrane disruption, causing the target
cells to lyse. There have been many models proposed that underpin the exact
mechanism by which this occurs. There are 3 models that have been particularly
well characterised namely, the carpet, barrel-stave pore and the toroidal pore model
(Brogden 2005; Park and Hahm 2005; Duclohier 2006). The carpet model involves
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the peptide covering the bacterial membrane surface and an electrostatic reaction
results in a detergent like disruption of the membrane. The barrel stave pore
mechanism involves the transversing of the target membrane by the peptide, with the
hydrophobic surfaces directed towards the lipid membrane and the hydrophilic
surfaces facing inwards. The resultant pore allows for membrane leakage of water
and electrolytes (Oren and Shai 1998). The toroidal pore model describes a similar
mechanism however, suggests that the peptides form aggregates that cause the lipid
monolayers to bend resulting with the lipid head groups facing the water core











Figure 1.3.1.1 Diagram taken from Duclohier (Duclohier 2006), demonstrating the 3
proposed models for the mechanisms employed by antimicrobial peptides in
interrupting microbial cell membranes.
The natural antimicrobial peptides target the membranes of microbes, these
membranes are sufficiently finely tuned that modification or adaptation is difficult to
achieve. Thus, bacterial resistance to natural antimicrobial peptides has rarely been
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observed (Hancock and Diamond 2000). The differences between that of the
bacterial and mammalian membranes, means that the peptides preferentially attack
that of the bacteria. This is due to the fact that the cationic peptides are attracted to
the negatively charged membranes as opposed to the neutrally charged mammalian
membranes. Bacterial membranes have a higher proportion of acidic phospholipids,
whilst eukaryotic membranes are made up of cholesterol and zwitterionic
phospholipids on the outer membrane, with the acidic phospholipids located on the
inside (Zasloff 2002). The lysis of the target cell is a well characterised mechanism
of action, however, other methods have been described (Brogden 2005). For
example antimicrobials which are proline-rich target intracellular mechanisms, such
as protein synthesis (Boman, Agerberth et al. 1993; Gennaro, Zanetti et al. 2002).
Whilst, the antifungal histatins, target the function of the mitochondria affecting ATP
efflux (Kavanagh and Dowd 2004). Many natural antimicrobials have additional
non-antimicrobial functions (Hancock and Diamond 2000). This is discussed further
in section 1.3.2 and section 1.4.3.
1.3.2 Other roles for antimicrobial peptides
It has been increasingly documented that asides from the role in the killing or
inhibition of microbials, the antimicrobial peptides have other functions within the
immune system (Hancock and Diamond 2000). Antimicrobial peptides have been
shown to be chemotactic and thus, serve to attract other immune effectors such as
leukocytes (Agerberth, Charo et al. 2000), monocytes (Territo, Ganz et al. 1989) and
T-cells, functioning within both the innate and adaptive immune system (Chertov,
Michiel et al. 1996; Agerberth, Charo et al. 2000). The use of has also demonstrated
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that these peptides have an immunomodulatory role. They can mediate the
upregulation of chemokines in epithelial cells and macrophages, and modulate the
differentiation of dendritic cells, thereby mediating their endocytic capacity
(Davidson, Currie et al. 2004; Bowdish, Davidson et al. 2005; Tjabringa, Vos et al.
2005). The role of these peptides in the modulation of the immune response is so
crucial; it is raising the question, of whether the antimicrobial effects are indeed the
primary function of these cells (Bowdish, Davidson et al. 2005; Bowdish, Davidson
et al. 2006). They are also involved in the neutralisation of LPS, increasing
phagocytosis, induction of mast cell degranulation and in the mediation of the
complement system (Larrick, Hirata et al. 1994; Larrick, Hirata et al. 1995; Sawa,
Kurahashi et al. 1998; Rosenfeld, Papo et al. 2006). A further multifunctional role
has been attributed to these molecules with an involvement in the process of
angiogenesis and re-epithelisation of wounds (Li, Post et al. 2000; Heilborn, Nilsson
et al. 2003; Galkowska, Olszewski et al. 2005).
1.3.3 Mammalian natural antimicrobial peptides
There are two major families of antimicrobial peptides expressed in mammals, the
Defensins and the cathelicidins, each with their own characteristics. The Defensins
are characterised by the presence of 3 disulphide bonds (Lehrer, Lichtenstein et al.
1993), whilst the cathelicidin family are recognised by the evolutionarily conserved
prepro region (Zanetti, Gennaro et al. 1995; Tomasinsig and Zanetti 2005; Zanetti
2005).
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The Defensins are further subdivided into distinct groupings based upon differences
within their respective structures. The 3 groups are designated a- P- and 0-
Defensins. The a- and P-defensins have the characteristic defensin structure, which
consists of amphipathic p-sheet rich region, but, differ in their primary structure and
positioning of the disulphide bonds (Ganz 2003). The a-defensins are expressed
mainly by neutrophils and by the paneth cells of the gut. They are expressed as
prepro-proteins requiring subsequent processing into mature peptides, which are
typically ~ 30 amino acids in length. Whilst the p-defensins are expressed mainly by
the epithelial cells, as pre-proteins and are spliced to produce mature peptides of~ 35
- 45 residues in length (Ganz 2003).
The 0-defensins were identified in the leukocytes of rhesus macaques and are circular
in shape, formed via the ligation of two short peptides (Tang, Yuan et al. 1999).
These molecules have been demonstrated to act against both bacteria and fungi. It
was further demonstrated that the circular structure of this 18 residue peptide is
important for function as linear analogues were less active (Tran, Tran et al. 2002).
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Classification and structure of mammalian defensins
a
P C
Figure 1.3.3.1 An illustration of the structure for each class of the mammalian
defensins (a, p and 9). The conserved cysteines (C) and consensus sequence for
each defensin are illustrated by dashed lines, with each dash representing a
residue. The green highlighted areas demonstrate the position of p-sheets, whilst
the blue shows the a-helice region. The disulphide bonds are illustrated by the blue
lines. Adapted from Yang et al. (Yang, Biragyn et al. 2002).
1.3.4 Human natural antimicrobial peptides
In humans the a-defensin family consists of 6 members; HNPl-4, the human
neutrophils peptides, which are expressed by neutrophils (Lehrer, Lichtenstein et al.
1993) and HD5-6, human Defensins 5 and 6, expressed by the paneth cells of the
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small intestine (Jones and Bevins 1992; Jones and Bevins 1993). HNP1-3 are stored
within the neutrophilic granules as mature peptides that become active when the
granules are fused with phago-lysozomes (Ganz 2003). Whilst HD5 has been
demonstrated to be stored within paneth cells as a pro-peptide, and proteolytically
cleaved by paneth cell trypsin (Jones and Bevins 1993).
There are at least 28 different human (3-defensins that have been identified within the
genome (Schutte, Mitros et al. 2002; Semple, Gautier et al. 2006) of which four have
been characterised, hBDl-4 (Bensch, Raida et al. 1995; Harder, Battels et al. 1997;
Garcia, Jaumann et al. 2001; Garcia, Krause et al. 2001; Harder, Battels et al. 2001).
They are mainly expressed by the epithelia and will be discussed in more detail as
they are investigated in this thesis.
There have been 6 9-defensins identified within humans, however the presence of
premature stop codons, designates these as pseudogenes (Nguyen, Cole et al. 2003).
However, their potential in therapeutics has been suggested by the existence of an
mRNA transcript for one of these genes within bone marrow. A synthetic replicate
of this potential protein, retrocyclin, was shown to protect cells from infection with
HIV (Cole, Hong et al. 2002; Munk, Wei et al. 2003).
There has been only one cathelicidin identified in humans, LL-37, the name is
derived from the structure - LL from the N-terminal peptides (Leucine, Leucine),
and the mature peptide is 37 residues in length (Gudmundsson, Agerberth et al.
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1996). However, the peptide exists in a proform, and is often referred to as hCAP18
(Larrick, Hirata et al. 1995).
1.4 Defensins
The mammalian defensins are variable in size and structure and characterised by the
position of 6 invariant cysteines in the formation of triple stranded (3-sheets. The
division of these peptides into a and (3 is based on differences at both the peptide and
gene level. The tertiary structures of both the a and p defensins are almost
superimposable (Zimmermann, Legault et al. 1995), the differences are attributable
to the position of the cysteine residues and their disulphide bonds (Huttner and
Bevins 1999; Raj and Dentino 2002).
1.4.1 a-defensins
Human a-defensins are expressed in neutrophils, granulocytes (HNP1-4), in the
paneth cells of the small intestine (HD5 and 6) (Lehrer, Lichtenstein et al. 1993;
Diamond and Bevins 1998; Folkvord, McCarter et al. 2006) and in the female
reproductive tract. HD5 has been found throughout the reproductive tract including
the endometrium, Fallopian tubes, vagina, ectocervix, endocervix and chorion
(Svinarich, Wolf et al. 1997; Quayle, Porter et al. 1998). HNP1-3 have been
identified in human vernix caseosa and amniotic fluid, which may reflect a role in
neonate immunity (Yoshio, Tollin et al. 2003). The endometrial expression of HD5
was found to be maximal during the early secretory phase of the menstrual cycle
(Quayle, Porter et al. 1998). The a-defensins are expressed in a pre-propeptide form
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and undergo post-translational modification, which can occur within cytoplasmic
granules of neutrophils or in lumen of the intestine. It was demonstrated that in the
murine intestine there is a co-localisation of MMP7 (matrilysin) in the paneth cells.
In vitro studies subsequently demonstrated the ability of the metalloprotease to
cleave the pro-segment of these peptides into their mature and active form (Wilson,
Ouellette et al. 1999). In the human paneth cells, a-defensins are stored as pro¬
peptides which are proteolytically cleaved by trypsin in the lumen of the gut (Ghosh,
Porter et al. 2002; Weeks, Tanabe et al. 2006).
1.4.2 (3-defensins
There are currently 4 well characterised human p-defensins (hBDl-4) and are
localised to the epithelial cells, monocytes and alveolar macrophages. Human P-
defensin l and 2 were first described in the skin, saliva, lung and plasma (Bensch,
Raida et al. 1995; Zhao, Wang et al. 1996; Harder, Bartels et al. 1997; Bals, Wang et
al. 1998). hBDl and 2 have also been isolated from the majority of the female
reproductive tract, including the mucosa of the vagina and cervix, ectocervix,
endocervix, uterus and the fallopian tubes (Valore, Park et al. 1998). It has also been
demonstrated that there is differential expression of hBDl-4 in the endometrium in
response to the menstrual cycle. Human P-defensin 1 shown to be expressed
throughout the cycle, hBD2 to be maximal during menses, hBD3 maximally
expressed during early to mid secretory phase and hBD4 maximally expressed during
the proliferative phase of the cycle (King, Critchley et al. 2003; King, Fleming et al.
2003). HBDl-3 have also been identified in the fetal membrane and placenta (King,
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Paltoo et al. 2007). Human P-defensin-3 has also been isolated from the heart,
skeletal muscle, placenta, skin, testis, oesophagus, gingival keratinocytes and trachea
(Garcia, Jaumann et al. 2001; Jia, Schutte et al. 2001). Human P-defensin 4 is the
least well understood but has been identified in the testis, uterus, lung, kidney and
thyroid gland in response to infection (Garcia, Krause et al. 2001). There have been
a growing number of defensin molecules that have been identified via a genomics
based approach (Jia, Schutte et al. 2001; Scheetz, Bartlett et al. 2002; Schutte, Mitros
et al. 2002) and presenting with many opportunities for the research into the function
of these immune effectors (Semple, Gautier et al. 2006; Semple, Taylor et al. 2006).
The genes for the P-defensins have all been localised to gene clusters on
chromosomes 6, 8 and 20 (Schutte, Mitros et al. 2002). Important consensus sites
have also been identified. The 5'-flanking region of hBDl has the consensus sites
for nuclear factor interleukin 6 (NF-IL-6) and IFNy (Raj and Dentino 2002); hBD2
has NF-kB, NF-IL-6, STAT and AP-1 (Tsutsumi-Ishii and Nagaoka 2002); hBD3
has NF-IL-6, STAT and API consensus sites (Jia, Schutte et al. 2001). These
consensus sites are inflammatory mediated sites that are common to immune
effectors; their presence suggests that hBD expression is mediated by inflammatory
mediators such as interleukins.
The hBDs are mainly expressed by the epithelia in a constitutive manner, and in
some cases are upregulated in response to infection (Zhao, Wang et al. 1996;
Krisanaprakornkit, Weinberg et al. 1998; Liu, Wang et al. 1998; Krisanaprakornkit,
Kimball et al. 2000; Krisanaprakornkit, Kimball et al. 2002; Liu, Destoumieux et al.
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2002). The process whereby the defensins are upregulated in response to infection or
inflammatory stimuli has been demonstrated using in vitro studies. The use of LPS
(G-ve mimic), and inflammatory cytokines such as 1L-1 and TNFa to stimulate
inflammatory events have been deployed in systems such as the lung, gut and
gingival linings (Diamond, Russell et al. 1996; O'Neil, Porter et al. 1999;
Krisanaprakornkit, Kimball et al. 2000; O'Neil, Cole et al. 2000; Harder, Bartels et
al. 2001). The use of inflammatory mimics have also been utilised for the
investigation of defensin expression in the female reproductive tract (King, Fleming
et al. 2002) and this was also demonstrated to be effective in obtaining an
inflammatory response with upregulation of antimicrobial expression.
The defensins that have been identified and characterised have been shown to be
microbicidal against a range of bacteria, fungi and viruses (Ganz, Selsted et al. 1985;
Miyasaki, Bodeau et al. 1990; Ganz, Oren et al. 1992; Lehrer, Lichtenstein et al.
1993; Harwig, Ganz et al. 1994; Porter, van Dam et al. 1997; Huang, Zhang et al.
2002; Lee, Andalibi et al. 2004).
The defensins have been reported to have different specificities or 'specialities', with
some being more potent against G+ve or G-ve bacteria, or against fungal agents or
viruses (Ganz, Selsted et al. 1985; Risso 2000). This effect may also be governed by
their respective locale, in that they may not respond to an organism that they
ordinarily would not expect to be exposed (Raj and Dentino 2002). They are also
affected by pH for example it has been demonstrated that sodium chloride is
inhibitory to hBD activity (Goldman, Anderson et al. 1997; Bals, Wang et al. 1998;
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Garcia, Krause et al. 2001). It has been reported that hBD3 is resistant to inhibition
in the presense of salt, which is significant with regard to cystic fibrosis (CF)
(Harder, Bartels et al. 2001), as it has been suggested that the higher physiologic
concentrations of salt in these patients is inhibitory to their innate defensins
(Guggino 1999).
1.4.3 Natural antimicrobial peptides as immune effectors
Antimicrobial peptides have been demonstrated to have roles within the immune
system distinct from their microbicidal function. They act as chemoattractants for
cells from both the innate and adaptive immune systems (Agerberth, Charo et al.
2000). This suggests that the peptides are able to function at the interface between
the innate and adaptive response. The immunomodulatory role of these peptides has
been demonstrated in a variety of primary and cultured cell lines. Davidson et al,
reported the role of LL-37 in the modulation of dendritic cell differentiation and
enhancing their endocytic capacity (Davidson, Currie et al. 2004). Further evidence
from the same laboratory has described the regulation of cytokines and a role in the
process of apoptosis by LL-37 (Bowdish, Davidson et al. 2005; Barlow, Li et al.
2006). The a-defensins have been shown to exhibit a role in the processing of
mature IL-ip and thereby enhancing the production of this cytokine. The p-
defensins have been shown to both act directly as and upregulate other chemokines,
attracting immune effectors to source of infection or injury (Perregaux, Bhavsar et al.
2002; Bowdish, Davidson et al. 2006). The P-defensins have also been shown to
upregulate the expression of inflammatory cytokines in peripheral blood
mononuclear cells (Boniotto, Jordan et al. 2006).
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1.5 Natural antimicrobial proteins
There are a number of proteins that have proved to exhibit antimicrobial activities.
The past two decades have given rise to a great deal of publication and research into
the function of innate antimicrobial proteins. However, this potential was first
realised as early as 1922, when Alexander Fleming reported the "remarkable
bacteriolytic element" (Fleming 1922) and "a powerful antibacterial ferment which
had a most extraordinary lytic effect on some bacteria" in his description of
lysozyme during his Nobel Laureate Lecture in 1945 (Fleming 1945). An increasing
number of proteins exhibiting antimicrobial properties have been described or
isolated from a wide variety of sources from plants, insects and mammals. However,
the antimicrobial proteins that are of interest to this thesis are discussed further
within this review and within the relevant data chapters.
1.5.1 Granulysin
Granulysin was first described in 1997, and is mainly produced by Natural Killer
(NK) cells and CD8 T-cells (Pena, Hanson et al. 1997; Pena and Krensky 1997).
The protein is 9 kDa and is a member of the saposin-like family and is colocalised
with granzyme and perforin within cytolytic granules. Granulysin has been shown to
have microbicidal effects upon both Gram +ve and Gram -ve species of bacteria,
fungi and parasites (Stenger, Rosat et al. 1999; Walch, Eppler et al. 2005). It has
also been reported that Granluysin along with perforin to have the abiltity to kill
cancerous tumours (Kishi, Takamori et al. 2002). Granulysin also has a role with the
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modulation of the immune response, and has been shown to be chemotactic for
monocytes, NK, dendritic and T cells (Deng, Chen et al. 2005). Granulysin is also
thought to have a role within the endometrium during the menstrual cycle with
maximal expression being observed during the late secretory phase and is likely to be
expressed by the infiltrating uterine NK (uNK) cells (King, Critchley et al. 2003).
The levels of granulysin have also been shown to be elevated during pre-eclampsia
and may serve as a useful diagnostic marker for the Thl/Th2 balance and thus, cell
mediated immunity (Sakai, Ogawa et al. 2004). Further diagnostic application has
been described with the presence of granulysin mRNA detected in urinary sediment,
providing an indication of a renal allograft rejection (Kotsch, Mashreghi et al. 2004).
1.5.2 Secretory Leukocyte Protease Inhibitor (SLPI)
SLPI was originally identified for being a serine protease inhibitor and was found in
the secretions obtained from mucosal surfaces. SLPI is 11.7 kDa, consisting of 107
amino acids including 16 cysteine residues (Seemuller, Arnhold et al. 1986) and
consists of two WAP (whey acid protein)/four disulphide core domains. SLPI has
been demonstrated to inhibit a variety of different proteases (Hiemstra 2002) and to
exhibit antimicrobial properties. However, the antimicrobial action of this protein is
thought to be independent of its anti-protease function. SLPI has been demonstrated
to be microbicidal against both G+ve and G-ve bacteria (Hiemstra, Maassen et al.
1996), fungi (Tomee, Hiemstra et al. 1997) and viruses, most notably HIV-1
(McNeely, Shugars et al. 1997; Wahl, McNeely et al. 1997; Shugars 1999; Shugars,
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Alexander et al. 1999). SLPI has been reported to be expressed by both neutrophils
(Bohm, Aigner et al. 1992) and epithelial cells (Abe, Kobayashi et al. 1991).
The anti-protease action of SLPI was originally described within the lung as being an
inhibitor of neutrophil elastase and has also been shown to exert this action against
cathepsin G, trypsin and chymotrypsin (Thompson and Ohlsson 1986). This anti-
protease activity serves to prevent damage to normal tissues during an inflammatory
response. This anti-inflammatory role has been further defined by the inhibition of
histamine (Dietze, Sommerhoff et al. 1990; He, Xie et al. 2004), and the prevention
of NF-kB activation (Lentsch, Jordan et al. 1999; Taggart, Cryan et al. 2005). Thus,
preventing further inflammation and damage (Ward and Lentsch 2002). It has been
reported to have an inhibitory effect upon the production of MMPs by monocytes via
the indirect action on PGE2 (Zhang, DeWitt et al. 1997). It is also thought that SLPI
has a role in the facilitation of wound repair, as SLPI knockout mice demonstrated an
impaired ability in cutaneous wound repair along with increased levels of elastase
and accompanying inflammation (Ashcroft, Lei et al. 2000; Angelov, Moutsopoulos
et al. 2004).
SLPI has been isolated from a variety of mucosal secretions and has been identified
amongst other immune effectors to have a site specific profile of expression
(Tjabringa, Vos et al. 2005). It is suggested that this site specific profile may
determine the role of SLPI as an immune effector across different mucosal environs.
SLPI has been shown to have antibacterial activity against a spectrum of different
organisms. This activity has been demonstrated against Escherichia coli and
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Staphylococcus aureus (Hiemstra, Maassen et al. 1996); P. aeruginosa and S.
epidermis from skin infections (Wiedow, Harder et al. 1998); and pathogens of the
gastrointestinal tract, Salmonella Typhimurium (Si-Tahar, Merlin et al. 2000), and
the downregulation of SLPI has been implicated in Helicobacter pylori mediated
gastritis (Wex, Ye et al. 2006). In the last decade the anti-viral activity of SLPI
against HIV-1 has been well documented, in vitro SLPI isolated from saliva was
shown to be inhibitory (McNeely, Dealy et al. 1995) and there are elevated levels of
SLPI in response to infection with HIV-1 (Skott, Lucht et al. 2002). It has also been
reported that lower endogenous levels of SLPI within vaginal fluids resulted in a
higher level of HIV-1, and thus, a greater level of maternal transfer (Pillay,
Coutsoudis et al. 2001).
The gene encoding SLPI has been located on chromosome 20ql2 (Kikuchi, Abe et
al. 1998). The promoter has been reported to have sites for the transcription factors
AP-1 and AP-2 (Abe, Kobayashi et al. 1991). The protein is composed of two
homologous domains and it has been shown that they have distinct roles. The C
terminal region is responsible for the anti-protease properties described (Eisenberg,
Hale et al. 1990; Kramps, van Twisk et al. 1990), whilst the N terminal region has
antimicrobial actions (Hiemstra, Maassen et al. 1996).
However, the precise mechanism of this antimicrobial function is not yet understood.
SLPI is cationic (isoelectric point =10.5) (Schnebli 1991), so it may be that this
enables a mechanism similar to that described for the defensins (Zelvyte, Wallmark
et al. 2004). SLPI is also similar to the defensins in respect of the molecules salt
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sensitivity, the microbicidal actions of SLP1 are reduced in higher salt conditions
(Hiemstra, Maassen et al. 1996).
1.5.3 Elafin
Elafin is also known as SKALP (skin derived anti-leukoprotease) and ESI (elastase
specific inhibitor). The 9.9 kDa protein was first isolated from skin samples obtained
from patients with psoriasis and in the lung, where it was described as an elastase
inhibitor (Schalkwijk, Chang et al. 1990; Sallenave and Ryle 1991; Wiedow, Young
et al. 1993). Elafin has two functional domains, consisting of a C terminus which
exhibits similarities to the WAP/four-disulphide core domain found in SLPI. The N
terminus is a region rich in Gin and Lys residue repeats and is known as the
cementoin domain and acts as a substrate for transglutaminase (Nara, Ito et al. 1994;
Tremblay, Vachon et al. 2002; Guyot, Zani et al. 2005). This domain has been
identified as a feature of the trappin family, of which elafin is the second member -
trappin-2. Trappin is an acronym for TRansglutaminase substrate and wAP domain
containing ProteIN, and is named due to the observation that the proteins are
'trapped' in tissues via covalent crosslinking (Schalkwijk, Wiedow et al. 1999). The
term trappin-2 (pre-elafin) refers to the whole molecule, whilst the term elafin is
more accurately used to describe the 6 kDa molecule which results after cleavage
(Zeeuwen, Hendriks et al. 1997; Schalkwijk, Wiedow et al. 1999). This truncated
molecule consists of the C-terminal domain which lacks the cementoin region. It has
been shown that when elafin lacks the cementoin the molecule is less effective as an
antiprotease in an in vivo model of elastase-induced injury to the lung (Tremblay,
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Vachon et al. 2002). Thus, it is believed that it is intact elafin (trappin-2), which is
the most effective as an antiprotease in the protection of tissues from elastase
mediated inflammation and damage.
Elafin was first characterised in psoriatic skin and is characterised with the high level
of neutrophil influx that is associated with this inflammatory condition (Alkemade,
Molhuizen et al. 1994; Nonomura, Yamanishi et al. 1994). The squamous
epithelium of the skin serves as an important barrier and as such is continuously
exposed to inflammatory stimuli and it has been shown that elafin expression is
constitutive within this region (Wiedow, Schroder et al. 1990; Pfundt, van Ruissen et
al. 1996). The expression of elafin in the lungs has also been well documented,
intitially detected in bronchial secretions (Sallenave, Marsden et al. 1992; Sallenave
and Silva 1993). Further studies identified that elafin was expressed by the bronchial
epithelial cells (Sallenave, Shulmann et al. 1994), alveolar epithelial cells (Sallenave,
Silva et al. 1993) and alveolar macrophages (Mihaila and Tremblay 2001). Elafin
expression has also been identified in the epithelia of the large intestine (Suzuki,
Furukawa et al. 2000), and recently a downregulation of both elafin and SLPI has
been associated with the inflammatory bowel condition Crohn's disease (Schmid,
Fellermann et al. 2007). Epithelial expression of elafin has also been described in
the endometrium (King, Critchley et al. 2003), amnion (Tromp, Kuivaniemi et al.
2004; King, Paltoo et al. 2007) and has also been observed in the neutrophil
population during menstruation (King, Critchley et al. 2003) (section 1.6).
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The use of cell lines and in vitro models have demonstrated the inducibility of elafin
in the presence of the inflammatory cytokines TNFa and IL-1 in the lung (Sallenave,
Shulmann et al. 1994), keratinocytes (Tanaka, Fujioka et al. 2000) endometrium
(King, Fleming et al. 2002) and mammary cells (Zhang, Magit et al. 1997). The
expression of elafin upon treatment with these pro-inflammatory cytokines may be
mediated via the c-jun, p38 mitogen activated protein kinase (MAPK) and nuclear
factor kB (NF-kB) pathways (Pfundt, Wingens et al. 2000; Bingle, Tetley et al. 2001;
Pfundt, van Vlijmen-Willems et al. 2001).
1.6 Natural antimicrobials in the female reproductive tract
The female reproductive tract consists of three distinct areas: the lower reproductive
tract which includes the vagina and ectocervix; the upper reproductive tract which
consists of the endocervix, which acts as an interface between the upper and lower
areas, the endometrium and the Fallopian tubes (Quayle 2002). The lower
reproductive tract is non-sterile, whilst the upper reproductive tract is considered to
be sterile in healthy women. The sterility of the ectocervix is variable in relation to
the phase of the menstrual cycle (Quayle 2002). The lower reproductive tract is
described as non-sterile due to the presence of a number of commensal organisms.
The presence of commensals such as Lactobacillus spp are thought to function as
part of the immune defense of the lower reproductive tract which is potentially
exposed to a number of pathogens and sexually transmitted diseases (STDs). Despite
the potential exposure and increasing prevalence of STDs (Cherpes, Meyn et al.
2003), the innate immune system of the female reproductive tract is poorly
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understood. However, recently it has been shown that the role of natural
antimicrobials is a major component in the maintenance of an infection free
reproductive tract, whilst tolerating the commensal population (Yedery and Reddy
2005). The natural antimicrobials have been demonstrated to be differentially
expressed throughtout the reproductive tract and this is further variable in response to
changes associated with the ovarian cycle (King, Critchley et al. 2003). However, it
is clear that there is broad coverage and this may be suggestive of the distinct roles,
mechanisms and interactions of the antimicrobials within the reproductive tract. A
summary of the major literature reports of natural antimicrobial expression within the
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Figure 1.6.1 A summary of natural antimicrobial expression in the female
reproductive tract, those reported in the literature (blue) and those described in the
current thesis and not yet published (green).
1.7 Inflammatory mediators within the female reproductive tract
The process of menstruation and implantation have been likened to inflammatory
events (Finn 1986; Salamonsen and Woolley 1999; Kelly, King et al. 2001). A
number of inflammatory mediators have been described as having a role within the
endometrium. These include cytokines, chemokines and prostaglandins, with a more
recent role being elucidated for natural antimicrobial peptides.
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1.7.1 Cytokines and growth factors
Cytokines are soluble polypeptides and are primarily involved with the immune
response with both autocrine and paracrine interactions. They are synthesised and
secreted by immune effector cells (Janeway, Travers et al. 2001). Cytokines are also
expressed by the epithelial, stromal and endothelial components of the endometrium.
They are involved with both the induction and resolution of immune inflammation.
Thus, some are described as being pro-inflammatory or anti-inflammatory. Cells
expressing cytokines can be classified according to their cytokine production as
either Th-1 or Th-2 (Mossmann, Bamberger et al. 1986). The Th-1 cytokines include
IFN-y, IL-2, IL-12 and TNFa, whilst examples of Th-2 cytokines include IL-4, IL-10
and IL-13.
Cytokines have a role to play within the endometrium in both the pregnant and non¬
pregnant state (Tabibzadeh 1991; Kelly, King et al. 2001). Cytokines also have roles
in neuroendocrine events via their interactions with pituitary and hypothalamic
hormones (Druker, Liberman et al. 2006).
1.7.1.1 Interleukin - 1 (IL-1)
IL-1 is a multi-functional cytokine and exists in two forms, IL-1 a and IL-1 p. There
is very little sequence homology (27%) between the two forms; however, they elicit
the same actions and utilise the same receptor, IL-1 type-1 (IL-1RI) (Dinarello
1991). A second receptor exists, IL-1 type-2 (IL-1RII), however, to which no
function has yet been attributed (Sims and Smith 2003). There is a receptor
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antagonist (IL-lra), which is secreted but, has also been located within decidual
glands, in isolated cells of the chorionic villus, intervillous space and within maternal
decidua (Simon and Polan 1994). In the human endometrium both IL-la and IL-ip
are expressed by the epithelial and stromal components (Tabibzadeh and Sun 1992;
Simon, Piquette et al. 1993). The levels of IL-1 are variable across the menstrual
cycle and are at their highest during the secretory phase, post ovulation (Rodgers,
Matrisian et al. 1994). Interleukin-1 has been connected with the process of
implantation and is expressed in both trophoblast and decidual cells along with the
receptor (Simon and Polan 1994; Simon, Pellicer et al. 1995). Endometrial stromal
cells (ESCs) elicit an immune response upon treatment with IL-la, and have been
demonstrated to phagocytose latex beads and E. coli (Ruiz, Montes et al. 1997). This
cytokine has also been shown to stimulate the production of MMP-1, which is
involved in the initiation of menstruation (Singer, Marbaix et al. 1997). Interleukin-
ip increases the levels of PGE2 in decidual and endometrial ESCs (Cole, Seki et al.
1995; Cole, Seki et al. 1995; Ishihara, Matsuoka et al. 1995). Interleukin-1 a
stimulates PGE2 and PGF20 production in ESCs (Kawano, Nakamura et al. 2001).
The actions of both IL-1 types is suggestive of a role in the regulation of
menstruation, via the stimulation of prostaglandins which are thought to be involved
in the vascular changes associated with the degradation of the endometrium (Baird,
Cameron et al. 1996; Gerard, Caillaud et al. 2004).
Interleukin-1 secretion can be induced by a number of factors including other
cytokines such as TNFa and IFN-y and can also be upregulated in response to
bacterial products (Gerard, Caillaud et al. 2004). There are also a number of
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inhibitors of IL-1 secretion, including PGE2, IL-6 and glucocorticoids (Tabibzadeh,
Kaffka et al. 1990). Interleukin-1 has been associated with a number of important
functions, activating T-helper cells and NK cells; stimulation of immunoglobulin
production; fibroblast proliferation and chemotaxis for neutrophils (Gerard, Caillaud
et al. 2004).
1.7.1.2 IL-1 Receptor
The IL-1 receptors 1 and 2 have extracellular domains which identifies them as
belonging to the immunoglobulin superfamily. It has been shown that after IL-1
binds to the type 1 receptor, an accessory protein docks thereby bringing about high
affinity binding (Sims and Smith 2003). The type 1 receptor has a structure
comprising of a single transmembrane segment and cytoplasmic domain. In the type
2 receptor this signalling cytoplasmic domain is absent (Gerard, Caillaud et al. 2004).
Once binding has occurred, a cascade of biochemical events ensue. This involves the
sequential phosphorylation and/or dephosphorylation of a number of kinases. This
results in the nuclear translocation of transcription factors and activation of proteins,
resulting in the translation of RNA. Amongst the proteins activated is the adapter
protein MyD88, IL-1 Receptor Associated Kinases (IRAK), and TNL Receptor-
Associated Lactor-6 (TRAL-6). However, most of the effects of IL-1 are following
the translocation of NLkB (nuclear factor-kappa B) and activating protein-1 (AP-1)
(Daun and Lenton 2000). The binding sites for NLkB and AP-1 are present in the
promoter regions of many of the IL-1 inducible genes including PGE2, IL-6 and IL-8.
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NFkB is an important transcription factor that is responsible for the activation of a
number of genes involved with both the innate and adaptive immune response.
1.7.1.3 Tumour Necrosis Factor a (TNFa)
TNFa is secreted by a wide variety of cells including macrophages, monocytes,
neutrophils, T lymphocytes, NK cells, fibroblasts and granulosa cells. TNFa
mediates its action through binding to cell bound receptors, p55 and p75 which
belong to the TNF-R gene family (Bazzoni and Beutler 1996). These receptors are
structurally similar but, exhibit independent functions and are also found in the
soluble form, in the circulation. The role of these soluble receptors is thought to be
as antagonists to the membrane forms, whilst it is also possible that the half-life of
circulating TNFa is increased in the presence of soluble receptors (Mohler, Torrance
etal. 1993).
In the endometrium TNFa has been shown to be expressed within the glandular
epithelium (Tabibzadeh 1991; Hunt, Chen et al. 1992; Tabibzadeh, Kong et al. 1994;
Tabibzadeh, Kong et al. 1995; Tabibzadeh, Zupi et al. 1995). The expression of
TNFa during the menstrual phase and the defined biological activity of the cytokine
suggests that it may have a role in the process of menstruation (Tabibzadeh, Zupi et
al. 1995; Tabibzadeh 1996; von Wolff, Thaler et al. 2000). Hunt et al (Hunt, Chen et
al. 1992), have shown TNFa mRNA to be low in the proliferative phase and is
increased during the secretory phase and this was later confirmed by others
(Philippeaux and Piguet 1993). However, in the late secretory phase TNFa declines
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within the glandular epithelium, whilst the stromal cells show strong expression
(Hunt, Chen et al. 1992).
The expression of TNFa can result from a number of inducible factors, such as
bacterial products, tumours and other cytokines such as IFN-y. However, there is
also expression of TNFa in normal tissue which is unlikely to be as a result of
bacterial products or other infection stimuli. There are also a wide range of factors
which have an inhibitory effect upon TNFa. Inhibitors include prostaglandins,
glucocorticoids and anti-inflammatory cytokines, such as IL-4 and IL-10. The role
of TNFa within the endometrium is undetermined, but, may have a role similar to
that of IL-1, acting as part of the immune defence and the processes of menstruation
and implantation. The known biological actions of TNFa are wide ranging and are
pro-inflammatory (Svensson, Mardh et al. 1985), cytotoxic and chemotactic (Ming,
Bersani et al. 1987). TNFa is capable of inducing gene expression, apoptosis and
necrosis, which illustrates the central role of this molecule in cell function and
physiology (Wajant, Pfizenmaier et al. 2003). TNFa is central to the innate immune
response to pathogens and injury (Kollias and Kontoyiannis 2002; Pfeffer 2003).
1.7.1.4 Transforming Growth Factor Beta-1 (TGFP-1)
TGFp-l is a polypeptide member of the transforming growth factor beta superfamily
of ligands. The secreted protein is a key regulator in immune defense, serving roles
in both the innate and adaptive components (Wahl 1992; Wahl and Chen 2003; Wahl
and Chen 2005; Li, Wan et al. 2006). TGFP-1 is involved in a number of cellular
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processes including proliferation, differentiation, cell death and the production of
cytokines (Shi and Massague 2003). Given this repertoire of functions it makes
sense that TGFp-1 and other family members are highly expressed in the
endometrium (Jones, Stoikos et al. 2006). TGFp-1 is expressed in both the sromal
and epithelial cells of the endometrium (Gold, Saxena et al. 1994; Godkin and Dore
1998), however, there doesn't appear to be any change in expression across the
menstrual cycle. TGFp-1 induces the upregulation of leukaemia inhibitory factor
(LIF), a cytokine suggested to be important for implantation (Perrier d'Hauterive,
Charlet-Renard et al. 2005).
TGFP-1 is also an important factor in the modulation of endometrial immune
response including mediating immune tolerance of seminal plasma and the
allogeneic conceptus in mice (Schmidt-Weber and Blaser 2004; Jones, Stoikos et al.
2006). TGFP-1 levels are upregulated in the endometrium when the concentration of
progesterone is increased and downregulated during progesterone withdrawal
(Casslen, Sandberg et al. 1998). Members of the matrix metalloproteinase (MMP)
family (1.7.3) are suppressed by progesterone and this may be via TGFp-1, as a
paracrine transducer (Bruner, Rodgers et al. 1995; Osteen, Keller et al. 1999; Osteen,
Igarashi et al. 2003).
1.7.2 Chemokines
Chemokines are a group of specialised cytokine-like molecules which exhibit
chemoattractive properties, and are involved with the promotion of leukocyte
recruitment (Baggiolini 2001). Chemokines play a complex role in the immune
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response with the induction of cell migration (Rossi and Zlotnik 2000). Chemokines
and their receptors are classified into four families based on the motif displayed by
the first two cysteine residues, figure 1.7.2.1. There are at least 17 CXC chemokines
that bind to one or more of the CXC receptors (CXCRs), of which there are six
(CXCR1-6). This group of chemokines includes IL-8 and IFN-y-inducible protein
(IP)-IO. The CC chemokines currently have 28 members and includes macrophage
inflammatory protein la, RANTES and eotaxins 1-3, and they bind to one or more of
the ten CC receptors (CCR1-10). There is one CX3C chemokine (fractalkine or
neurotaxin), which binds to the CX3CR1, which is currently the only receptor.
There are two XC chemokines, including Lymphotaxin; this family has only one
receptor, XCR1. In 2000 a new nomenclature system was proposed, in which each
of the chemokines is designated as a numbered ligand for its respective receptor
family, for example IL-8 is a CXC ligand and is designated CXCL-8, an update has
also been recently published (Prieschl, Kulmburg et al. 1995; Hortsch 1997; Murphy,
Baggiolini et al. 2000; 2001; 2002; Bacon, Baggiolini et al. 2002; 2003). A table
showing the chemokine families with the new nomenclature, common names and the
relevant receptors is included below (table 1.7.2.1).
The cells of inflamed tissue are capable of the release of a variety of chemokines,
and upon infection with bacteria or viruses, the chemokines are involved in the
recruitment of immune effector cells. There is a tight interplay between cytokines
and chemokines in the determination of the specific immune response required
(Bisset and Schmid-Grendelmeier 2005). Chemokines can be increased or
inactivated by tissue proteases, such as MMPs (McQuibban, Butler et al. 2001).
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Structure of chemokine classes
Figure 1.7.2.1 A schematic of the four chemokine classes based on the the
positioning of conserved cysteine residues and disulphide bonds. The CX3C
chemokine also has a hydrophobe domain and a mucin-like domain.
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CC chemokines CXC chemokines
Official
name
Other name(s) Receptor Official name Other name(s) Receptor
CCL1 1-309, TCA-3 CCR8 CXCL1 Gro-ct, GROl, NAP-
3
CXCR2
CCL2 MCP-1 CCR2 CXCL2 Gro-P, GR02, MIP-
2a
CXCR2
CCL3 MlP-la CCR1, CCR5 CXCL3 Gro-y, GR03, MIP-
2P
CXCR2
CCL4 MIP-1(5 CCR5 CXCL4 PF-4
CCL5 RANTES CCR1, CCR3,
CCR5
CXCL5 ENA-78 CXCR2
CCL6 CIO, MRP-2 CXCL6 GCP-2 CXCR2
CCL7 MARC, MCP-3 CCR1, CCR2,
CCR3
CXCL7 NAP-2, CTAPIII, p-
Ta, PEP CXCR2










CCR1 CXCL9 MIG, CRG-10 CXCR3
CCL11 Eotaxin CCR3 CXCL10 IP-10, CRG-2 CXCR3





CXCL12 SDF-1, PBSF CXCR4
CCL14 HCC-1, MCIF, Ckpi,
NCC-2, CCL
CCR1 CXCL13 BCA-1, BLC CXCR5
CCL15 Leukotactin-1, MIP-5,
HCC-2, NCC-3
CCR1, CCR3 CXCL14 BRAK, bolekine
CCL16 LEC, NCC-4, LMC,
Ckpi2
CCR1 CXCL15 Lungkine, WECHE
CCL17 TARC, dendrokine,
ABCD-2










CCR6 Official name Other name(s) Receptor






CCL22 MDC, DC/p-CK CCR4 C chemokines
CCL23 MP1F-1, Ckp8, MIP-3,
MPIF-1
CCR1 Official name Other name(s) Receptor
CCL24 Eotaxin-2, MPIF-2,
Ckp6
CCR3 CL1 Lymphotactin a,
SCM-la, ATAC
XCR1










Table 1.7.2.1 Table adapted and updated based on data from Janeway et al.
(Janeway, Travers et al. 2001).
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1.7.2.1 Interleukin - 8 (IL-8; CXCL-8)
IL-8, also known as neutrophil-activating peptide-1 and is secreted by a number of
different cell types in response to immune stimuli. These cell types include, NK
cells (Saito, Kasahara et al. 1994; De Sanctis, Blanca et al. 1997; Marti, Bertran et al.
2002), neutrophils (Fujishima, Hoffman et al. 1993), monocytes (Abe, Kobayashi et
al. 1991), fibroblasts , endothelial (Gimbrone, Obin et al. 1989) and epithelial cells.
Within the endometrium IL-8 has a role in angiogenesis and the induction of stromal
cell proliferation (Arici, Seli et al. 1998) and is produced by both ESCs and
endometrial epithelial cells (EECs) in culture. However, there appears to be little or
no expression of IL-8 by the stromal cells in vivo (Critchley, Jones et al. 1999). IL-8
has been localised to both surface and glandular epithelium, as well as to the
perivascular cells (Critchley, Kelly et al. 1994; Jones, Kelly et al. 1997). The
expression of IL-8 is modulated via the inflammatory cytokines TNFa and IL-lp
(Arici, Seli et al. 1998). It has also been demonstrated that IL-8 is upregulated in
response to progesterone withdrawal in vivo (Critchley, Jones et al. 1999). IL-8
levels have been found to be maximal during the late secretory and menstrual phase
of the menstrual cycle (Lam, Briton-Jones et al. 2004). The expression of IL-8
during the late secretory phase is believed to be involved with the recruitment of
neutrophils which are known to invade the endometrium prior to menstruation (Lam,
Briton-Jones et al. 2004).
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1.7.3 Matrix Metalloproteinases (MMPs)
The actions of MMPs were first observed during frog metamorphosis where the
enzymes were involved in the resorption of the tail, this was later identified as
collagenase (Curry and Osteen 2003). The MMPs are a family proteases, that have
been described as being zinc and calcium dependent endopeptidases that function to
maintain the ECM (Egeblad and Werb 2002). MMPs are regarded as multifunctional
enzymes due to the range of subtrates and have been identified to have a role in
processes such as embryogenesis, angiogenesis, wound repair and tissue
remodelling. MMPs also have the ability to interact and modulate cytokines and
growth factors (McCawley and Matrisian 2001), suggesting a role in the immune
response. MMPs and their inhibitors, TIMPs also have an important role in the
female reproductive tract (Salamonsen 2003; Kaitu'u, Shen et al. 2005).
1.7.3.1 MMPs in menstruation
The matrix metalloproteinases (MMPs) are enzymes which are released by the
infiltrating immune cells and by the stromal cells. MMPs have also been implicated
with the breakdown of the extracellular matrix (Schatz, Krikun et al. 1997;
Lockwood, Krikun et al. 1998; Salamonsen and Woolley 1999). The role of MMPs
in menstruation is characterised by the timing of their expression within the
endometrium (Rodgers, Osteen et al. 1993; Rodgers, Matrisian et al. 1994; Li, Post et
al. 2000). Some at least of the MMPs are presumed to be under the control of
progesterone. The withdrawal of progesterone from endometrial stromal cells
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(ESCs) in culture showed an enhancement in the production of pro-MMP-2 (Irwin,
Kirk et al. 1996) and pro-MMP-3 (stromelysin-1) (Schatz, Papp et al. 1994;
Lockwood, Krikun et al. 1998). This was further supported with human ESCs in
culture mimicking the luteal phase, MMP-1, 2, 3 and 4 in latent form were
upregulated with progesterone withdrawal (Salamonsen, Butt et al. 1997). The MMP
tissue inhibitors (TIMPs) were also investigated with respect to the withdrawal of
progesterone, however, no regulation of TIMPs 1, 2 or 3 was observed. This is an
indication that the regulation of MMPs is more complex than simply being
progesterone regulated. Leukocytes also provide a source of MMPs and their control
may be via the paracrine interaction between the stromal and epithelial cells
(Salamonsen and Lathbury 2000).
1.7.3.2 Matrilysin (MMP-7)
Matrilysin is one of the smallest members of the MMP family, 28 kDa and was first
discovered in the uterus of the rat and designated the name "pump" for putative
uterine metalloproteinase (Woessner 1996). Recently, there has been much research
interest in the role for matrilysin in mucosal immunity. In contrast to the expression
of other MMPs, it has been demonstrated that matrilysin is expressed in non-
damaged mucosa as well as part of the inflammatory process in the event of injury or
infection. It has also been recognised that MMP-7 is constitutively expressed across
mucosal areas and specifically those associated with vulnerability to infection as they
are exposed to the environment such as the lining of the gut (Wielockx, Libert et al.
2004). However, this was shown in the rodent and it was suggested that this was not
the case in humans as there is an absence of MMP-7 in the gut. Wilson et al
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(Wilson, Ouellette et al. 1999) reported the co-expression of matrilysin and pro-a-
defensins in the paneth cells of the murine gut, suggesting that the enzyme has a role
in regulating the activity of defensins. In vitro studies revealed that matrilysin can
cleave the pro-peptides into their mature and active forms. Mouse knockouts for
matrilysin showed a deficiency in producing active antimicrobials and further
leaving the animals vulnerable to exogenous microbes (Wilson, Ouellette et al.
1999). However, later work demonstrated the cleavage of the pre-form of human
defensin 5, by a murine intestinal trypsin into its active form. Matrilysin was shown
to cleave HD5 but, in the wrong place (Ghosh, Porter et al. 2002). The role for
matrilysin in the cleavage of pro-peptides in the human has been dismissed as it has
not been detected within the gut (Wielockx, Libert et al. 2004). However, matrilysin
has been found to be expressed in the female reproductive tract (Rodgers, Osteen et
al. 1993).
1.8 Menstruation as an inflammatory event
Menstruation occurs in the event of implantation failure, and results in the functional
layer of the endometrium being shed. The overall process occurs in response to the
declining progesterone levels that results from the demise of the corpus luteum.
However, the process is described as being multi-factorial, where the hormonal
influence is only a part of the story (Jabbour, Kelly et al. 2006). The premenstrual
withdrawal of progesterone initiates the upregulation of inflammatory mediators such
as cytokines, chemokines, matrix metalloproteinases (MMPs) and the influx of
leukocytes. The presence and active role of these immune cells and factors have led
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to the process of menstruation being described as an inflammatory event (Finn 1986;
Kelly, Illingworth et al. 1994; Critchley, Kelly et al. 2001).
1.8.1 Leukocytes within the female reproductive tract
The leukocyte population is composed of macrophages, uterine Natural Killer (uNK)
cells and neutrophils. These cells can be modulated indirectly via the sex steroid
hormones, in the absence of classical nuclear receptors this is believed to be
mediated via paracrine factors (Poropatich, Rojas et al. 1987; Henderson, Saunders et
al. 2003). However, it is also possible for sex steroid responsiveness to be mediated
via the glucocorticoid receptor (GR) binding of progesterone (Wira, Fahey et al.
2005). Neutrophils are present in low numbers within the endometrium across the
cycle. Their numbers are however, greatly increased immediately prior to the onset
of menstruation, similar to that described in the event of inflammation (Noyes,
Hertig et al. 1950; Kamat and Isaacson 1987; Poropatich, Rojas et al. 1987). In the
event of pregnancy there is a large number of large granular lymphocytes (LGL), and
represent approximately 70% of the total number of leukocytes present in the 1st
trimester with a subsequent decline during the 2nd trimester (Loke, King et al. 1995),
thus, indicating a role for these cells in the process of implantation and placentation,
however, their exact role has still to be defined (Loke, King et al. 1995; King,
Burrows et al. 1998; King 2000). However, the presence of an infection or an over-
zealous immune response would clearly be harmful to the pregnancy. The presence
of high levels of NK cells within endometrium is associated with a greater incidence
of pregnancy loss (Yamada, Morikawa et al. 2003; Carp 2004; Shimada, Kato et al.
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2004). In the absence of pregnancy the number of NK cells decline, however, there
are conflicts within the literature as to whether these cells undergo apoptosis (Jones,
Bulmer et al. 1998; Jones, Searle et al. 1998; King 2000; Pongcharoen, Bulmer et al.
2004), this is discussed further in section 1.8.5 of the current thesis. A table
(1.8.1.1) summarising the leukocyte populations present in the pregnant and non¬









Neutrophils a -/+" -/+ -
Eosinophils - - - -
Basophils - - - -
Lymphocytes
B Cells -(+)c -(+) -(+) -(+)
T Cells +d + + +
NK Cells (LGL) + +++e +++++ +++
Macrophages + + +++ +
Table 1.1.8.1 Summary of the presence and timing of the leukocyte populations in
the endometrium from (King, Burrows et al. 1998). Letters: a - indicates no cells; b
- variable numbers of cells; c - variable, low density of cells; d - high number of
cells present; e - > +++ indicates the density of cells present.
1.8.2 Neutrophils and eosinophils
In the lower reproductive tract the role of the neutrophil is to prevent the cervical and
vaginal regions from becoming infected, the phagocytosis of dead and damaged
sperm; and cervical maturation during parturition (Smith, Wira et al. 2006). In the
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upper reproductive tract the neutrophils are believed to have an additional role in the
breakdown and remodelling of tissue. They are present in very low numbers in the
endometrium until immediately prior to the onset of menstruation when the numbers
can increase and comprise up to 15% of the total cell number (Salamonsen and
Lathbury 2000).
It has recently been suggested that the neutrophils localised to the Fallopian tube
exhibit a different phenotype from those within peripheral blood (Smith, Wira et al.
2006). Smith et al (Smith, Wira et al. 2006), suggest that this difference in
phenotype enables a more rapid innate immune response, in protection of both the
Fallopian tube and the peritoneal cavity.
Eosinophils exhibit a similar pattern of occurrence as described for the neutrophils in
the cyclic endometrium. There is an increase in the number of these cells at
menstruation, where they form aggregations and can make up around 5% of the total
number of cells at this time (Poropatich, Rojas et al. 1987; Salamonsen and Lathbury
2000).
1.8.3 Lymphocytes
The lymphocyte population consists of B-lymphocytes and T-lymphocytes and are
found within aggregates in the basal layer of endometrium. They are present
throughout the menstrual cycle and in relatively low numbers (Bulmer, Longfellow
et al. 1991). The number of B-lymphocytes does not vary, whilst T-lymphocytes
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numbers are slightly elevated perimenstrually. T-lymphocytes have also been
identified within the functional layer of endometrium and intraepithelial sites (Loke,
King et al. 1995).
Approximately 85% of the T cells are positive for the ap T cell receptor (TCR+),
with the remainder of the endometrial population identified as y5 TCR+ (Chen,
Huang et al. 1995). The yST cells and apT cells are members of different
components of the immune system, the innate and adaptive respectively (Hayday,
Theodoridis et al. 2001). The y8T cells are a component of the innate immune
system and are responsible for the recognition of antigens, allogens and self-antigens
as part of the first line of defence (Mincheva-Nilsson 2003). The presence of these
cells may be to regulate the adaptation of the maternal immune system to the
presence of a semiallogeneic embryo (Mincheva-Nilsson, Hammarstrom et al. 1992;
Meeusen, Bischof et al. 2001). The function of TCR+ cells in the endometrium may
be as immunosuppressors with or without cytolytic activity, however, it remains
unconfirmed (Suzuki, Hiromatsu et al. 1995; Mincheva-Nilsson, Nagaeva et al.
2000). There are greater numbers of CD8+ cells relative to the number CD4+ cells
within the endometrium than the ratio observed in peripheral blood. The CD8+ cells
exert cytolytic activity during the proliferative phase of the menstrual cycle; this
activity ceases at the onset of the secretory phase (White, Crassi et a!. 1997; Yeaman,
Guyre et al. 1997).
B cells have been characterised in the mucosa of the gut and lung, and function to
produce IgA antibodies in providing immune protection. There have been
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descriptions of IgA synthesising plasma cells in the vagina, ectocervix and
endocervix. The presence of plasma cells within the endometrium has been
considered to be an indication of endometritis (Buckley 1989). However, recently
this view has been questioned with reports of plasma cells within healthy
endometrium (Achilles, Amortegui et al. 2005).
1.8.4 Macrophages
The macrophages have been identified to be widely distributed in the female
reproductive tract and are representative of approx. 10% of the total number of
leukocytes in the female reproductive tract (Givan, White et al. 1997). The changes
in steroid hormone levels appear to be coincident with macrophage migration,
especially within the endometrium (Jones, Kelly et al. 1997; DeLoia, Stewart-Akers
et al. 2002). The cyclic variation in macrophage numbers may be as an indirect
consequence of steroid hormone mediated changes in the levels of circulating
cytokines and chemokines (Wira, Fahey et al. 2005), (table 1.1.8.1). The majority of
endometrial macrophages express major histocompatibility complex (MHC) class I
or class II (Bulmer, Lunny et al. 1988), suggesting a role as antigen presenting cells
(APCs). Macrophages are responsible both for the secretion of and response to
cytokines, and have a pivotal role in the inflammatory response (Wira, Fahey et al.
2005).
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1.8.5 Natural Killer cells
Natural Killer (NK) cells are large granular lymphocytes (LGL) and have a pivotal
role as part of the innate immune system, exerting effects on both immune and non¬
immune cells. They have the ability to kill tumour cells and are responsible for the
secretion of a number of cytokines. They have been described as being sentinels of
the innate immune response having the ability to attack pathogens and they can
upregulate other immune effectors.
NK cells express the cell surface antigens CD56, an isoform of NCAM (neural cell
adhesion molecule) and most express the low affinity Fc-y receptor, CD 16. NK cells
are found in peripheral blood, lymphoid organs, liver and mucosal tissues including
the uterus. The cells within the blood have been divided into two classes and this has
been based on the expression density of the surface antigen CD56. In the blood over
90% of the cells are described as being CD56dim. This subset of cells has been
shown to have a high level of lytic activity against tumour cells, and are further
characterised by the expression of CD 16 (FcRylll), and killer cell Ig-like receptors
(KIRs). Many of these cells also express CD57 (Jacobs, Flintzen et al. 2001; Wendt,
Wilk et al. 2006). The remainder of NK cells are described as being CD56bri8ht and
have the ability to produce cytokines when stimulated by monokines (Jacobs,
Hintzen et al. 2001; Cooper, Fehniger et al. 2004; Wendt, Wilk et al. 2006). Within
the female reproductive tract the NK cells have been shown to have a distinct
phenotype from that of peripheral blood, and have been described in the literature as
endometrial granulocytes, granular endometrial stromal cells and decidual NK (dNK)
cells (Bulmer, Longfellow et al. 1991). NK cells of the uterus are CD56bnght and
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most lack CD16. Uterine NK (uNK) cells also express KIRs, CD9 and CD69 on
their cell surface (Verma, King et al. 1997; Koopman, Kopcow et al. 2003; Eriksson,
Meadows et al. 2004; Eriksson, Meadows et al. 2006).
Uterine NK cells are present in low numbers throughout the menstrual cycle.
However, there is a dramatic increase in their numbers during the secretory phase
(Bulmer, Longfellow et al. 1991; Loke, King et al. 1995; King, Burrows et al. 1996;
Jones, Bulmer et al. 1998; King 2000). They form a major cellular component of the
endometrial stroma and are occasionally located within the functional layer within
intraepithelial sites.
1.9 Implantation
The process of implantation and endometrial receptivity is mediated by hormones,
cytokines and growth factors (Carson, Bagchi et al. 2000). As the blastocyst arrives
into the uterine cavity it is free floating and initiates the implantation process by
establishing communication with the endometrium. A number of factors need to be
in place in order for the hostile endometrium to be receptive and some of the
mediators of this process are discussed below (1.9.1) (Achache and Revel 2006).
Once dialogue is established there follows a series of synchronised events. The next
step is apposition, where the blastocyst becomes loosely attached to the wall of the
endometrium. This allows for local paracrine signalling which gives rise to a
stronger attachment. This stronger attachment allows the trophectoderm cells from
the blastocyst to migrate through the epithelial cells of the endometrium, and into the
basement membrane. This is followed by the trophoblastic invasion of the stroma.
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If the endometrium is not receptive to taking part in any of these events then
implantation will fail (Norwitz, Schust et al. 2001; Sharkey and Smith 2003). The
receptive endometrium has been characterised at the histological level which
includes the increased activity of the secretory glands, an increase in vascularity and
the development of pinopodes (Norwitz, Schust et al. 2001). This brief progesterone
dependent appearance of pinopodes has come to be regarded as an indicator of a
receptive endometrium, typically days 20 - 24 of the menstrual cycle (Bergh and
Navot 1992; Norwitz, Schust et al. 2001). The role of the steroid hormones in the
mediation of implantation has been subject to much research, however, much of the
molecular mechanisms remain to be determined (Norwitz, Schust et al. 2001).
1.9.1 Mediators of endometrial receptivity
Uterine preparation for implantation involves the synchronisation of a number of
cytokines, steroid hormones, growth factors, adhesion molecules and other factors
that have been identified as important for the preparation of the endometrium for
implantation (Beier-Hellwig, Sterzik et al. 1994; Beier and Beier-Hellwig 1998;
Achache and Revel 2006). As with the pinopodes mentioned above a number of
markers for endometrial receptivity have been identified and many of these are
subject to regulation by the steroid hormones (Lessey, Yeh et al. 1996; Lessey 2003).
During the secretory phase, the endometrium undergoes a number of morphological
changes under the influence of progesterone and differentiates into decidua. The
decidualisation of the stroma and increase in secretory glandular epithelium is
essential for the establishment of pregnancy (Loke, King et al. 1995; King 2000;
Achache and Revel 2006). The glandular epithelium secretes a number of
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hormonally regulated proteins such as albumin and glycodelin1. Progesterone also
functions as an antagonist for oestrogen directed proliferation. The inhibition of
oestradiol levels results from the downregulation of ERa by progesterone which acts
as an antagonist (Lessey 2003). This downregulation of ERa also indirectly results
in an increase in expression of integrins which is inhibited by oestradiol. Another
example of indirect regulation by progesterone is via the direct increase in the
expression of calcitonin (Ding, Zhu et al. 1994; Kumar, Zhu et al. 1998; Zhu,
Cullinan-Bove et al. 1998), which increases the level of intracellular calcium and this
allows for the regulation of E-cadherins. Progesterone increases the amount of
osteopontin and its receptor, alphavbeta (3) (avP3) integrin expression (Apparao,
Murray et al. 2001; Johnson, Burghardt et al. 2003; von Wolff, Bohlmann et al.
2004). The integrin av03 and its ligand osteopontin has been suggested as a receptor
for embryonic attachment (Lessey 2003). Progesterone may also regulate paracrine
stromal factors such as epidermal growth factor (EGF) and heparin-binding EGF
(HB-EGF) which increase the epithelial expression of P3 integrins (Somkuti, Yuan et
al. 1997; Lessey 2003), which are important for the formation of avP3. Another
molecule associated with endometrial receptivity is MUC1, a member of the mucin
family of glycoproteins. It is possible that MUC1 expression is downregulated in the
presence of high levels of progesterone and that MUC1 is inhibitory to implantation
(DeSouza, Surveyor et al. 1999). However, in the human it has been shown that the
expression of MUC1 is increased from the proliferative to mid-secretory phase of the
menstrual cycle (Hey, Graham et al. 1994; Aplin and Hey 1995). The data
surrounding MUC1 expression in the human endometrium appears to be
1
Glycodelin is also reported as progesterone associated endometrial protein, lactoglobulin,
a-uterine protein, a-2 microglobulin, pregnancy associated a-2 globulin and placental protein
14.
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contradictory. However, it has been suggested that there may be a local acting
mechanism for the inhibition of MUC1 (Thathiah and Carson 2004). The surface of
pinopodes are devoid of MUCl molecules (Home, Lalani et al. 2006), and this has
been suggested to function by providing an area for embryo implantation. Meseguer
et al have demonstrated that the site of blastocyst implantation is devoid of MUC1
molecules (Meseguer, Aplin et al. 2001), however, they also suggest that
progesterone results in the upregulation of the molecule and that the blastocyst is
responsible for the local downregulation. The role of the blastocyst in the mediation
of MUCl expression has also been demonstrated recently by Thathiah and Carson
(Thathiah and Carson 2004).
1.10 The morphology and role of the Fallopian tubes
The Fallopian tube is a paired organ which bilaterally connects the peri-ovarian
space with the uterus. This tubular organ has distinct regions extending and opening
into the peritoneal cavity from the ovary to the uterus; namely the fimbria, ampulla
and isthmus (figure l.lO.l (A)). The convoluted nature of the lumen is demonstrated
in a histological cross section (figure 1.10.1 (B)). From the centre these areas are
characterised as the lumen, which is surrounded by the endosalpinx, myosalpinx and
the mesosalpinx as the final layer. Each of these regions and layers demonstrate
distinct morphologies which are representative of the distinct roles within the organ
(Croxatto 2002). The endosalpinx is the mucosal layer and is made up of
monostratified epithelia. The myosalpinx is made up of smooth muscle which is
thick and thin at the isthmus and ampulla regions, respectively.
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The ampulla exhibits a large surface area which is composed mainly of ciliated
epithelia. In contrast the isthmus region has fewer folds and has epithelium which is
predominantly made up of secretory cells. The fimbria functions in the catching of
the oocyte after ovulation, prior to its transport along the ampullary region. This is
the region in which the controlled arrival of the spermatozoa is mediated until the
oocytes are fertilised. Following fertilisation, the zygote commences its pre-
implantation development as it travels through the isthmus and on its way to the
uterus. The morphology and function of the Fallopian tube is controlled via the
ovarian steroids (Croxatto 2002). Ovarian endocrine mechanisms arise from the
Graafian follicles as they prepare to ovulate, and functions to mediate the
synchronisation of events required for successful fertilisation (Hunter and Rodriguez-
Martinez 2004). There is a sequential gradient from the production of oestradiol
from follicular secretions to that of progesterone resulting from the pre-ovulatory
increase in the level of gonadotrophin (Hunter and Rodriguez-Martinez 2004). The
increase in progesterone and decline in oestradiol has a major influence upon the
structure and function of the Fallopian tubes. This ovarian endocrine influence is
believed to be essential for the controlled capacitation of sperm, by ensuring timely
presentation and favourable sperm:egg ratios (Hunter 1993; Hunter 1995; Hunter
1996). The influence of progesterone upon the epithelial cells of the Fallopian tube
has also been documented (Hunter 1987; Mburu, Einarsson et al. 1996; Lefebvre, Lo
et al. 1997; Mburu, Rodriguez-Martinez et al. 1997; Suarez and Pacey 2006).
However, there is still little understood about some of the morphological changes
that are assumed to take place within the human Fallopian tube.
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Figure 1.10.1 Schematic diagram illustrating the main structural components of the
Fallopian tube in relation to the rest of the female reproductive tract (A).
Haematoxylin and eosin staining of a cross-section of a Fallopian tube biopsy from
the ampulla (B), the method used for the H&E staining is detailed in section 2.7.
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1.10.1 The capacitation of spermatozoa and fertilisation
The capacitation of sperm within the female reproductive tract was first described as
an important pre-fertilisation event 55 years ago (Schalkwijk, Chang et al. 1990).
However, despite this early description and a significant amount of research into the
area, much of the process is still poorly understood. A number of publications have
served to both clarify and evaluate the sequential nature and physiological location of
the steps involved in the capacitation of sperm. All of which is adequately reviewed
by Hunter and Rodriguez-Martinez (Hunter and Rodriguez-Martinez 2004).
Much of the current knowledge of the sequential processes involved with the
capacitation of sperm has resulted from observations made from in vivo timecourse
experiments. These experiments have suggested that the uterus and the Fallopian
tube function with synergism in the capacitation and preparation of sperm prior to
fertilisation (Hunter 1969; Hunter and Hall 1974; Hunter and Hall 1974b; Lund,
Alexopoulou et al. 2004). A number of publications have demonstrated that if sperm
are placed directly into the Fallopian tube, capacitation takes longer than if the sperm
is placed first within the uterus (Bedford 1970; Lund, Alexopoulou et al. 2004). The
progression of sperm through the female reproductive tract allows for the actions of a
variety of molecules and biochemistry to occur in a timely and sequential manner
(Hunter and Rodriguez-Martinez 2004).
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1.10.2 Transport of the ovum
Fertilisation commonly occurs in the ampullary region of the Fallopian tube where
the nuclei of the egg and the sperm fuse to forming a diploid zygote. The zygote
undergoes a series of cell divisions to form the morula. The zygote remains in the
upper third of the female reproductive tract, normally for around 24 hours, before the
cilliary and peristaltic action of the Fallopian tube moves the dividing zygote towards
the uterine cavity (Croxatto 2002). The journey occurs over 4-5 days, during which
the zygote will undergo a number of divisions under the constraint of the zona
pellucida, causing the cells to get smaller with each division. By the time the
resultant morula reaches the uterus, it will have divided into 8-16 daughter cells
(blastomeres) (Croxatto 2002).
Upon arrival to the endometrial cavity, the blastomeres begin to polarise with the
outer cells becoming flattened against the zona pellucida, whilst the inner cells
continue to divide. Uterine fluid containing nutrients enters the morula and the
blastocyst is formed (Pulkkinen 1995; Croxatto 2002).
Following fertilisation the zona pelucida serves to prevent the blastocyst from
adhering to the Fallopian tube wall. Flowever, upon arrival to the uterus and before
implantation can occur the blastocyst must "hatch" from this protective layer
(Mastroianni 1999). The degradation of the zona pelicuda is thought to be brought
about via the secretions of both the blastocyst and the uterus. After the shedding of
this protective, glycoprotein layer the blastocyst is ready to commence the process of
implantation (Edwards 1994; Mastroianni 1999).
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1.10.3 Ectopic pregnancy
Ectopic pregnancy is an important cause of maternal death during the first trimester
of pregnancy (RCOG 2004). Sites of ectopic gestation include the Fallopian tube,
cervix, ovary and abdominal cavity (figure 1.10.3.1). Over 95% of ectopic
pregnancies occur in the Fallopian tube, 70% occur in the ampulla, 12% in the
isthmus, 11% in the fimbria, and 2% in the interstitial/cornual region (figure
1.10.3.1) (Breen 1970; Bouyer, Coste et al. 2002; Corpa 2006). The precise
mechanisms and causes of an ectopic implantation are not clearly understood,
however, a number of risk factors have been identified (Farquhar 2005). Some of the
main risk factors include, previous tubal surgery, genital infection and smoking
(Farquhar 2005). The impairment of tubal transport is widely thought to be a major
cause of tubal pregnancy (Corpa 2006), and some of the causes are discussed in more






Figure 1.10.3.1 Diagrammatic demonstration of the documented sites of ectopic
pregnancy. The figure was redrawn and adapted from Corpa. (Corpa 2006).
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1.11 Aims of the thesis
The female reproductive tract is potentially exposed to a wide range of pathogens
and the risk of infection is thought to be variable across the menstrual cycle. The
maintenance of an infection free reproductive tract is essential for the successful
conception and maintenance of pregnancy. In common with other mucosal regions
the female reproductive tract has a range of innate immune effectors including the
recently identified natural antimicrobials. These peptides and proteins have been
shown to be differentially expressed across the menstrual cycle giving rise to
considerations for the possible distinct roles of these molecules. Their relationship
with the sex steroids and with other immune factors is similary subject to cyclical
variance in expression.
Natural antimicrobials are described as being rapid and short term acting members of
the innate immune system and function as a bridge to the adaptive immune system.
The timing of their expression may be relevant as a means of ascertaining their
specific roles and possible interactions. The expression of these molecules in
relation to time has not been investigated.
The effect of progesterone upon the expression of these molecules is apparent both in
culture and in primary material. Progesterone has been shown to inhibit or increase
the expression of others, such as human (3-defensin 2 and secretory leukocyte
protease inhibitor (SLPI), respectively. The precise nature of this effect has not been
fully elucidated. The role of paracrine interaction between stromal and epithelial
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components of the endometrium upon the expression of natural antimicrobials has
also not been investigated.
The natural antimicrobials have been characterised in the cycling endometrium,
cervix and vagina. However, there is comparatively very little described for the
presence or actions of natural antimicrobials in the Fallopian tube. The Fallopian
tube is the target for a number of sexually transmitted infections and thus has a
requirement for an innate immune response. The influence of the ovarian cycle upon
the expression of these molecules in the Fallopian tube has also to be elucidated.
In order to determine further the role of natural antimicrobials in the Fallopian tube,
consideration of the effect of an ectopic implantation upon their expression would be
useful. The causes of ectopic implantation are poorly understood and the role of
innate immune effectors such as the antimicrobials may provide an insight into both
the causes and implications. The effect of an ectopic implantation upon the uterus
has not been fully elucidated and may offer opportunities for early diagnosis and the
identification of candidate molecular markers. The expression of natural
antimicrobials in the uterine decidua sampled from women with an ectopic gestation
has not been described.
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Thus, the aims of the thesis are:
1. To characterise the expression and regulation of a range of natural antimicrobials
within the human endometrium using representative cell lines.
2. To investigate the role(s) played by the interaction between epithelial and
stromal cells in the expression of these molecules.
3. To identify the interactions between the antimicrobials and with other innate
immune effector molecules.
4. To elucidate the role of sex steroids in the regulation of natural antimicrobials.
5. To examine the expression patterns of these molecules over time in response to
infection.
6. To describe the expression of antimicrobials in human Fallopian tubes with and
without an ectopic gestation.
7. To examine the expression of natural antimicrobials in the uterine decidua of







Reagents and Materials are detailed in Appendix 1.
2.1 Sample Collection
Tissue samples to be used for immunohistochemistry were collected in Roswell Park
Memorial Institute (RPMI) 1640 culture media. Some of the sample was fixed in
10% neutral buffered formalin (NBF) overnight at 4°C and subsequently stored in
70% ethanol until finally being embedded in wax. Tissue was also collected for PCR
analysis, collected in RNA later and stored at -70°C until further processing as
detailed in section 2.3. Finally, portions of tissue were also utilised for cell culture as
detailed in section 2.2.
Written informed consent was obtained from all patients prior to biopsy collection
and ethical approval was received from Lothian Research Ethics Committee
(LREC/05/51104/12 and LREC 04/S1103/20). The details of which are provided
below next to the applicable samples and further detailed within the relative data
chapters within the current thesis.
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2.1.1 Human uterine tissue
Endometrial biopsies were collected from women (18-45), undergoing
gynaecological procedures for benign conditions. Samples were collected as full
thickness (lumen to endometrial/myometrial junction) endometrial biopsies or with
the use of an endometrial suction curette (Pipelle, Laboratoire CCD, Paris, France).
All women reported regular menstrual cycles (25-35 days) and had not received any
form of hormonal treatment in the three months prior to biopsy collection. Biopsies
were dated according to stated last menstrual period (LMP) and were confirmed by
histological assessment according to criteria of Noyes et al (Noyes, Hertig et al.
1950). Furthermore, circulating oestradiol and progesterone levels were measured at
the time of biopsy collection and were consistent for both LMP and histological
assignment of menstrual cycle stage. The concentration of oestradiol (E2) and
progesterone (P4) were measured by radioimmunoassay (MRC HRSU assay lab).
First trimester decidua (8-11 weeks gestation) was obtained from patients (aged 18-
45 years), undergoing surgical termination of pregnancy or surgical management of
miscarriage and not received RU486. Decidual tissue collected during surgical
management of an ectopic gestation was obtained with an endometrial suction curette
(Pipelle).
2.1.2 Human Fallopian tube
Fallopian tube biopsies (n=10) were collected from fertile woman undergoing
hysterectomy procedures for benign indications (age 18-45 years). The details of
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these samples are provided in chapter 6 table 6.2.1.1. Fallopian tube biopsies (n=9)
were in addition collected from women undergoing surgical management of ectopic
pregnancy (age 25-40 years). The details of these samples are provided in chapter 6
in table 6.2.1.2.
2.2 Cell Culture
2.2.1 Separation of endometrial biopsies into glandular and stromal
components.
The method utilised for the separation of the glandular and stromal components of
the endometrium was adapted from that described by Osteen et al. (Osteen, Hill et al.
1989). The modifications that were made are outlined. The endometrial biopsies are
washed 3 times in PBS and divided into smaller fragments. The fragments are
immersed in collagenase (1 mg/ml), DNAase (0.1 mg/ml) and incubated for 80
minutes at 37°C. Culture media (RPMI 1640) was then added and the tissue
disaggregated. This resulted with a suspension made up of single cells and larger
glandular fragments. The suspension was centrifuged (3000 rpm, 3 minutes); the
pellet resuspended with culture media and allowed to separate by the process of
density sedimentation. The supernatant containing the stromal component was
removed. Culture media was added and the density sedimentation step was repeated.
The stromal cells were then placed into culture flasks with F' supplemented RPMI
and maintained as in 2.2.2. The remaining glandular fraction was centrifuged as
described previously. The pellet was resuspended in collagenase/DNAse, incubated
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for 2 hour at 37°C. The suspension was centrifuged (3000 rpm, 3 minutes) and the
resultant pellet resuspended in 50% matrigel.
2.2.2 Primary Endometrial Stromal Cells
Cells were cultured in complete RPMI (cRPMI) supplemented with basic fibroblast
growth factor (bFGF) and oestradiol (10"8 M).
2.2.3 Cell lines
The human endometrial carcinoma derived cell line Hec-IA (human endometrial
cancer-one) (Kuramoto, Tamura et al. 1972), was maintained in 75 cm2 culture flasks
(Corning Incorporated). The cells were grown in RPMI (Sigma) culture media
supplemented with 10% fetal calf serum (FCS) (Mycoplex; PAA, Teddington, UK),
L-glutamine (2 mM; Gibco BRL), penicillin (50 pg/ml; Sigma), streptomycin (50
pg/ml; Sigma) and gentamycin (5 pg/ml; Sigma). For treatment, cells were plated at
a density of 5.2x105 and grown overnight in 4 ml RPMI (2% FCS) in 6-well plates
(Corning Incorporated). Treatments were added and incubated for an appropriate
time (as described in data chapters). The culture supernatants were then removed
and stored at -20 °C for analysis with ELISA. The cells were treated directly with
Total RNA Isolation Reagent (TRIR; Abgene) for RNA extraction.
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2.2.4 Treatment of Cells
Epithelial cells were seeded at 5x10s cells per/well (6 well plate) and allowed to
adhere overnight in 2% cRPMI (complete media). The cells were treated with a
variety of mimics of infection (detailed in chapters 3, 4 and 8), in serum free
conditions. Controls were grown under the same relevant culture conditions and
were included throughout.
2.2.5 Co-Culture
In co-culture experiments endometrial stromal cells (ESCs) were seeded into 6 well
culture plates and allowed to reach confluence. After attachment the media
containing serum and hormones was removed and replaced with serum free RPMI.
Hec-IA epithelial cells were seeded (1.3xl05 cells/ml) into the interior of transwell
culture inserts in 2% cRPMI and allowed to adhere. The inserts containing the
epithelial cells were placed in the wells containing the stromal cells and the media
replaced prior to treatment with inflammatory mimics with or without steroid
hormones (detailed in chapter 4). Co-culture controls without treatment and single
culture controls for both ESC and Hec-IA (treated and untreated) cells were included
throughout. The co-culture set-up and methods of treatment are demonstrated in
figure 2.2.5.1.
78
Figure 2.2.5.1 Co-Culture experiment set-up. This figure outlines the different
set-up of culture plates for the investigation into the role of paracrine signalling in the
expression of natural antimicrobials. (A) demonstrates the co-culture plate set-up;
the epithelial cells were placed within the well insert - transwell. Whilst the stromal
cells were plated within the original wells of the plate - these were described as co-
culture cells. (B) The relevant treatments were added to the media contained within
the transwell i.e. directly to the epithelial cells. (C) Depicts the media surrounding
the stromal cells being treated. (D) Demonstrates the treatment of both components
of the culture well set-up. All wells and transwells contained the same media with
the exception of the relevant treatments where indicated.
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2.2.6 Mycoplasma Screening and Treatment of Cells
There was regular screening and treatment of cultured cells for contamination with
Mycoplasma spp. The maintenance of infection free culture conditions was essential
in order to prevent unreliable data being obtained. A PCR-based method was
employed to detect the commonest forms of mycoplasma. In the event that
contamination was detected the cells were treated with plasmocin.
A mycoplasma test kit was obtained from Cambio Ltd. (Venor®GeM). Cell culture
supernatant (100 pi) was heated at 95°C for 5 minutes and briefly centrifuged. The
sample was then prepared for PCR as follows: 2 pi sample (dH20 negative control;
DNA template for mycoplasma positive control), 15.3 pi dH20, 2.5 pi lOx reaction
buffer, 3 pi 50 mM MgCl2, 2.5 pi primer/nucleotide mix, 2.5 pi internal control and
0.2 pi Taq polymerase. The reaction was carried out with the following conditions:
94°C for 2 minutes 1 cycle, 94°C 30 seconds, 55°C 30 seconds and 72°C for 39
cycles. The resultant products were analysed on an agarose gel (1.5 %, appendix II).
A schematic summary of the protocol and an example of set of results is shown in
figure 2.2.6.1.
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5 pi of PCR product loaded onto
agarose gel for analysis
Figure 2.2.6.1 Schematic summary of the protocol utilised in the screening of cell
culture stocks for the presence of Mycoplasma spp. Lane 1: 100 bp ladder; lane 2:
positive control; lane 3: negative control; lane 4: non-contaminated sample and lane
5: contaminated sample.
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2.3 RNA extraction and Quantitative Reverse Transcription Polymerase Chain
Reaction (Q-RT-PCR).
2.3.1 RNA Extraction
(i) Total RNA Isolation Reagent (TRIR) and Phase Lock Gel Tubes (cell lines)
We extracted total RNA from the cell lines, which had been cultured in 6-well plates.
500 pi of TRIR was added to each of the wells and incubated on ice for 5 minutes to
allow for cell lysis. The contents of the wells were then transferred into Phase Lock
Gel (PLG) tubes (Eppendorf). Chloroform was added to each of the tubes at 0.2 x
volume (100 pi) and the tubes shaken vigorously for 10 seconds and replaced on ice
for a further 10 minutes. The tubes were placed in a centrifuge pre-cooled to 4 °C at
14000 rpm for 20 minutes. The organic phase containing protein and DNA becomes
trapped beneath the gel layer, whilst the top aqueous phase containing the mRNA is
poured off into clean 2 ml Eppendorfs. An equal volume of isopropanol was then
added and the tubes inverted 2-3 times and replaced on ice and incubated for an hour.
The tubes were centrifuged at 4 °C and 14000 rpm for 15 minutes. The isopropanol
was removed and the resultant pellets washed with 70 % ethanol and centrifuged for
a further 5 minutes and the remaining liquid removed. The pellets were dissolved in
25 - 50 pi RNA storage buffer (RSB; Ambion), determined by the size of pellet.
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(ii) Qiagen RNA Extraction Columns (Tissue)
The RNeasy Mini Kit (Qiagen) was used and the extraction was performed according
to the supplied protocol. The tissue was placed into a 2 ml tube containing 300pl of
Buffer RLT with P-mercaptoethanol and a sterile stainless steel bead. The Qiagen
tissue lyser was then used to homogenize the tissue at 30 Hz for 3 minutes. Nuclease
free water (590 pi) and 10 pi of proteinase K solution was added to the homogenate
and mixed with pipetting. The tubes were incubated at 55 °C for 10 minutes, before
being centrifuged for 3 minutes at 10,000 rpm at room temperature. The resultant
supernatant was poured off into an RNeasy mini spin column and the pellet
discarded. Ethanol was added to the column and was centrifuged for 15 seconds at
10,000 rpm and the flow through was discarded. The column was washed with the
addition of 350pl of buffer RW1 and centrifuged for 15 seconds at 10,000 rpm. This
was followed by the addition of DNase treatment (lOpl DNase I + 70pl Buffer RDD)
and incubated at room temperature for 15 minutes, and then the column was washed
as previously described. Two further washes with 500pl of Buffer RPE was added to
the RNeasy spin column and centrifuged for 15 seconds at 10,000 rpm; a final wash
was added and centrifuged for 2 minutes. The RNeasy spin column was then
transferred into a 1.5 ml collection tube and centrifuged at 14000 rpm for a further
minute. For elution, 32 ul of nuclease free water was placed directly onto the
RNeasy silica gel membrane after 5 minutes the tube was centrifuged for a further
min at 10000 rpm. This step was repeated with the resultant eluant (RNA).
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2.3.2 Reverse Transcription
The concentrations of the extracted RNA were determined using the formula: 260
nm value x dilution of RNA x 40 = RNA concentration (ng/pl). The concentration of
the samples was adjusted with the addition of DEPC dFEO (100 ng/pl).
The RNA samples were reversed transcribed using random primers with MgC^ (5.5
mmol/1), dNTPs (1 mmol/1), random hexamers (2.5 pmol/1), RNAse inhibitor (0.4
IU/pl) and Multiscribe reverse transcriptase (1.25 IU/pl). The resultant master mix
was aliquoted 16 pi per tube with 400 ng template RNA (4 pi, 100 ng/pl). Mineral
oil was added to the tubes and the PCR run with the following conditions: 20 minutes
25°C; 60 minutes 42°C and 95°C for 5 minutes. The resultant cDNA was diluted
2.5x with lxTE buffer.
2.3.3 Real time quantitative polymerase chain reaction (Taqman; Q-RT-PCR)
This method of PCR utilises the release of a fluorescent reporter dye as a means of
measuring the amount of PCR product obtained. This process is adequately
reviewed and compared to that of conventional RT-PCR methods by Bustin, (Bustin
2000). Primers are used in order to detect the sequence of interest, and are
concurrently used with a probe which targets the sequence specific to that between
the annealed primers. The probe is labelled with two fluorescent dyes: a 5' reporter
dye, FAM (6-carboxyfluorescein) and a 3' quencher dye, TAMRA (6-
carboxytetramethylhodamine). The reporter dye on the probe utilised for the
measurement of 18S is VIC in place of FAM. When the probe is annealed to the
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target sequence the reporter dye is suppressed due to the quencher dye being in close
vicinity. As the target sequence is amplified the probe is cleaved by the actions of
the taq polymerase, separating the two dyes and thus, increasing the level of
fluorescence as the quencher becomes distanced from the reporter dye. This increase
in the level of fluorescence can be measured and is only detected if the target
sequence has been amplified. The amount of specific amplicon is related to the
amount of ribosomal 18S RNA and is constant to the amount of cDNA and acts as an
internal control. It is possible to detect 18S concurrently within the reaction due to
the different wavelength of fluorescence emitted by the VIC reporter dye.
A PCR mix (Applied Biosystems) containing Amperase is prepared with the addition
of forward and reverse primers and probe (300 nmol/1) for the relevant sequence of
interest. The primer and probes for the detection of 18S are also added (50 nmol/1).
The resultant mixture is aliquoted into the requisite number of tubes and the relevant
cDNA sample is added to each (2.5 pl/reaction replicate). 20 pi of this mixture is
added in duplicate or triplicate to the wells of a 96 well PCR plate. For each plate
the following controls are included: no template (dFEO), a negative control from the
experiment and a positive control where available. The plates are sealed with optical
covers.
The reactions were carried out on ABI Prism 7900 (PE Biosystems) using a Taqman
specific protocol. The conditions were as follows: 2 minutes 50°C; 10 minutes 95°C;
followed with 40 cycles of the denaturing stage comprising 95°C 15 seconds and the
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annealing/extension phase, 60°C 1 minute; the latter is also that of the data
acquisition stage (figure 2.3.3.1).
The primers and probes were designed using PRIMER express software (PE
Biosystems) and the sequences for all the primers and probes used are detailed in
table 2.3.3.1
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Figure 2.3.3.1 Quantitative Polymerase Chain Reaction (Taqman). Stage 1
demonstrates the initiation of polymerisation. During this stage the probe anneals to
the desired sequence and the reporter (R), FAM and quencher (Q), TAMRA dye are
in close proximity to one another. The reporter dye is suppressed, resulting in a
decrease in the amount of fluorescence detected. Stage 2 the forward primer
extends along the template which results in the displacement of the reporter dye of
the probe. Stage 3 Taq polymerase cleaves the probe breaking the link between
the reporter and quencher dyes. This results in an increased amount of 'free'
reporter dye (FAM), thus there is an increase in the level of fluorescence detected.
Stage 4 in the last stage the polymerisation reaction is completed. The amount of
fluorescence detected will be proportional to the amount of PCR product generated.
This will be representative of the initial quantities of the desired sequence. This
figure and description has been adapted from the Taqman user's manual.
87
2.4 Enzyme Linked Immunosorbent Assays (ELISA)
2.4.1 Elafin ELISA
Elafin protein concentrations in cell culture supernatants were determined by ELISA.
The method was adapted from the method described by Sallenave et al. (Sallenave et
al. 1994). ELISA plates were coated overnight with anti-elafin IgG (1:500 in
carbonate buffer, pH 9.6) at 4°C. The elafin antibody was an RIgG fraction
(Sallenave et al. 1994). The plates were blocked, and samples/standards diluted in
PBS (with 1% BSA and 0.05% Tween 20) were added to the plate and incubated for
2 hours at 37°C. The standards were added in duplicate and the range was from 0.4 -
100 ng/ml. The plates were then incubated with biotinylated anti-elafin IgG (2
gg/ml) for 2 hours, followed by streptavidin horseradish peroxidase (sigma) for a
further 2 hours; both at 37°C. Plates were washed and chromogenic substrate 100
pl/well (2,2'-azino-bis-3-ethyl benz-thiazoline-6-sulfonic acid) with 0.001% H2O2
was added. Absorbance was measured at 490 nm on a microplate reader.
2.4.2 SLPI ELISA
The SLPI ELISA is a two site sandwich assay and has been described previously
(King, Fleming et al. 2002). Throughout the assay all relevant dilutions were
completed in SLPI ELISA buffer. ELISA 96 well assay plates were coated overnight
at 4°C with goat-anti-SLPI antibody (2 pg/ml), 200 pl/well. The plates were blocked
for 30 minutes at 37°C. Plates were washed 3 times with wash buffer prior to the
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addition of the relevant standards and samples. The standards were added in
duplicate and the concentration range was from 0.024 to 25 ng/ml of recombinant
SLPI. On each plate 2 wells were included as controls for non-specific binding,
containing 200 pi buffer. The plates were incubated at room temperature for 2 hours
on a plate shaker. The plates were washed and incubated for a further hour with
biotinylated mouse anti-human SLPI (1:10000), 200 pl/well. The plates were
washed before the addition of streptavidin peroxidase (1:4000), 200 pl/well and
incubated for 20 minutes at room temperature. The plates were again washed prior
to the addition of the ELISA substrate, 200 pl/well. After 10 minutes or strong
colour change, the reaction was stopped with the addition 50 pl/well of 2N sulphuric
acid. The plates were read in a plate reader at 450 nm.
2.4.3 Chloramphenicol AcetylTransferase (CAT) Reporter ELISA
The CAT ELISA was used to measure the level of CAT expression in Hec-IA cells
following transfection with the pCAT-reporter plasmid described in section 2.5. The
sandwich ELISA quantitatively measures the amount of CAT enzyme expression as
mediated via the elafin promoter in response to treatment as detailed in chapter 8.
Following treatment the cells were washed with chilled PBS and 1 ml of lysis buffer
added to each well and incubated at 25°C for 25 minutes. The resultant supernatant
was transferred into microfuge tubes and centrifuged for 15 minutes at 14,000 rpm
and 4°C.
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A calibration curve was prepared with a serial dilution of the stock enzyme. The
standards and samples were placed into pre-coated micro-titre wells (200 pl/well) in
duplicate. The wells were covered and incubated in the dark for 1 hour at 37°C. The
samples/standards were removed and the wells washed 5 times with wash buffer, 250
pl/well, before the addition of anti-CAT-DIG 200 pl/well and incubated as before.
The solution was removed and the wells washed as previously described, then 200
pl/well of anti-CAT-DIG-POD was added. The wells were incubated and washed as
described before the addition of the POD substrate 200 pl/well. The wells were
incubated in the dark at room temperature until sufficient colour development was
observed (approximately 20 minutes). The absorbance was measured at 405 nm with
a reference range of 490 nm, on a microplate reader.
2.5 Transfection of Hec-1A cells
2.5.1 Preparation of Plasmid DNA
The provision of E. coli glycerol stocks containing the plasmid constructs used in
this thesis were a gift from Professor Jean-Michelle Sallenave of the Pasteur Institut,
Paris.
The bacteria were grown in Luria Bertani (LB) medium containing ampicillin
(appendix II), to a density of 4xl09 cells/ml after approx. 16 hours growth to ensure
the transition from logarithmic phase to stationary phase growth. The extraction of
plasmid DNA was carried out with a Qiagen Maxi-prep kit using the protocol
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supplied with the following options. The cultured bacteria were harvested with
centrifugation at 6000 xg for 15 minutes at 4°C and the resultant pellet was
resuspended in 4 ml lysis buffer and vortexed. Then 4 ml buffer P2 was added to the
suspension and mixed with inversion and incubated for 5 minutes at room
temperature. The solution was precipitated with the addition of 4 ml of chilled buffer
P3, mixed with inversion and incubated on ice for 15 minutes with periodic mixing.
After incubation the solution was poured into QIAfilter cartridges and the flow
through collected into a clean falcon tube on ice. QIAGEN-tips were allowed to
equilibriate with the addition of buffer QBT prior to the addition of the supernatant,
followed by the addition of wash buffer QC, 2 x 10 ml per tip. The DNA was eluted
from the filter with the addition of 5 ml buffer QF, the eluate was collected into
falcon tubes and precipitated with the addition of 3.5 ml of isopropanol at room
temperature. The mixed solution was centrifuged at 15, 000 xg for 30 minutes at
room temperature. The resultant pellet was washed twice with 70% ethanol, air dried
and resuspended in TE buffer. The final concentration was measured using a
spectrophotometer at 260 nm and checked on an agarose gel.
2.5.2 P-Gal reporter optimisation of transfection
Hec-IA cells were transfected with p-galactosidase reporter constructs in order to
optimise the transfection efficiency.
Following transfection the cells were histochemically stained for p-galactosidase
activity. The cells were stained using X-gal (5-Bromo-4-chloro-3-indolyl-P-D-
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gaiactopyranoside), a clear soluble substrate, which hydrolyses to an indolyl, that
then oxidises to an indoxyl and this self couples to form an insoluble idigo-blue and
this allows for the localisation of transfected cells (figure 2.5.2.1). This method was
adapted from the one in Methods in Molecular Biology (McGreggor 1991).
The culture media was removed from the Hec-IA cells and washed 3 times with
PBS. Fix solution (3 ml/well) was added to the cells and incubated for 5 minutes at
room temperature. The cells were washed with PBS prior to the addition of X-gal
histochemical reaction mixture (3 ml/well) and incubated at 37 °C until the
development of blue colour could be confirmed under the microscope. The cells
were washed with PBS and the cells photographed (figure 2.5.2.1). All solutions are
detailed within appendix II.
Hec-1A Control Transfected with P-gal reporter
Figure 2.5.2.1 Images of Hec-1A cells transfected with the p-gal reporter construct
and stained for (3-galactosidase activity.
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2.5.3 pCAT transfection; elafin promoter
Hec-IA cells were transiently transfected with the constructs in figure 2.5.3.1. The
transfection conditions were optimised using the P-gal reporter construct (section
2.5.2). The cells were plated at 70% confluence into 6 well culture plates. The
transefection complex was optimised to the following: 4 pi Fugene HD transfection
reagent, 1 pg/ml plasmid DNA and 100 pi of Opti-MEM culture medium. The
mixture was added to the cells in a drop-wise fashion and the plates were gently
swirled to ensure an even distribution. The cells were incubated with the complex
for 12 hours prior to a change in media and the addition of treatments as detailed in
chapter 8.
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Figure 2.5.3.1 The vector maps used in the pCAT reporter assays. (A) The basic
vector lacks a promoter and therefore will not express the CAT enzyme and serves
as a negative control. (B) The control vector contains an SV40 promoter element
which will drive the expression of the CAT enzyme and serves as a positive control
for the experiments. (C) The basic vector with the SV40 promoter element replaced
with the elafin promoter sequence (blue).
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2.6 Immunohistochemistry
Immunohistochemistry was performed in order to detect SLPI and Elafin proteins in
fixed paraffin embedded tissue biopsies (5 pm). The protocols were optimised and
the appropriate conditions for maximum immunostaining were determined. The
antibodies used were obtained from a variety of sources and are detailed were
relevant.
2.6.1 Elafin
Tissue sections were dewaxed in xylene for 10 minutes and then rehydrated in
descending grades of alcohol. Subsequent to washing with PBS, a microwave antigen
retrieval step was performed (antigen retrieval solution; Vector). Non-specific
endogenous peroxidase activity was blocked with 2% hydrogen peroxide (Sigma
Aldrich) in distilled water for 10 minutes at room temperature. Avidin-biotin and
protein blocks were applied to the tissue sections for 20 minutes each at room
temperature with alternate 5 minutes PBS washes. Sections were then incubated
overnight at 4 °C with rabbit anti-elafin polyclonal antibody (Sallenave, Shulmann et
al. 1994) which was diluted at 1:700 in diluent (Dako antibody diluent). In negative
control sections the primary antibody was substituted with an approximately
equivalent Ig concentration of rabbit IgG (RIgG; Vector). Sections were incubated
with biotinylated goat anti-rabbit (Vector) and were then subjected to an avidin-
biotin peroxidase detection system (Vector; both were incubated for 30 minutes at
room temperature). The peroxidase substrate, diaminobenzidine (Dakocytomation),
was used to identify positive staining. Sections were counterstained with Harris's
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haematoxylin (Pioneer research chemicals), dehydrated in ascending grades of
alcohol, and mounted from xylene in Pertex (Cell path).
2.6.2 SLPI
SLPI immunohistochemistry was carried out on formalin fixed tissue obtained from
the endometrium, decidua and the fallopian tube. The use of SLPI
immunohistochemistry has been previously described (King, Fleming et al. 2002).
The method used was identical to the elafin immunohistochemistry protocol, with the
following exceptions. The primary antibody was mouse anti-SLPI (Hycult
Biotechnology) diluted at 1:20 in diluent, negative controls were incubated with an
equimolar concentration of mouse IgG (MIgG), and the secondary antibody was
biotinylated horse antimouse Ig (Vector).
2.7 Haematoxylin and Eosin Staining
Tissue sections were dewaxed in xylene for 10 minutes and then rehydrated in
descending grades of alcohol. The slides were then placed in Harris's haematoxylin
(Pioneer research chemicals) for 5 minutes and washed in tap water. The sections
were then placed in 1% acid alcohol solution for a few seconds and washed in tap
water. The sections were placed in eosin solution for 5 minutes and washed in tap
water. The sections were dehydrated in ascending grades of alcohol, and mounted
from xylene in Pertex (Cell path).
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2.8 Statistical Analysis
When the numerical variables were normally distributed the data was determined by
Student's t-test. When results did not conform to normal distribution, non-
parametric statistical analysis was performed. Fisher's protected least significant
difference (PLSD) was used to assign individual differences.
Statistical significance was assigned to ap value of <0.05.
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Chapter 3:




The female reproductive tract needs to be free of infection in order for there to be
successful conception, implantation and pregnancy. The presence of an effective
immune response is therefore essential in order to prevent deleterious infection or
inflammation. It is the function of the innate immune system primarily to fulfil this
role, by means of mucosal secretions and mechanical barriers. The natural
antimicrobials function as part of the innate protection of the female reproductive
tract, some are constitutively expressed whilst other respond to specific pathogens or
stimulus.
It has been shown that the expression of natural antimicrobials can be upregulated in
culture experiments with the addition of mimics of infection, such as pro¬
inflammatory cytokines TNFa and IL-ip (Sallenave, Shulmann et al. 1994;
Diamond, Russell et al. 1996; Russell, Diamond et al. 1996; King, Fleming et al.
2002; Tsutsumi-Ishii and Nagaoka 2003; Pivarcsi, Nagy et al. 2005). These
cytokines are expressed by the innate immune system in response to infection or
injury and serve as the initial mechanism of alert. Investigations into the effects of
specific pathogens have also been undertaken with the use of inactive cell surface
proteins that are recognised by the immune system. These are described as being
pathogen associated molecular patterns (PAMPs), and include lipopolysaccharide
(LPS), lipoteichoic acid (LTA) and Poly I:C; representative of G-ve, G+ve bacteria
and viruses, respectively (King, Fleming et al. 2002; Tsutsumi-Ishii and Nagaoka
2003; Pivarcsi, Nagy et al. 2005). The immune response to the recognition of
pathogens is mediated via the Toll-like receptors (TLR). Members of the TLR
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family have been shown to have specificity to different pathogens and to modulate
the expression of cytokines and natural antimicrobials in response (Pasare and
Medzhitov 2005).
Thus, the treatment of cell lines or primary tissue explants has allowed the study of
natural antimicrobial expression. It has been shown that natural antimicrobials
exhibit differential expression in response to stimuli, and natural antimicrobials
respond to specific pathogens. Some antimicrobials such as hBDl and SLPI have
been shown to be endogenously expressed (Bensch, Raida et al. 1995; Williams,
Brown et al. 2006). It has also been demonstrated that the differential expression of
these proteins is subject to modulation by the steroid hormone levels in the female
reproductive tract, as observed during the menstrual cycle (Fleming, King et al.
2003).
In this thesis, the use of the endometrial epithelial cell line Hec-IA (Kuramoto,
Tamura et al. 1972) was used to investigate further the role of inflammatory
mediators and steroid hormones in the expression of natural antimicrobials. The
Hec-IA cell line was derived from an endometrial adenocarcinoma of glandular
origin (Kuramoto, Tamura et al. 1972). Hec-IA cells have been utilised as a model
for the function of endometrial glandular epithelium (Fahey and Wira 2002), and are
considered to be a good model for the functional analysis of endometrial epithelia.
The aim of this study was to investigate the expression of natural antimicrobials by
the Hec-IA cell line and how this might be related to the role of these proteins in the
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endometrium. The data are presented in two sections; with part A, examining the
effects of mimics of infection (LTA and LPS) and part B investigating the role of the
steroid hormones in addition to inflammatory mediators (TNFa and IL-ip).
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Chapter 3 Part A:
Temporal expression of natural antimicrobials in an
endometrial epithelial cell line in response to inflammatory
mimics.
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3.2 Part A: Temporal expression of natural antimicrobials in an
endometrial epithelial cell line in response to inflammatory mimics.
Introduction
The presence of natural antimicrobials within the female reproductive tract has been
described previously (Svinarich, Wolf et al. 1997; Quayle, Porter et al. 1998; Valore,
Park et al. 1998; Quayle 2002; King, Critchley et al. 2003; King, Critchley et al.
2003; King, Fleming et al. 2003; Buhimschi, Jabr et al. 2004; Pivarcsi, Nagy et al.
2005). Inflammatory cytokines and other inflammatory mediators have also been
shown to up-regulate the mRNA expression of NAPs in the female reproductive tract
and in other systems such as the lung and the gut (Diamond, Russell et al. 1996; Jin,
Nathan et al. 1998; Krisanaprakornkit, Kimball et al. 2000). The female
reproductive tract has been demonstrated to yield differences in the endogenous
levels of inflammatory mediators such as the cytokines 1L-8, IL-ip and TNFa.
These levels are variable in response to the changes associated with the menstrual
cycle. The effect of time upon the expression of natural antimicrobial has not been
examined previously.
Hence, this study aimed to investigate the effect of time upon the expression of
natural antimicrobials in a human endometrial epithelial cell line. This was
motivated by inconsistencies observed in previous experiments involving the
treatment of cultured cell lines with inflammatory mimics and mediators of
inflammation. It became apparent that the temporal expression of natural
antimicrobials may be subject to time. Primarily these experiments were undertaken
with the aim of optimising conditions in order to allow for further study. The effect
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of the inflammatory cytokines TNFa, IL-lp; and mimics of infection LPS and LTA
upon antimicrobial expression in the cultured cell line Hec-IA was investigated. In
addition the effect of the cytokine TGFp-1 was also examined due to some
suggestions within the literature that this cytokine may have an anti-inflammatory
role.
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3.3 Materials and Methods
3.3.1 Cell culture
The human endometrial epithelial cell line Hec-IA (human endometrial cancer-one)
(Kuramoto, Tamura et al. 1972), were cultured as described in 2.2.3.








Table 3.3.1.1 Details of treatment of Hec-1A endometrial cell line. Supplier
information is contained within appendix I.
The treatments were added to the cells at time 0, and the reaction stopped and
processed at each of the relevant time points (2 - 24 hr) as detailed within the results
section An untreated control was included for each of the time points and this was
subsequently used as the comparator for the purposes of mRNA analysis.
3.3.2 RNA extraction and Q-RT-PCR
Following treatment and incubation for the relevant time point, the RNA was
extracted from the cells and cDNA prepared as described in section 2.3. Elafin,
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SLPI, IL-8 and hBD mRNA levels were measured in these cDNA samples by
quantitative PCR (2.3). The sequence details of the primer-probe sets used are
detailed in table 2.3.3.1, materials and methods.
3.3.3 Elafin and SLPI ELISA
The culture supernatants removed from the cells during the timecourse experiments
were collected, sterile filtered and assayed by the relevant ELISA as detailed in
section 2.4.
3.3.4 Statistics
The data presented in this chapter is illustrative and was not subjected to statistical
analysis. The charts aim to demonstrate that there is a temporal expression of mRNA
for the natural antimicrobials. An n=3 set of results was selected based upon the




3.4.1 (a) TNFa and IL-1 p have differential effects over time on the expression
of natural antimicrobials (elafin, SLPI, hBD1-3 and 5).
Elafin mRNA levels are increased in response to treatment with TNFa, IL-lp and
TNFa + IL-ip (figure 3.4.1.1). The addition of each of these treatments results in
different expression patterns relative to time. TNFa (green) alone mediates a lower
and more gradual increase in elafin mRNA when compared to the other treatments.
IL-ip (red) treatment demonstrates 3 peaks in mRNA expression at 6, 12 and 18 hr;
each of these peaks is immediately followed by a decrease in mRNA demonstrated at
the 8 hr and 14 hr time points. The addition of TNFa + IL-ip (blue) increases the
level of elafin mRNA further with maximal expression observed at 8 and 12 hr.
The amount of elafin protein (figure 3.4.1.2) demonstrates an increase and
accumulation over 24 hr. Protein levels increase and are maintained at the same
level between 8 and 12 hr. After 14 hr there is a sequential increase in the level of
elafin protein as the timecourse progresses
Study of SLPI mRNA exhibited a phasic level of expression (figure 3.4.1.3) in
response to treatment with TNFa + IL-1 p. Three peaks in mRNA levels are
observed at 6, 10 and 14 hr. The relative change in expression of SLPI mRNA is low
and this is attributed to the high endogenous levels prior to treatment. This assertion
is confirmed by the level of protein observed within the untreated culture media
controls (figure 3.4.1.4). SLPI protein increases and is cumulative over time in both
the untreated and treated culture media.
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The expression of human p-defensins 1 (3.4.1.5); 2 (3.4.1.6); 3 (3.4.1.7) and 5
(3.4.1.8), mRNA levels were measured across time in response to treatment with
TNFa + IL-ip. The patterns exhibit differences relative to time and to each other.
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Figure 3.4.1.1. Elafin mRNA expression within the Hec-1A cells in response to
treatment with TNFa (green), IL-1 (3 (red) and TNFa + IL-1 (3 (blue). The samples
were taken at 2 hourly intervals for 18 hr. The data are presented as relative to a
control (untreated Hec-1A cells for each time point); given a nominal value of 1,
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Figure 3.4.1.2. Elafin protein (pg/ml) detected within the culture media of HEC-1A
cells, treated with TNFa (green), IL-1 (3 (red), TNFa + IL-1 (3 (blue) and untreated
controls (pale blue) for 24 hr and collected at 2 hr intervals. Culture media treated
with TNFa + IL-1 (3 and IL-1 (3, elafin increase was significant (24hr vs 2hr; P<0.001).




































Figure 3.4.1.3. SLPI mRNA expression within the Hec-1A cells in response to
treatment with TNFa + IL-113. The samples were taken at 2 hourly intervals for 18
hr. The data are presented as relative to a control (untreated Hec-1A cells for each
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Figure 3.4.1.4. SLPI protein (pg/ml) detected within the culture media of Hec-1A
cells, treated with TNFa + IL-1 (3 (green) and untreated controls (pale green) for 14 hr
collected at 2 hr intervals and at 18 hr. Error bars are representative of ± s.e.m
between experiments (n=3).
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Figure 3.4.1.5. hBD1 mRNA expression within the Hec-1A cells in response to
treatment with TNFa + IL-1(3. The samples were taken at 2 hourly intervals for 18
hr. The data are presented as relative to a control (untreated Hec-1A cells for each
time point); given a nominal value of 1, mean ± s.e.m (n=3).
hBD2 in response to TNFa + IL-ip
Time (hr)
Figure 3.4.1.6. hBD2 mRNA expression within the Hec-1A cells in response to
treatment with TNFa + IL-ip. The samples were taken at 2 hourly intervals for 18
hr. The data are presented as relative to a control (untreated Flec-1A cells for each
time point); given a nominal value of 1, mean ± s.e.m (n=3).
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Figure 3.4.1.7. hBD3 mRNA expression within the Hec-1A cells in response to
treatment with TNFa + IL-ip. The samples were taken at 2 hourly intervals for 18
hr. The data are presented as relative to a control (untreated Hec-1A cells for each
time point); given a nominal value of 1, mean ± s.e.m (n=3).
Figure 3.4.1.8. hBD5 mRNA expression within the Hec-1A cells in response to
treatment with TNFa + IL-1 p. The samples were taken at 2 hourly intervals for 18
hr. The data are presented as relative to a control (untreated Hec-1A cells for each
time point); given a nominal value of 1, mean ± s.e.m (n=3).
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3.4.1 (b) The effect of inflammatory cytokines TNFa + IL-1p upon the
expression of IL-6 and IL-8
In order to elucidate further the patterns of expression observed with natural
antimicrobials, an investigation into the effects upon other inflammatory mediators
such as the pro-inflammatory cytokine IL-8; and the anti-inflammatory cytokine, IL-
6 was undertaken. These cytokines function as part of the innate immune response
and respond to the same stimuli as that described for the natural antimicrobials.
Thus, the response of these cytokines over time was investigated and compared to
that of the natural antimicrobials.
Interleukin-6 mRNA, figure 3.4.1b (A), is increased in response to treatment with
TNFa, IL-1 p and TNFa + IL-1 p. Messenger RNA expression is maximal for each of
the conditions at the 6 hr time point. TNFa and IL-|3 elicit a short response with a
decrease in IL-6 mRNA being noted after 6 hr. This decline in expression was
observed to continue for the remainder of the examined time, with TNFa induced a
slight increase 10 - 12 hr. The greatest (approx. 30) relative increase in IL-6 mRNA
resulted from the addition of TNFa + IL-1 (3 and at 6 - 8 hr, a gradual decrease is
evident after 10 hr, and from 12 hr until cessation of experiment (18 hr) a relative
difference of 4 of IL-6 mRNA is consistent and represents the levels observed at the
beginning of the timecourse at 2-4 hr.
Interleukin-8 mRNA (B) is maximal (226 relative expression) and most rapid (4 hr)
in response to TNFa + IL-1 p (blue) and is immediately followed by a decrease (64
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relative difference) at 6 hr. At 8 hr IL-8 increases to that observed at 2 hr (1st time
point) of 140 relative expression; before gradually decreasing from 10 - 18 hr.
Interleukin-ip brings about a 140 relative increase in IL-8 mRNA expression at 2 hr
and this is maintained at 4 hr. Maximal IL-8 expression in response to IL-ip is noted
after 6 hr (200). There then follows a rapid decrease (18) at 8 hr, with a subsequent
increase to 40 at 10 hr, which is then maintained until the end of the experiment.
TNFa increases IL-8 mRNA 40 at 2 hr with a maximal increase observed at 6 hr






Figure 3.4.1 (b) lnterleukin-6 (A) and IL-8 (B) mRNA expression within the Hec-1A
cells in response to treatment with TNFa + IL-1(3 (note the different scales for the y
axes). The samples were taken at 2 hourly intervals for 18 hr. The data are
presented as relative to a control (untreated Hec-1A cells for each time point); given
a nominal value of 1, mean ± s.e.m (n=3).
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3.4.2 Reciprocal patterns of elafin and SLPI mRNA in response to treatment
with TNFa + IL-1p in HEC-1A cells.
SLPI and elafin mRNA expression in response to time was observed to demonstrate
a reciprocal pattern. The relative values for each protein was plotted onto the same
chart (figure 3.4.2.1). It appears that the drop in elafin mRNA coincides with an
increase in the level of SLPI mRNA and vice versa. This is evident at 6, 8, 10, 12
and 14 hr. The expression of SLPI is endogenous and present at high levels basally,
and thus demonstrates a smaller change. Whilst elafin expression is in response to
stimulus and therefore exhibits a higher 'relative change' over an untreated control.
The mRNA of the respective proteins is presented on the same graph with two axes
in order for relative changes to be compared directly.
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Figure 3.4.2.1 Messenger RNA expression over time, SLPI (A), elafin (B) and both
(C). The axis on the left is representative of SLPI (green), whilst that on the right
hand side is relevant to elafin (blue). Note the difference in the scale for elafin and
SLPI.
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3.4.3 The effect of TGFp-1 on natural antimicrobial mRNA expression of cells
treated with inflammatory mediators.
The results of the timecourse experiments demonstrated the upregulation of natural
antimicrobials in response to treatment with mimics of infection. However, it was
also apparent that there was a rapid downregulation in mRNA expression following
peak expression levels. This led us to question the possibility of interactions with
anti-inflammatory mediators. It has been suggested in the literature that TCIF[3-1
may have such a role during an inflammatory event (Fadok, Bratton et al. 1998).
Therefore it was decided to examine the effects of TGFP-1 on the expression of
natural antimicrobials in epithelial cells treated with mimics of infection.
The addition of TGFP-1 to Hec-IA cells treated with IL-lp, LPS + IL-lp and LTA +
IL-ip reduced the expression of elafin mRNA when compared to treatment with the
inflammatory mediators alone figure 3.4.3.1. However, there appeared to be little or
no effect of TGFp-1 upon elafin mRNA when treated with either LPS or LTA. The
decrease in elafin mRNA expression observed in cells treated with TGFp-1 + IL-ip
compared with IL-1 p; and TGFp-1 + IL-ip + LTA compared with IL-ip + LTA was
significant (n=4; P<0.001).
Cells were also treated with the pro-inflammatory cytokines IL-1P + TNFa, with
(red) and without (blue) TGFp-1; figure 3.4.3.2. Elafin expression was shown to be




Control LPS LTA IL-ip LPS + IL-1p LTA+IL-1P
Figure 3.4.3.1 Elafin mRNA expression in Hec-1A cells in response to treatment
with mimics of infection; LPS, LTA, IL-1 (3, LPS + IL-ip and LTA + IL-1p (blue); the
addition of TGFP-1 (red). The data are presented as relative to a control (untreated
HEC-1A cells for each time point); given a nominal value of 1, mean ± s.e.m. Each
experiment (n=4) was performed at 4, 8 and 12 hr; the 3 time points were averaged
and served to allow for variances in response to time.
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Figure 3.4.3.2 Elafin mRNA expression in Hec-1A cells in response to treatment
with pro-inflammatory cytokines TNFa + IL-ip (blue); the addition of TGFp-1 (red).
The data are presented as relative to a control (untreated Hec-1 A cells for each time
point); given a nominal value of 1, mean ±s.e.m. Each experiment (n=8) was
performed at 4, 8 and 12 hr; the 3 time points were averaged and served to allow for
variances in response to time.
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Summary of results:
1. Natural antimicrobial expression is differential across time.
2. Natural antimicrobial expression is phasic and distinct for each protein.
3. Messenger RNA expression of elafin and SLPI appears to be reciprocal.
4. TGFP-1 inhibits the inflammatory expression of elafin mRNA
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3.5 Discussion
Mucosal surfaces act as a barrier to infection and the epithelial cells of these surfaces
are the main components of this barrier. Epithelial cells are known to express a
number of inflammatory mediators in order to ensure an adequate immune response.
In the event of an infection, epithelial cells express pro-inflammatory cytokines such
as IL-8, IL-ip and TNFa, which function centrally to the innate immune response.
These cytokines have also been demonstrated to have a role in the expression of
natural antimicrobials, with the treatment of cell lines such as those of the lung
(Sallenave, Shulmann et al. 1994; Tsutsumi-Ishii and Nagaoka 2003); a breast cancer
cell line (King, Morgan et al. 2003) and a vaginal epithelial cell line (Pivarcsi, Nagy
et al. 2005). In the endometrium the cell lines MFE-296 (Hackenberg, Beck et al.
1994) and HES (Desai, Kennard et al. 1994) have similary been shown to be
responsive to pro-inflammatory cytokines (King, Fleming et al. 2002) causing an
increase in natural antimicrobial expression. It has been shown in this thesis that the
endometrial cell line Hec-IA expresses natural animicrobials both constitutively and
through stimulation with inflammatory cytokines. Although, a rapid response to
infection is necessary it is also important that such a reaction is short acting and
downregulated in order to prevent too much inflammation which can be damaging to
the host. Thus, as part of the innate response there are also anti-inflammatory
mediators which serve to reduce the expression of pro-inflammatory mediators.
There have been many anti-inflammatory mediators described in the literature
including the cytokine TGFp-1, which has been shown to inhibit the expression of
SLPI (Jaumann, Elssner et al. 2000).
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In this chapter the expression of natural antimicrobials by Hec-IA cells has been
demonstrated to be both temporal and differential in relation to time. The expression
pattern of the (3-defensins, SLPI and elafin were found to be different, with many
showing considerable overlap, for example across the 2-14 & 18 hr period. The
expression patterns of the natural antimicrobials are summarised, demonstrating the
times of maximal expression in relation to one another (figure 3.5.1). There is
maximal expression of different antimicrobials at different times with some being co-
expressed, such as hBDl and hBD3 at 18 hr. It has also been suggested within the
literature that the actions of natural antimicrobials and/or expression may also be
synergistic or additive in nature (Nagaoka, Hirota et al. 2000; Singh, Tack et al.
2000; Yanagi, Ashitani et al. 2007). Perhaps the overlapping nature of mRNA
expression across time is also suggestive of such combined actions.
The schematic summary of the peaks and troughs in mRNA expression of natural
antimicrobials (figure 3.5.1) demonstrates that there is broad coverage across time
with at least one antimicrobial (mRNA) being expressed at each time point. It was
also consistently observed that maximal expression of mRNA was obtained in
response to treatment with both IL-ip and TNFa, suggesting a synergistic action of
these cytokines upon the expression of natural antimicrobials (King, Fleming et al.
2002). This interaction between IL-ip and TNFa has also been previously described
in other systems (Moore, Lahiri et al. 2001).
The analysis of elafin and SLPI protein levels showed an accumulation in
concentration, however, it is of note that there are high levels of SLPI protein in the
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untreated cell culture media - confirming the observations of constitutive expression.
However, questions arise surrounding the accumulative increase of SLPI protein
observed in untreated samples - timed constitutive expression; stress of serum
removal? Elafin protein was detected at low levels after 8 hr, which may be an
indication of the time required from the time of mRNA production to translation.
However, it is difficult to make this conclusion with the current data and presently
the time between elafin mRNA expression and the production of protein is not
known. It may be relevant that the fall in the level of elafin mRNA (fig 3.4.1.1)
expression appears to be mirrored in a slightly lowered level of protein (fig 3.4.1.2)
at 10 hr.
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Summary of expression patterns obtained from treatment
of HEC-1A cells with TNFa + IL-1P across time
A Schematic summary of human p-defensin expression during a timecourse
B
6 8 10 12 14 18
I hBDlfM hBD3
I h8D2l 1 h8D5
Schematic summary of elafin and SLPI expression during a timecourse
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Figure 3.5.1 Schematic summary of the maximal expression of defensins 1-3 & 5
(A); SLPI and Elafin (B) and pro-inflammatory cytokines (C) in relation to time,
based upon the mRNA data presented in this chapter.
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It has been suggested that many innate immune mediators are produced as precursors
and stored, and that in the event of infection or injury are spliced or cleaved into their
active form (Raj and Dentino 2002; Guyot, Zani et al. 2005; Weeks, Tanabe et al.
2006). It is known and was discussed in chapter 1 that most NAPs have pre-active
forms, and currently, there is much speculation into the possible mediators or
enzymes involved in this transformation.
The examination of mRNA of the cytokines IL-6 and IL-8 was also undertaken, this
was to enable a comparison to be made with other innate immune mediators. The
cytokines also demonstrated temporal mRNA expression in response to treatment
with inflammatory mediators; however, this was more gradual. This suggested that
the rapid up-regulation and down-regulation in natural antimicrobial mRNA
expression may be unique to them, as opposed to a common response exhibited by
all innate immune respondents. There is also the possibility of a feedback
mechanism whereby the timed response of one molecule brings about the
upregulation of another. Thus, the upregulation of inflammatory cytokines such as
IL-8 may be responsible for the sequential increase in NAP mRNA as observed
herein. It would be useful to undertake experiments whereby the relevant cytokines
are antagonised or blocked, and the resultant expression patterns of NAPs examined.
It also has to be considered that in this artificial set-up there is no adaptive immune
response available. The consequence is that many of these proteins function as short
acting alarm signals and as chemotactic agents for the adaptive mediators, which are
thought to 'take over' and resolve inflammation etc. Perhaps, this lack of adaptive
response gives rise to re-signalling events as a possible explanation for the phasic
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and transient expression of NAP mRNA. The upregulation of natural antimicrobial
mRNA may serve as signalling mechanism for the action of other molecules. A
consequence of this may be the downregulation of the NAPs, in the form of a self-
regulatory mechanism in the prevention of sepsis or damage resulting from an over
zealous immune response.
The examination of the mRNA expression patterns of SLPI and elafin demonstrated
a reciprocal relationship. In order to show this relationship the relative mRNA data
for the respective proteins was plotted on two axes (figure 3.4.2.1). The suggestion
of a relationship or association between these two molecules has not previously been
demonstrated. A previous observation on the expression of these proteins in the
endometrium has shown them to be expressed at different times during the menstrual
cycle (King, Critchley et al. 2003; King, Critchley et al. 2003; King, Fleming et al.
2003). The possible association between these two proteins is examined further in
the later chapters of this thesis (chapters 6-8).
There are a number of molecules that have been reported to have an anti¬
inflammatory mode of action within the immune response. TGFp-1 has been shown
to inhibit the expression of SLPI mRNA in human bronchial epithelial cells
(Jaumann, Elssner et al. 2000). The effect of the cytokine TGFp-1 was investigated
as part of this study in order to examine its possible role in the limitation of an
inflammatory response. Here it is shown that TGFP-1 has an inhibitory effect upon
the expression of elafin mRNA (figure 3.4.3.1) and this has not previously been
observed. It has been reported that TGFp-1 is decreased during the secretory phase
127
of the menstrual cycle in rhesus monkeys (Ace and Okulicz 2004). Thus, it may be
possible that the decrease in the level of TGFp-1 in the secretory phase may in part
contribute to the observed increase in elafin expression during the late secretory and
menstrual phases of the human menstrual cycle. However, there have been no
conclusive studies of cyclical changes in TGFp-1 expression, but, an increase in the
level of the isoform TGFP-3 is observed in the late secretory phase of the human
endometrium (Jones, Stoikos et al. 2006). The co-treatment of the Hec-IA
endometrial epithelial cell line with TGFp-1 in this chapter has provided some
preliminary data that has shown that there is an inhibition of SLPI mRNA,
confirming the observations of Jaumann et al. in bronchial epithelial cells (Jaumann,
Elssner et al. 2000), figure 3.5.2.
o 6
SLPI mRNA (Hec-1 A cells)
TNFa + IL-1 p
n=2
TNFa + IL-1 p + TGFp-1
Figure 3.5.2 SLPI mRNA expression in Hec-1 A cells in response to treatment with
pro-inflammatory cytokines TNFa + IL-1 p (green); the addition of TGFP-1 (red). The
data are presented as relative to a control (untreated Hec-1 A cells for each time
point); given a nominal value of 1, mean ±s.e.m. Each experiment (n=2) was
performed at 4, 8 and 12 hr; the 3 time points were averaged and served to allow for
variances in response to time
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The expression of hBD4 mRNA was not detected during this study and this is
consistent with the literature. This protein is not upregulated by inflammatory
cytokines (De Smet and Contreras 2005). The expression of hBD4 has been
observed in the testis (Yamaguchi, Nagase et al. 2002) and in the proliferative
endometrium (King, Fleming et al. 2003). There have been no reports of hBD4
expression in epithelial cell lines.
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In summary, it has been shown here that the expression of natural antimicrobial
mRNA is both temporal and differential in relation to time. It has also been
demonstrated that the expression patterns (figure 3.5.1) for the natural antimicrobials
may be suggestive of combined or cooperative action. The expression patterns for
SLPI and elafin appear to be reciprocal in relationship, and will be investigated
further (chapters 6-8).
The cytokines IL-8 (inflammatory) and IL-6 (anti-inflammatory), exhibited a
different pattern of mRNA expression than that observed for the natural
antimicrobials (figure 3.5.1). Finally, it has been shown that TGFp-1 has an
inhibitory action on elafin mRNA expression and this has been previously reported
for SLPI (Jaumann, Elssner et al. 2000). It is not possible to conclude whether this
effect is direct or indirect based on the data presented and this issue will be subject to
further investigation in this thesis (chapt 8). The data presented in this chapter is
summarised in figure 3.5.3.
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Schematic summary of chapter 3 (A)
Mimics of Infection Natural Antimicrobials
TNFa + IL-1 p /\ 1 TGFp-1
< \ 1 ' ^Feedback I





(Jaumann et al. 2000)
Endometrial Epithelial Cells
Figure 3.5.3 Mimics of infection and pro-inflammatory cytokines up-regulate the
expression of NAPs in the endometrial cell line (Hec-1A). Timecourse analysis
demonstrated a sequential down-regulation of NAPs. Further investigation into the




There were a number of questions that arose during the investigations undertaken
within this chapter. The timecourse experiments demonstrated the rapid upregulation
of natural antimicrobials. However, the observation that this upregulation was
followed by downregulation gave rise to the question of what factor(s) or
mechanisms could be responsible for this downregulation. As discussed previously,
from the literature and the work presented herein, TGF(3-1 has been identified as an
inhibitor for the expression of both SLPI and elafin mRNA. In order to fully
elucidate the inhibitory nature of TGFp-1, it would be necessary to examine the
effects upon other innate immune effectors, such as the P-defensins and both pro-
and anti-inflammatory cytokines. It may be that TGFp-1 mediates its inhibitory
effect indirectly through interaction with other cytokines for example if TGFP-1
could also downregulate epithelial production of pro-inflammatory cytokines, such
as IL-lp and TNFa.
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Chapter 3 Part B:
The effect of steroid hormones and inflammatory mediators
on the expression of natural antimicrobials in an endometrial
epithelial cell line
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3.6 Part B: The effect of steroid hormones and inflammatory mediators on
the expression of natural antimicrobials in an endometrial epithelial cell line.
Introduction
It has been shown that natural antimicrobial expression is variable through the
menstrual cycle (King, Critchley et al. 2003; King, Critchley et al. 2003; King,
Fleming et al. 2003). It has been further shown that this expression can be
suppressed in the presence of hormonal contraceptives (Fleming, King et al. 2003).
The hormonal influence over natural antimicrobial expression could be direct, for
example, SLP1 which has been shown to have a progesterone response element
(PRE) like sequence (Velarde, Iruthayanathan et al. 2006). The effect may also be
indirect as hormones are known to modulate the expression of other molecules such
as pro-inflammatory cytokines which may in turn act upon natural antimicrobials
(Tabibzadeh and Sun 1992; Simon, Piquette et al. 1993; Hunt, Miller et al. 1997).
SLPI has previously been demonstrated to be maximal during the mid secretory
phase of the menstrual cycle when circulatory progesterone levels are maximal
(King, Critchley et al. 2003). SLPI was also found to be upregulated in vitro in the
breast cancer cell line (T47D) in response to treatment with progesterone (King,
Morgan et al. 2003). Elafin is upregulated during the progesterone withdrawal
mediated late secretory phase and is maximally expressed during the menstrual phase
when progesterone levels are low (King, Critchley et al. 2003). Human P-defensin 2
has also been shown to be maximally expressed during the menstrual phase
suggestive of progesterone inhibition (Fleming, King et al. 2003). Human p-defensin
1 has been reported to be constitutively expressed in other systems
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(Krisanaprakornkit, Weinberg et al. 1998; O'Neil, Cole et al. 2000). In the
endometrium it has been shown that hBDl mRNA is maximal during times of high
progesterone (King, Fleming et al. 2002). Previous work within our laboratory
demonstrated the maximal expression of granulysin in late secretory endometrium
and it has been suggested that this may originate from the uNK cells (Fleming, King
et al. 2003; King, Critchley et al. 2003).
This study investigates the expression of natural antimicrobials in the endometrial
epithelial cell line (Hec-1 A), in response to mimics of infection and the sex steroid
hormones. How this relates to antimicrobial expression in endometrium through the
menstrual cycle and how this might relate to function will be considered. The
expression of natural antimicrobials both in response to sex steroids and without has
not previously been described for Hec-1 A cells in culture.
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3.7 Materials and Methods
3.7.1 Cell culture and treatments
The Hec-IA cells were cultured as described in section 3.3.1. The epithelial cells
were then treated with inflammatory mediators IL-ip and TNFa, (table 3.3.1.1) with
the addition of the hormonal steroid progesterone (10 6 M; (Kelly, King et al. 2002))
and the progesterone antagonist mifepristone (RU486; 10~6 M). Progesterone and
RU486 are prepared in ethanol and thus ethanol was added to the relevant controls.
3.7.2 RNA extraction and Q-RT-PCR
Following treatments the cells were harvested in Tri reagent, RNA extracted and
cDNA prepared as described in section 2.3.2. The level of natural antimicrobial
mRNA was determined using Taqman RT-PCR (see section 2.3.3 for details of the
method, the sequence details for all primer sets used are detailed in table 2.3.3.1).
3.7.3 Statistical analysis
The PCR results in this chapter were analysed by ANOVA for significant difference.
Fisher's protected least significant difference (PLSD) was used to assign individual
differences (PRISM). No analysis was performed on the co-culture data due to low
number.
Each n=l is equal to the mean of 3 individual time points (4, 8 and 12 hr), in order to
account for the variances in expression across time and allow for comparison on the
basis of treatment conditions alone.
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3.8 Results
3.8.1 In vitro treatment of HEC-1A cells with progesterone increases elafin
mRNA expression in response to inflammatory mimics.
Elafin mRNA was increased in the presence of progesterone when compared to cells
treated in RPMI culture media (figure 3.8.1.1). There is a 30 relative level of
increase in elafin mRNA in cells treated with IL-p and progesterone; and an 80-point
increase in response to IL-(3 + TNFa. The data are presented as relative to a control
(untreated Hec-IA cells for each time point); given a nominal value of 1, mean ±
s.e.m. Three time points 4, 8 and 12 hr were obtained and the combined mean value
equated to n=l; to allow for the fluctuations in expression observed in part A
3.8.2 Progesterone stimulates granulysin mRNA expression in response to
inflammatory mimics.
Granulysin mRNA increased in the presence of progesterone and mimics of infection
when compared to an untreated control (figure 3.8.2.1). At least a 15 relative
increase was observed when Hec-IA cells where treated with IL-ip and progesterone
(blue), when compared to non-progesterone (RPMI) IL-ip treated cells (green;
undetected). However, the addition of TNFa, EPS and ETA with IL-ip reduced the
level of granulysin mRNA compared with IL-lp alone. The samples treated with
inflammatory cytokines in the presence of progesterone demonstrated a significantly












Figure 3.8.1.1 Elafin mRNA expression in Hec-1A cells treated with the pro¬
inflammatory cytokines TNFa, IL-1 p and in combination. The treatments were
undertaken with or without progesterone. The increase in elafin expression in the
presence of progesterone is significantly increased for treatment with IL-1 (3 (red;
P<0.05) and IL-113 + TNFa (blue; P<0.001). Data presented as relative to an
untreated control (progesterone is in an ethanol solution thus, controls were treated




control IL-1B TNFa + IL-1 B LPS + IL-1 B LTA + IL-1B
Figure 3.8.2.1 Granulysin mRNA expression in Hec-1A cells treated with IL-1P,
TNFa + IL-P; LPS + IL-1 (3; and LTA + IL-1 (3. The treatments were undertaken with
(blue) or without progesterone (green). Data presented as relative to an untreated
control (progesterone is in an ethanol solution thus, controls were treated with an
equal volume of ethanol), and represents 3 separate time points (4, 8 & 12 hr), n=4.
P<0.001
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3.8.3 The comparative effect of progesterone and progesterone antagonism
with RU486 on the expression of natural antimicrobials.
The effect of the progesterone and the progesterone antagonist RU486 upon the
expression of antimicrobials was examined.
SLPI mRNA (figure 3.8.3.1) was maximal with progesterone and inflammatory
mediators TNFa + IL-ip; at least 4 points greater than the RPMI equivalent
(PO.OOl). The synergistic response usually observed with TNFa + IL-ip treatment
is not observed in the cells treated in RPMI. Concurrent treatment with RU486 or
RU486 + progesterone, and pro-inflammatory cytokines; resulted in a decrease in the
SLPI mRNA when compared to RPMI (not significantly)
Elafin mRNA (figure 3.8.3.2) was observed to increase when treated with pro¬
inflammatory cytokines in the presence of progesterone; IL-ip prog 27 points
increase over IL-ip RPMI; TNFa + IL-ip 30-point increase and there was no effect
with TNFa alone. Treatment with RU486 decreased elafin mRNA and the
synergism was lost when compared to progesterone treatment, however, the addition
of RU486 demonstrated a 10-point increase over that observed for RPMI with IL-ip,
whilst there was no change in the response to IL-1 p + TNFa. Maximal elafin mRNA
expression was observed in the presence of progesterone + RU486 when compared
to all other treatments. The greatest increase was demonstrated with IL-1 p 25-point
increase over the progesterone counterpart. It was also apparent that the synergistic
effect obtained from both cytokines is not maintained under these conditions,
although there is a 6-point increase over progesterone alone it is 13-point lower than
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the level obtained from IL-ip alone under the same treatment conditions. Both the
RU486 and the RU486 + progesterone treatments give rise to this 'inhibition of
synergism' phenomenon.
Human P-defensin 2 mRNA (figure 3.8.3.3) was decreased when treated with
progesterone in comparison with cells treated without the presence of progesterone
(RPMI). In the presence of progesterone, a 45-point decrease in expression in
response to IL-lp; and a 65-point decrease in response to treatment with IL-ip +
TNFa, when compared to treatment without progesterone. A further decrease was
observed in samples treated in the presence of RU486 - 10-point reduction in
comparison with prog samples for IL-ip and a 17-point reduction for IL-lp + TNFa.
Concurrent treatment with both progesterone and RU486 gave rise to maximal hBD2
expression within these experiments. 110 IL-ip and a 152 for IL-ip + TNFa; 66 and
94
Nearly a 45 point increase over RPMI for IL-IP; and a 58-point increase for





RPMI PROG RU486 PROG + RU486
Figure 3.8.3.1 SLPI mRNA expression in Hec-1A cells treated with the pro¬
inflammatory cytokines TNFa, IL-1 (3 and in combination. The treatments were
undertaken with RPMI, progesterone, RU486 and progesterone + RU486. The
increase in SLPI expression in the presence of progesterone is significantly
increased for treatment with IL-1 p + TNFa (blue; P<0.001). Data presented as
relative to an untreated control (progesterone and RU486 are in an ethanol solution
thus, controls were treated with an equal volume of ethanol) and represents 3
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RPMI PROG RU486 PROG + RU486
Figure 3.8.3.2 Elafin mRNA expression in Hec-1A cells treated with the pro¬
inflammatory cytokines TNFa, IL-1(3 and in combination. The treatments were
undertaken with RPMI, progesterone, RU486 and progesterone + RU486. The
increase in elafin expression in the presence of progesterone is significantly
increased for treatment with IL-ip (red; P<0.01) and IL-1(3 + TNFa (blue; P<0.001).
Treatment in the presence of progesterone + RU486 increases elafin expression
significantly with IL-1 (3 (red; P<0.001) and ll_-1(3 + TNFa (blue; P<0.001). Data
presented as relative to an untreated control (progesterone and RU486 are in an
ethanol solution thus, controls were treated with an equal volume of ethanol), and
represents 3 separate time points (4, 8 & 12 hr), n=5.
143
180
Human p-defensin 2 mRNA expression
ED Control
RPMI PROG RU486 PROG + RU486
Figure 3.8.3.3 Human P-defensin 2 mRNA expression in Hec-1A cells treated with
the pro-inflammatory cytokines TNFa, IL-1P and in combination. The treatments
were undertaken with RPMI, progesterone, RU486 and progesterone + RU486. The
decrease in hBD2 expression in the presence of progesterone is significant for
treatment with IL-1 p (red; P<0.01) and IL-1 p + TNFa (blue; P<0.001). In the
presence of RU486, there is significant decrease in hBD2 mRNA in response to IL-
1P (red; P<0.001) and IL-1 p + TNFa (blue; P<0.001). Treatment in the presence of
progesterone + RU486 increases hBD2 expression significantly with IL-1 p (red;
P<0.001) and IL-1 p + TNFa (blue; P<0.001). Data presented as relative to an
untreated control (progesterone and RU486 are in an ethanol solution thus, controls
were treated with an equal volume of ethanol), and represents 3 separate time
points (4, 8 & 12 hr), n=5.
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3.9 Discussion
The effect of the sex steroid progesterone and the antagonist RU486 upon the
expression of natural antimicrobials in response to inflammatory mediators in the
Hec-1 A cells was examined and is summarised in table 3.9.1. A comparison with the
published observations in primary endometrial material is summarised in table 3.9.2.
Hec-1 A cells RPMI Progesterone RU486 Progesterone+ RU486
Elafin T TT No change TTT
Granulysin tt n/a n/a
hBD2 T U TT
SLPI T TT i i
Figure 3.9.1 Elafin, hBD2 and SLPI mRNA was expressed in response to TNFa +
IL-1(3. Granulysin mRNA was undetected until the addition of progesterone, which
also upregulated elafin and SLPI over the levels observed in RPMI. Human p-
defensin 2 was downregulated in the presence of progesterone. Elafin mRNA levels
were unchanged in the presence of RU486 when compared to RPMI, whilst hBD2
was greatly decreased and SLPI slightly decreased. Progesterone + RU486 greatly
increased the level of elafin mRNA, increases hBD2 level above that observed for
RPMI and decreases SLPI below the observed RPMI levels of SLPI.
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hBD2 TT - - (Fleming, Kinget al. 2003)




Figure 3.9.2 Summary of natural antimicrobial expression in primary endometrial
material across the menstrual cycle.
It has been previously shown that elafin is maximally expressed during the menstrual
phase of the menstrual cycle, when the circulatory concentration of progesterone is
low (King, Critchley et al. 2003). This may be suggestive of progesterone being
inhibitory upon the expression of elafin. This was previously investigated further
with the uterine epithelial cell lines ishikawa and HeLa, which have been shown not
to express the nuclear progesterone receptor and were thus, not considered to be
good models for progesterone responsiveness. The breast epithelial cell line T47D
has been demonstrated to constitutively express the nuclear progesterone receptor
(Horwitz, Mockus et al. 1982) and have been utilised in the study of elafin and SLPI
(King, Morgan et al. 2003). King et al, demonstrated that there was no effect upon
elafin expression with the addition of progesterone with the T47D cell line and
suggested that the cyclic dependence of elafin expression in the endometrium may be
as an indirect consequence of progesterone mediated regulation of other
inflammatory mediators (King, Morgan et al. 2003). The endometrial epithelial cell
line Hec-IA has been shown to express the nuclear progesterone receptor (Di Nezza,
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Jobling et al. 2003). It has been demonstrated in this chapter that the Hec-IA cell
line shows an increase in elafin mRNA expression in response to treatment with
progesterone (figure 3.8.1.1 and 3.8.3.2). This is in contrast with the data presented
in chapter 5 and reported previously (King, Critchley et al. 2003), where elafin is
expressed in primary endometrial material obtained when circulating levels of
progesterone were low. Primary endometrial material is made up of different cell
types the major components being epithelial and stromal cells. Thus, it could be that
the role of progesterone is indirect and acts via paracrine factor(s), which are not
present when treating an epithelial cell line in culture. The role of stromal cells upon
the epithelial expression of natural antimicrobials is addressed in chapter 4.
The treatment of Hec-IA cells with progesterone also demonstrated a significant
increase in the expression of granulysin mainly a product of T lymphocytes and
natural killer cells (Krensky 2000), and has not previously been shown to be
expressed in an epithelial cell line. In primary endometrial material, granulysin was
found to be maximally expressed during the late secretory phase of the menstrual
cycle concurrent with the withdrawal of progesterone (King, Critchley et al. 2003)
and the influx of NK cells (Fleming, King et al. 2003). The greatest level of
granulysin mRNA in the Hec-IA cells was observed with the combined treatment of
progesterone and IL-1(3. The consistently observed synergism observed with the
addition of other inflammatory mediators with IL-1(3 has not been repeated with
respect to granulysin expression (figure 3.8.2.1). The data suggest that the addition
of TNFa, LPS or LTA inhibits the level of granulysin expression observed with IL-
1 (3 alone. In order to further understand the effect of progesterone and inflammatory
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mediators upon the epithelial expression of granulysin, further experiments with
TNFa, LPS and LTA without IL-ip would be necessary.
SLPI is maximally expressed during the mid secretory phase of the menstrual cycle
which is concurrent with a high circulating concentration of progesterone (King,
Critchley et al. 2000). The increase in SLPI expression in response to progesterone
was also shown with the treatment of cervical explants (Denison, Calder et al. 1999).
The treatment of the cell line T47D with progesterone and inflammatory mediators
gave rise to an increase in SLPI expression (King, Morgan et al. 2003). The data
presented herein demonstrates that SLPI is expressed by the Hec-IA cell line and is
also increased in response to TNFa + IL-ip in the presence of progesterone (figure
3.8.3.1). This increase was prevented with the addition of the progesterone
antagonist RU486. SLPI has been described as a progesterone regulated gene and
was shown to possess a progesterone response element (PRE) (King, Morgan et al.
2003). The Hec-IA cell line is derived from glandular epithelium and SLPI has been
shown to be predominantly expressed in the glands of the endometrium (King,
Critchley et al. 2000). Thus, the Hec-IA cells represent a fair model for the in vitro
investigation in to the role of SLPI in the endometrium.
The treatment of Hec-IA cells with the progesterone antagonist RU486 increased the
expression of elafin in response to IL-1 p, 10-point over RPMI (figure 3.8.3.2). There
was no change observed upon the IL-1 p + TNFa combination with the addition of
RU486, but, IL-ip alone produced a higher level of elafin (not significant). The
presence of both progesterone and RU486 enhanced the response to IL-1 (3 and IL-1 p
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+ TNFa over the increase observed in the presence of progesterone. This may
suggest that the withdrawal of progesterone acts as a stimulator for the increase in
elafin expression and would support the observation that elafin is increased in the
late secretory - perimenstrual phase, when progesterone levels are in decline (King,
Critchley et al. 2003). However, as was observed in the presence of RU486, elafin
expression is maximal in response to treatment with IL-ip as opposed to IL-ip +
TNFa in the presence of RU486 + progesterone. There is also a slight decrease in
elafin in response to treatment with TNFa in the presence of RU486 and there could
be an inhibitory effect on TNFa, thus explaining the loss of synergism between
TNFa and IL-ip.
Human P-defensin 2 mRNA expression was inhibited when treated with TNFa and
IL-ip in the presence of progesterone (figure 3.8.3.3) in the Hec-IA cells. Human P-
defensin 2 has been shown to be maximally expressed during the menstrual phase
(Fleming, King et al. 2003), which supports the data observed with the Hec-IA cells.
This may be suggestive of a direct inhibitory role for progesterone in the expression
of hBD2 or an indirect effect via other progesterone mediated factor(s). As was
observed for elafin, there is a further increase in hBD2 mRNA expression in the
presence of RU486 and progesterone, which may also indicate a response to
progesterone withdrawal.
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In summary, the presence of nuclear progesterone receptors in the Hec-IA
endometrial epithelial cell line, allows for the analysis of effects upon antimicrobials
mediated by progesterone. Herein it has been shown that progesterone upregulates
SLPI, elafin and granulysin mRNA, whilst downregulating hBD2. The upregulation
of SLPI is in support of observations from primary endometrial samples (table 3.9.2),
where SLPI is maximal during the mid secretory phase (high progesterone).
Similarly, the progesterone mediated downregulation of hBD2 may be predicted as
this antimicrobial has been shown to be maximally expressed during menstrual phase
(low progesterone) endometrial biopsies (table 3.9.2). However, there was an
upregulation of elafin in the presence of progesterone and this was unexpected as
elafin has also been demonstrated to be increased (late secretory) and maximally
expressed during the menstrual phase in endometrial biopsies. It may be that
progesterone exerts an effect via other mediators or paracrine factor(s), and this is
subject to further investigation in chapter 4. The treatment of Hec-IA cells with
TNFa + IL-ip in the presence of progesterone and the progesterone antagonist
RU486 increased the expression of elafin and hBD2 when compared to the levels
observed with progesterone alone. This may simulate progesterone withdrawal and
in turn brings about the upregulation of other factors that may give rise to the
increase in antimicrobial expression.
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Mimics of Infection
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Figure 3.9.2 The addition of progesterone (blue) caused a further increase in
expression of elafin and SLPI. HBD2 was downregulated with the addition of
progesterone. Mifepristone (RU486) treatment (orange) resulted in a further
increase in elafin mRNA expression and restored hBD2 expression. SLPI was
downregulated in response to mifepristone.
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Chapter 4:
Paracrine influences of endometrial epithelial stromal cell
interaction in the expression of elafin
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Chapter 4: Paracrine influences of endometrial epithelial-stromal cell
interaction in the expression of elafin.
4.1 Introduction
Elafin is a serine protease inhibitor and is expressed by a number of epithelial and
immune cells in response to injury or infection (Sallenave 2000; Hiemstra 2002;
Sallenave 2002). Elafin has also been demonstrated to have antimicrobial actions
against bacteria, fungi and viruses (Hiemstra, Maassen et al. 1996; Simpson,
Maxwell et al. 1999; Sallenave 2002). The epithelial expression of elafin has been
described in the endometrium (King, Critchley et al. 2003) and was confirmed in
chapter 5 of the current thesis to be maximally expressed during the menstrual phase.
It has also been observed that there is elafin expression within the neutrophil
population of the endometrium during the menstrual phase (King, Critchley et al.
2003). Elafin expression was also observed within the leukocyte population of the
Fallopian tube (chapter 6) and in the decidua from women with an ectopic gestation
(chapter 7).
The use of cell lines and in vitro models have demonstrated the inducibility of elafin
in the presence of the inflammatory cytokines TNFa and IL-1 in the lung (Sallenave,
Shulmann et al. 1994), keratinocytes (Tanaka, Fujioka et al. 2000) endometrium
(King, Fleming et al. 2002) and mammary cells (Zhang, Magit et al. 1997). In
chapter 3 of the current thesis it was shown that elafin expression is inducible in the
glandular endometrial epithelial cell line, Hec-1 A.
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The human endometrium is composed of a number of different cell types and subject
to change in response to different signalling and interaction mechanisms. The
interaction between these different cell types is becoming increasingly recognised as
important to the function of the endometrium. The interaction between the stroma
and the extracellular matrix (ECM) is important for the regulation of cell
proliferation and growth (Cunha, Bigsby et al. 1985). This interaction is also
required for the process of embryonic cell differentiation (Arnold, Lessey et al.
2002). The interaction between endometrial stromal and epithelial cells has also
been identified as important for progesterone mediated events (Kurita, Wang et al.
2001; Cunha, Cooke et al. 2004).
In chapter 3, it was shown that the inflammatory stimulus of Hec-IA cells in the
presence of progesterone increased the expression of elafin (chapter 3; figure
3.8.1.1). This was in contrast to previous observations that elafin is maximally
expressed during the menstrual phase, when circulating progesterone levels are low
(King, Critchley et al. 2003) and demonstrated herein (chapter 5; figure 5.3.2.1).
This led to the assumption that progesterone was inhibitory either directly or
indirectly for the expression of elafin. However, in vitro studies using the T47D cell
line showed elafin mRNA to be unaffected by the presence of progesterone. The
endometrial biopsies investigated for elafin expression consisted of both stromal and
epithelial components. This may be suggestive of a role for paracrine factor(s) of
stromal origin which may influence the epithelial expression of elafin in response to
progesterone. The influence of stromal mediated paracrine factors upon the
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expression of natural antimicrobials has not previously been described and will be
the focus of the current chapter.
In order to investigate the role of stromal mediated factors upon the epithelial
expression of elafin, an in vitro model was deemed necessary. In the current study,
two approaches where adopted. The first utilised conditioned media which was
removed from stromal cells and placed upon epithelial cells prior to treatment with
inflammatory stimuli described in section 4.2.1.1 and summarised in figure 4.2.1.1.
The second method employed involved the use of a co-culture set-up as described in
chapter 2 (section 2.2.5) and in section 4.2.1.2 and figure 4.2.1.2 of the current
chapter. The latter method allowed for 'two-way' communication between the
endometrial stromal cells and the epithelial Hec-IA cell line.
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Figure 4.1.1 A schematic diagram showing the structure and positional
arrangement of the stromal and epithelial cells of the endometrium. The Hec-1 A cell
line was derived from the glandular epithelium, whilst the stromal cells were
obtained from primary culture as described in section 2.1.1. The endometrial
explants examined for natural antimicrobial expression (chapter 5), are also
demonstrated and show the presence of both stroma and epithelia.
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Investigate whether there are paracrine factors in the epithelial
expression of elafin [as described in chapt 3]
Investigate paracrine mediated effects in the presence of progesterone
Suggest candidate paracrine factors involved in any elafin relevant
interaction between epithelial and stromal cells.
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4.2 Materials and Methods
4.2.1 Cell culture
The human endometrial epithelial cell line Hec-IA (human endometrial cancer-one)
(Kuramoto, Tamura et al. 1972), were cultured as described in 2.2.3. The stromal
cells were derived from primary endometrial biopsies and were prepared as described







Table 4.2.1.1 Details of treatment of Hec-1A endometrial cell line. Supplier
information is contained within appendix I.
4.2.1.1 Conditioned culture media
Conditioned culture media was prepared as follows: complete RPMI culture media
with or without progesterone was placed upon endometrial stromal cells (70%
confluent) and incubated for 24 hr. The media was then removed and filter sterilised
via a vacuum pump (Nalgene) and supplemented with new media with a ratio 50:50.
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The filtered media was replenished to ensure that the cells were sufficiently
nourished. The media was added to the Hec-IA cells supplemented with the relevant
treatment as detailed for each relevant experiment (TNFa, IL-ip and TNFa + IL-P).






Media removed and filtered
Fresh media
Conditioned media added to Hec-1A cells
Hec-1A
Epithefial celte
Treatment with inflammatory stimuli
Figure 4.2.1.1 Schematic summary of the preparation of stromal conditioned media.
Culture media (RPMI) with or without progesterone was incubated for 24 hr with
endometrial stromal cells at 70% confluence. The media was then poured off,
filtered and replenished with new culture media (50:50). The media was then
utilised for the culture and treatment of Hec-1 A epithelial cells.
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4.2.1.2 Co-culture of endometrial stromal cells and the Hec-1A epithelial cell
line
Co-culture experiments were made up of the following: endometrial stromal cells
(ESCs) were seeded into 6 well culture plates and allowed to reach confluence. After
attachment the media containing serum and hormones was removed and replaced
with serum free RPMI. Hec-IA epithelial cell line was seeded (1.3xl05 cells/ml)
into the interior of transwell culture inserts in 2% cRPMI and allowed to adhere. The
inserts containing the epithelial cells were then placed in the wells containing the
stromal cells and the media replaced prior to treatment with inflammatory mimics
(IL-1 (3 and TNFa) with or without steroid hormones (progesterone). Co-culture
controls without treatment and single culture controls for both ESC and Hec-IA
(treated and untreated) cells were included throughout. The co-culture set-up and
methods of treatment are demonstrated in chapter 2; figure 2.2.5.1, and indicated
where relevant in the results section by numbers which are presented as a key to the





Figure 4.2.1.2 Diagram depicting the different treatment methods used with co-
culture plates. The circled numbers are included within the results to indicate which
of the above arrangements was employed. ® Stromal cells alone; © epithelial cells
alone; © co-culture plate where the stromal compartment is treated; © co-culture
plate where the epithelial compartment is treated; © co-culture plate where the
media is treated prior to being placed in both compartments equally.
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4.2.2 RNA extraction and Q-RT-PCR
Following treatment and incubation for the relevant time point, the RNA was
extracted from the cells and cDNA prepared as described in section 2.3. Elafin
mRNA levels were measured in these cDNA samples by quantitative PCR (2.3). The
sequence details of the primer-probe sets used are detailed in table 2.3.3.1, materials
and methods.
4.2.3 ELISA
The culture supernatants were removed from the cells, sterile filtered and the amount
of elafin protein was determined via an ELISA as detailed in section 2.4.
4.2.4 Statistical analysis
The PCR results in this chapter were analysed by ANOVA for significant difference.
Fisher's protected least significant difference (PLSD) was used to assign individual
differences (PRISM).
Each n=l is equal to the mean of 3 individual time points (4, 8 and 12 hr), in order to
account for the variances in expression across time and allow for comparison on the
basis of treatment conditions alone.
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4.3 Results
4.3.1 The effect of stromal conditioned media upon the expression of elafin
mRNA in Hec-1A cells treated with TNFa and IL-1 p.
In order to investigate the role of stromal mediated paracrine factors upon the
expression of elafin, culture media previously cultured with endometrial stromal cells
was placed upon Hec-IA cells concurrently with treatment with pro-inflammatory
cytokines, TNFa and IL-1 p. This was undertaken both with and without the
presence of progesterone as described in section 4.2.1.
Elafin mRNA, figure 4.3.1.1, was increased when treated with TNFa, IL~P and
TNFa + IL-1 (3, in the presence of stromal conditioned media. Elafin mRNA was
11.3 point greater with TNFa, 301-point greater with IL-ip (PO.OOl), and 26-point
greater with TNFa + IL-lp, in the presence of stromal conditioned media, when
compared to RPMI alone (n=6; derived as explained in section 4.2.4). The
synergistic response of elafin mRNA expression in response to treatment with TNFa
+ IL-ip in less than that observed for the treatment with IL-ip alone in the presence
of stromal conditioned media. Elafin mRNA is 237-point greater in response to IL-
ip, when compared with the addition of TNFa, in the presence of stromal
conditioned media.
In the presence of progesterone (10~6 M), stromal conditioned media reduced the
expression of elafin mRNA (figure 4.3.1.2), in response to treatment with TNFa,
TNFa + IL-ip (PO.OOl). Elafin mRNA was decreased 13-point in response to
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TNFa and 128-point in response to treatment with TNFa + IL-ip (P<0.001), in the
presence of stromal conditioned media with progesterone. However, the addition of
IL-ip in the stromal conditioned media increased elafin mRNA expression (27-point)
when compared to unconditioned progesterone treated media. Furthermore as with
figure 4.3.1.1, the synergistic action of TNFa + IL-1 p upon elafin mRNA, was
reduced below that observed for IL 1 p (22-point) in the presence of stromal














TNFa 6 17 21 8
IL-1p 70 371 75 102
TNFa + IL-1p 108 134 208 79
Table 4.3.1.1 Summary of elafin relative mRNA results shown in figures 4.3.1.1 and
4.3.1.2
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Elafin expression in HEC-1A cells
•kick
Figure 4.3.1.1 Elafin mRNA expression in Hec-1A cells in response to treatment
with inflammatory cytokines, TNFa (green), ll_-1(3 (red) and TNFa + IL1(3 (blue), with
and without the presence of stromal conditioned media. Media that was removed
after 24 hour incubation with endometrial stromal cells was supplemented with 50%
RPMI (detailed in section 4.2.1). Elafin mRNA was significantly increased in
response to treatment with IL-1 (3 in the presence of stromal conditioned media
compared to RPMI alone (P<0.001). Data are presented as relevant to a control
(untreated Hec-1A cells for each time point); given a nominal value of 1, mean
±s.e.m. Each experiment (n=6) was performed at 4, 8 and 12 hr; the 3 time points
were averaged, taken as n=1, and served to allow for variances in response to time.
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Elafin expression in HEC 1A cells
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Figure 4.3.1.2 Elafin mRNA expression in Hec-1A cells in response to treatment in
progesterone (1CT6 M) and TNFa (green), IL-1 p (red) and TNFa + IL1 p (blue), with
and without the presence of stromal conditioned media. Progesterone
supplemented media, which was removed after 24 hour incubation with endometrial
stromal cells was supplemented with 50% RPMI (detailed in section 4.2.1). Elafin
mRNA was significantly decreased when treated with TNFa + IL-1 (3 in the presence
of stromal conditioned media when compared to RPMI alone (P<0.001). Data are
presented as relevant to a control (untreated Hec-1 A cells for each time point); given
a nominal value of 1, mean ±s.e.m. Each experiment (n=6) was performed at 4, 8
and 12 hr; the 3 time points were averaged, taken as n=1 and served to allow for
variances in response to time.
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4.3.2 The effect of the co-culture of endometrial stromal cells with the Hec-1A
epithelial cell line when treated with pro-inflammatory cytokines upon the
expression of elafin mRNA.
Further to the data obtained in section 4.3.1 which indicated the presence of stromal
mediated factors, it was deemed necessary to examine the effect of two-way
communication between endometrial stromal cells and Heel A epithelial cells, thus,
a co-culture set-up was investigated (figure 4.2.1.2).
Hec-IA expression of elafin mRNA, figure 4.3.2.1 (n=2; derived as described in
section 4.2.4), was increased when treated with TNFa, IL-ip and TNFa + IL-ip, in
the presence of stromal cells in co-culture, when compared to Heel A cells alone.
Elafin mRNA was increased 3-point with TNFa, 19-point with ILlp, and 20-point
with TNFa + IL-ip in the presence of stromal cells. There was no notable difference
in the level of elafin mRNA expression in stromal cells in the presence of epithelial
cells for any of the pro-inflammatory cytokines.
In the presence of progesterone the co-culture of Hec-IA cells with endometrial
stromal cells greatly decreases the level of elafin mRNA expression in response to
treatment with TNFa (1.5-point), ILip (18-point) and TNFa + IL-ip (83-point) in
comparison with epithelial cells alone, figure 4.3.2.2 (n=2). The stromal cells did not
demonstrate any difference in the expression of elafin mRNA in co-culture or alone.
The stromal cells only express elafin mRNA at a very low level.
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Further analysis of the co-culture model was undertaken to examine the effect of
treating the individual components of the set-up with inflammatory stimuli.
Therefore, the effect of treating only the stromal cells or epithelial cells in co-culture
was examined for changes in elafin mRNA.
Elafin mRNA was increased in Hec-IA cells in response to the treatment of stromal
cells in co-culture with TNFa (1.5-point), IL-ip (16-point) and TNFa + IL-ip (23-
point), when compared with the same treatment of epithelial cells alone figure
4.3.2.3. The treatment of the stromal cells also increased the stromal expression of
elafin mRNA, TNFa, 3.5-point; IL-ip, 6-point and TNFa + IL-ip, 9-point, (n=2).
Treatment of the Hec-1 A cells with inflammatory stimuli increased the expression of
elafin mRNA from both the Hec-IA cells and the stromal cells when compared with
the level of expression observed for each of the cell types cultured alone, figure
4.3.2.3, (n=2). The stromal cells increased elafin mRNA expression in response to
TNFa (3-point), IL-ip (6-point) and TNFa + IL-ip (10-point), when Hec-IA cells
were treated in co-culture in comparison with stromal cells alone. Elafin mRNA
expression was also increased in the Hec-IA cells treated in co-culture with stromal
cells, IL-ip (9-point) and TNFa + IL-lp (11-point). The treatment of stromal cells in
co-culture demonstrated the greatest increase in elafin mRNA expression in the Hec-
IA cells.
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Figure 4.3.2.1 Elafin mRNA expression in Hec-1A and stromal cells in response to
treatment with pro-inflammatory cytokines, TNFa (green), IL-1 (3 (red) and TNFa +
IL-1p (blue). The culture plate was set-up as shown in figure 4.2.1.2, with the
numbers indicating the precise arrangement. (1) Endometrial stromal cells (ESC)
alone; (2) Hec-1A epithelial cell line and (5) co-culture containing ESCs and FlecIA
cells, the media was treated prior to the addition to both compartments concurrently.
ESC cells showed no difference in elafin mRNA expression when treated in co-
culture to cells alone. Flec-1A cells demonstrated an increase in elafin mRNA in
response to inflammatory cytokines in the co-culture set-up. Data are presented as
relevant to a control (untreated ESC or Flec-1A); given a nominal value of 1, mean ±
s.e.m. Each experiment (n=2) was performed at 4, 8 and 12 hr; the 3 time points
were averaged, taken as n=1 and served to allow for variances in response to time.
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Figure 4.3.2.2 Elafin mRNA expression in Hec-1A and stromal cells in response to
treatment with pro-inflammatory cytokines, TNFa (green), IL-1p (red) and TNFa +
IL-13 (blue), in the presence of progesterone (10 ® M). The culture plate was set-up
as shown in figure 4.2.1.2, with the numbers indicating the precise arrangement. (1)
Endometrial stromal cells (ESC) alone; (2) Hec-1A epithelial cell line and (5) co-
culture containing ESCs and HecIA cells, the media was treated prior to the
addition to both compartments concurrently. ESC cells showed no difference in
elafin mRNA expression when treated in co-culture to cells alone. Hec-1A cells
demonstrated a decrease in elafin mRNA in response to progesterone and
inflammatory cytokines in the co-culture set-up. Data are presented as relevant to a
control (untreated ESC or Hec-1A); given a nominal value of 1, mean ± s.e.m. Each
experiment (n=2) was performed at 4, 8 and 12 hr; the 3 time points were averaged,
taken as n=1 and served to allow for variances in response to time.
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Co-culture Treatments in the presence of progesterone
Figure 4.3.2.3 Elafin mRNA expression in Hec-1A and stromal cells in response to
treatment with pro-inflammatory cytokines, TNFa (green), IL-1(3 (red) and TNFa +
IL-1P (blue), in the presence of progesterone (1CT6 M). The culture plate was set-up
as shown in figure 4.2.1.1, with the numbers indicating the precise arrangement. (1)
Endometrial stromal cells (ESC) alone; (2) Flec-1A epithelial cell line and (4) co-
culture containing ESCs and HecIA cells, the media was treated prior to the
addition to both compartments concurrently. ESC cells showed no difference in
elafin mRNA expression when treated in co-culture to cells alone. Hec-1A cells
demonstrated a increase in elafin mRNA in response to progesterone and
inflammatory cytokines in the co-culture set-up. Data are presented as relevant to a
control (untreated ESC or Hec-1A); given a nominal value of 1, mean ± s.e.m. Each
experiment (n=2) was performed at 4, 8 and 12 hr; the 3 time points were averaged,
taken as n=1 and served to allow for variances in response to time.
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4.3.3 The effects of the co-culture of endometrial stromal cells with the Hec-1 A
epithelial cell line and treatment with TNFa and IL-1 p on the expression of
elafin protein.
The expression of elafin protein (figure 4.3.3.1 - 4.3.3.3) in the presence of TNFa
and IL-ip, with progesterone (blue) and without (purple) in the co-culture set-up
described in figure 4.2.1.2, was found to be differential depending on where the
culture media was sampled.
Treatment of the stromal cells (figure 4.3.3.1; n=2) with TNFa and IL-ip singly and
in combination in RPMI demonstrated similar levels of elafin protein in the co-
culture (stromal) and transwell (Hec-1 A) culture media. In the presence of
progesterone there was more elafin protein in the co-culture and transwell media,
170-point and 130-point, respectively, when treated with TNFa + IL-1 p.
Treatment of the epithelial cells (figure 4.3.3.2; n=2) with TNFa and IL-ip was
shown to increase the levels of elafin protein and lower levels were obtained in the
presence of progesterone except in the transwell media treated with TNFa + IL-ip,
where 284 pg/ml of elafin was detected with progesterone compared to 155 pg/ml.
In the corresponding co-culture well the treatment of the Hec-1 A cells with TNFa +
IL-ip gave rise to 550 pg/ ml of elafin, and in the presence of progesterone this was
reduced (200 pg/ml).
Treatment of the media prior to the addition to both cell compartments, figure 4.3.3.3
(n=2) gave a different pattern of elafin protein expression. The stromal co-culture
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media in the presence of progesterone and treated with IL-ip contained more elafin
protein (250 pg/ml) than without the presence of progesterone (105 pg/ml).
Treatment with the combined cytokines in the presence of progesterone reduced the
level of elafin protein (350 pg/ml) when compared to the level of elafin detected in
the absence of progesterone (568 pg/ml). The media collected from the transwell
(Hec-IA) contained less elafin protein than was detected in the stromal area.
Treatment with IL-ip produced 88 pg/ml and this was found to be reduced in the
presence of progesterone, 14 pg/ml. With the treatment with TNFa + IL-ip, 122
pg/ml of elafin protein was detected and this was found to be increased in the
presence of progesterone, 252 pg/ml.
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Figure 4.3.3.1 Elafin protein (pg/ml) detected within the culture supernatants from
stromal and epithelial cells. The supernatants were collected from the stromal
component (co-culture) and the Hec-1A cells (transwell). The stromal cells were
treated with pro-inflammatory cytokines, TNFa, IL-ip and TNFa + IL-1 p (figure
4.2.1.2 (D). The cells were treated with (blue) and without (purple), progesterone
(106 M). An equal amount of ethanol was added to the cells without progesterone
(the progesterone is made up with ethanol). NB. co-culture wells contain
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Figure 4.3.3.2 Elafin protein (pg/ml) detected within the culture supernatants from
stromal and epithelial cells. The supernatants were collected from the stromal
component (co-culture) and the Hec-1A cells (transwell). The Hec-1A epithelial cells
were treated with pro-inflammatory cytokines, TNFa, IL-ip and TNFa + IL-ip (figure
4.2.1.2 ©). The cells were treated with (blue) and without (purple), progesterone
(1CT6 M). An equal amount of ethanol was added to the cells without progesterone
as a control (the progesterone is made up with ethanol). NB. co-culture wells
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Figure 4.3.3.3 Elafin protein (pg/ml) detected within the culture supernatants from
stromal and epithelial cells. The supernatants were collected from the stromal
component (co-culture) and the Hec-1A cells (transwell). The media was treated
with pro-inflammatory cytokines, TNFa, IL-1 p and TNFa + IL-1(3 (figure 4.2.1.2 ©),
prior to the addition to the culture plates. The treatments were undertaken with
(blue) and without (purple), progesterone (10~6 M). An equal amount of ethanol was
added to the cells without progesterone as a control (the progesterone is made up
with ethanol). NB. co-culture wells contain endometrial stromal cells and the
transwells contained Hec-1 A epithelial cells.
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Summary of results
1. Stromal derived media increases epithelial (Hec-IA) expression of elafin
mRNA
2. Hec-IA expression of elafin mRNA is inhibited with the addition of
progesterone + stromal derived media.
3. Co-culture of ESCs (endometrial stromal cells) and Hec-IA epithelial cells
with and without progesterone produced similar data as stromal conditioned
media experiments (1 & 2 above).
4. ESCs express elafin in the presence of Hec-IA cells, when treated directly
(stromal compartment) or indirectly (transwell) with inflammatory stimuli
5. ESC treatment of co-cultures caused the greatest increase in elafin mRNA by
Hec-IA cells.
6. Elafin protein was detected to be variable between compartments, suggesting
that little culture media is exchanged.
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4.4 Discussion
The investigation into the expression of elafin in the endometrium has been
undertaken both within the current thesis and in previous studies, involving the use
of primary endometrial explants collected from women across the menstrual cycle
(King, Critchley et al. 2003) and in chapter 5 of the present thesis. The data obtained
from these studies demonstrated that elafin was maximally expressed during the
menstrual phase of the cycle, where circulating levels of progesterone are low (figure
5.3.2.1). This was suggestive that progesterone may directly or indirectly have an
inhibitory role in the expression of elafin (King, Critchley et al. 2003). This was
further predicted with the demonstration that SLPI contains a progesterone response
element (PRE) and thus, is up-regulated directly in response to progesterone, and is
maximally expressed during the mid secretory phase (high circulating levels of
progesterone) (King, Critchley et al. 2003; King, Morgan et al. 2003). However,
although in vitro cell line work confirmed the up-regulation of SLPI by progesterone,
there was no effect described for elafin in the breast cancer cell line T47D (King,
Morgan et al. 2003). The use of the Hec-IA endometrial epithelial cell line in
chapter 3 of the current thesis, however, did give rise to a response in the presence of
progesterone (figure 3.8.1.1), with an increase in elafin expression. The data
obtained for the expression of elafin across the menstrual cycle, was from the
analysis of endometrial explants (figure 4.1.1), which consists of a number of
different cells, predominantly that of the stroma and epithelia. Thus, the effect of
paracrine interaction between these two cell types upon the expression of elafin was
investigated.
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Initial investigations utilised cell conditioned media as shown in figure 4.2.1.1
(section 4.2.1.1). Briefly, the media was pre-conditioned with endometrial stromal
cells for 24 hour, prior to being filtered and replenished with fresh media at a ratio of
50:50. This media was then placed upon the Hec-IA cell line, along with the pro¬
inflammatory cytokines TNFa and IL-ip. The addition of this stromal conditioned
media was shown to increase the expression of elafin mRNA by the Hec-IA cell line.
The expression of elafin mRNA in response to treatment with TNFa in stromal
conditioned media was over 11-point increased and 26-point greater when treated
with TNFa + IL-ip, when compared to unconditioned media (figure 4.3.1.1).
However, it was the treatment of Hec-IA cells with IL-ip in the presence of stromal
conditioned media which was demonstrated to give the greatest increase in elafin
mRNA expression, 301-point greater (P<0.001). This is in contrast to the previously
observed (chapter 3), synergistic response to treatment with both TNFa and IL-ip
and as shown in the unconditioned media treatment for the same experiment (figure
4.3.1.1). This greater expression in elafin mRNA in response to IL-ip over the level
observed when treated with TNFa + IL-lp was also seen in chapter 3 (figure 3.8.3.2),
when the Hec-IA cells were treated in the presence of RU486 (mifepristone), a
progesterone antagonist. The reasons for this are unclear, but, it appears that there is
some inhibition with the addition of TNFa to IL-ip, however, a direct inhibition on
the expression of elafin in response to TNFa alone was not observed. Thus, it can
therefore be assumed that there is some sort of interference in the synergistic actions
of both these cytokines arising from the stromal conditioned media and this may
merit further investigation. The overall increase in elafin expression in response to
the inflammatory cytokines in the presence of stromal conditioned media is
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suggestive of the presence of paracrine factor(s) from the stromal cells that may have
a role in the up-regulation of elafin mRNA. The addition of progesterone to the
media prior to the incubation with stromal cells was observed to reduce the
expression of elafin mRNA (figure 4.3.1.2) when concurrently treated with TNFa
(13-point) and TNFa + IL-1(3 (128-point; P<0.001), when compared to treatment in
the presence of unconditioned progesterone supplemented media. As was observed
for the previous conditioned media experiment (figure 4.3.1.2), the expression of
elafin in response to the synergistic actions of TNFa + IL-1 (3 was lower (22-point)
than was observed when treated with IL-1 p alone in the presence of stromal
conditioned media (table 4.3.1.1). However, the inhibition of elafin mRNA in the
presence of progesterone treated stromal conditioned media (figure 4.3.1.2) when
compared to non-progesterone stromal conditioned media (figure 4.3.1.1 and table
4.3.1.1), supports the data obtained with menstrual phase endometrial explants
(chapter 5), where elafin mRNA is maximal in biopsies obtained when circulating
progesterone levels are low (King, Critchley et al. 2003). The endometrial explants
are composed of a number of different cell types including stromal and epithelial
cells (figure 4.1.1). Elafin has also been shown to be expressed by neutrophils which
have also been observed to be present in the endometrium during menstruation
(King, Critchley et al. 2003).
There may be some 'preparatory factor(s)' for the expression of elafin by epithelial
cells that enables rapid expression upon exposure to inflammatory stimuli. An
investigation was undertaken into the need for the inclusion of a 'spent' media
control, which consisted of pre-conditioned epithelial media; replenished with 50%
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fresh media (figure 4.1.1). These preliminary data (n=2) revealed that the Hec-IA
cells that were exposed to epithelial conditioned media, expressed elafin more
rapidly than unconditioned media and on average there was a slightly elevated level
of elafin mRNA with conditioned media when the time points were averaged (figure
4.4.1; chart inset). The need for innate immune effectors to respond rapidly in the
event of injury or infection may necessitate the need for 'ready to go' or 'on demand'
mechanisms or factors. This would enable cells to perhaps mediate an interim
response whilst the more timely preparation or infiltration of other innate or adaptive
immune players.
Further consideration was given to the role of paracrine interactions and the role of
epithelial signalling with respect to two-way signalling between the epithelial and










































Figure 4.4.1 Elafin mRNA expression in the presence of pre-conditioned epithelial
media (dark blue) and in unconditioned RPMI (light blue). The time courses were
undertaken over 12 hour with 2 hourly sampling points (A and B). The bar chart
inset shows the all the time point values averaged for A and B.
The use of a co-culture set-up was utilised and is described in section 4.2.1 and
figure 4.2.1.1. The placement of the Hec-1 A endometrial epithelial cell line with the
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endometrial stromal cells (primary culture) and treatment with inflammatory
cytokines TNFa and IL-ip allowed for the examination of epithelial-stromal
interactions. Elafin mRNA expression by the Hec-IA cells was increased in the
presence of stromal cells, and there was no change in the level of elafin mRNA
expression in the stromal cells in the presence of Hec-IA cells (figure 4.3.2.1). This
was in further support that there are stromal mediated factors involved in the up-
regulation of elafin mRNA as was shown previously (figure 4.3.1.1). In chapter 3 it
was also shown that progesterone was responsible for the up-regulation of elafin
mRNA in response to inflammatory stimuli (figure 3.8.1.1). However, in the current
chapter (figure 4.3.1.2), this effect was shown to be inhibited in the presence of
stromal conditioned media. This was further demonstrated in the co-culture
experiments (figure 4.3.2.2), where the presence of progesterone in co-culture
inhibited the Hec-IA epithelial expression of elafin mRNA. This was in contrast
with the increased expression observed with progesterone treated Hec-IA cells alone.
There was no noticeable effect observed upon the expression of elafin by ESCs in
mono or co-culture conditions. An investigation into the effect of treating the
different components of the co-culture set-up was undertaken (figure 4.2.1.1). When
the co-culture was treated in the bottom (stromal compartment), there was an
increase in the level of elafin mRNA by both the ESCs and Hec-IA cells. The Hec-
IA expression of elafin was greatest in response to treatment of the stromal cells
with inflammatory cytokines (TNFa and IL-1(3) compared with both Hec-IA cells
alone and that where Hec-IA cells were treated directly in co-culture with ESCs.
This may suggest that in the event of inflammation that greater urgency is attributed
to the fact the stroma have received direct stimulation. This may be an indication of
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the severity of an infection as it may be that the overlying epithelia may have been
unable to address the initial threat or has been damaged in some way therefore
allowing direct access to the underlying stroma (figure 4.1.1). An alternative
explanation is that during the menstrual phase the functional layer of the
endometrium (Stratum functionalis; figure 4.1.1), is shed, exposing the stroma to
inflammatory mediators (Critchley, Kelly et al. 2006). This is also a period of
increased vulnerability for the endometrium and perhaps this necessitates the need
for expression of elafin by the stromal cells. This may also suggest an explanation
for the high level of elafin mRNA observed in endometrial explants collected from
the menstrual phase of the cycle (chapter 5; and (King, Critchley et al. 2003).
However, the stromal expression of elafin protein was not shown during the
menstrual phase, but, was localised to the neutrophil population (King, Critchley et
al. 2003).
Preliminary analyses of elafin protein within the co-culture set-up (figures 4.3.3.1 to
4.3.3.3), revealed some interesting data and this merits further investigation. The
main observation was the consistent differences in the level of elafin protein that
could be detected within the co-culture wells. The different components of the well
are separated by a thin membrane designed to allow the exchange of cell signalling
molecules. The protein data demonstrates that there is very little mixing of the
culture media between the two compartments.
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In summary, the endometrium is made up of a number of different cell types and
these cells are involved in cell-cell communication and thus, a number of paracrine
factors need to be considered. In the current chapter it has been shown that there are
stromal mediated factors which influence the expression of elafin by epithelial cells
(Hec-IA) and this is summarised in figure 4.4.2. An increase in elafin mRNA was
observed in the presence of stromal derived media or in the presence of stromal cells
in co-culture. It was further demonstrated that the effect of progesterone upon the
epithelial expression of elafin mRNA may be mediated via the stromal cells. The
treatment of Hec-IA cells with progesterone along with inflammatory stimuli
increases elafin expression (chapter 3 and 4), however, the presence of stromal cells
or stromal derived media, elafin mRNA was inhibited. Elafin mRNA has been
shown to be maximally expressed in the endometrium during the menstrual phase
when circulating levels of progesterone are low in chapter 5 (figure 3.8.1.1) and in
previous studies (King, Critchley et al. 2003). This is suggestive that the effect of
progesterone upon the epithelial expression of elafin is indirect and may be as a
consequence of progesterone mediated effects upon the stroma which in turn exhibits
an effect upon the epithelium. Progesterone has been shown to stimulate a number
of factors from the stromal cells which may act upon the epithelial cells of the
endometrium. It may be that progesterone acts to produce an inhibitor of elafin
expression via the stromal cells. It was demonstrated in chapter 3 that the cytokine
TGFp-1 caused a decrease in the expression of elafin in Hec-IA cells treated with
inflammatory stimuli (figures 3.4.3.1 and 3.4.3.2). The inhibition of SLPI has also
been reported in response to TGFP-1 (Jaumann, Elssner et al. 2000). In the
endometrium it has been demonstrated that progesterone increases stromal
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expression of TGF|3 (Bruner, Rodgers et al. 1995). Thus, it may be that the
progesterone mediated expression of TGFp-1 by the stroma is responsible for the
inhibition of elafin mRNA in menstrual endometrium (King, Critchley et al. 2003),
and in the presence of stromal cells or stromal derived media with progesterone. The
stromal mediated expression of TGFP-1 in response to progesterone has also been
shown to inhibit the epithelial expression of the matrix metalloproteinase, MMP-7
(matrilysin) (Bruner, Rodgers et al. 1995). MMP-7 is co-expressed with a-defensins
in the paneth cells of the murine gut, and has the ability to cleave pro-a-defensins
into the active and mature form (Wilson, Ouellette et al. 1999). Elafin is also
expressed as a pro-form, trappin-2 (Guyot, Zani et al. 2005) and investigations in the
lung have identified tryptase as a candidate elafin-releasing enzyme (Guyot, Zani et
al. 2005). Thus, the role of MMP-7 in endometrial expression of natural
antimicrobials including elafin was investigated further within this thesis (chapter 5-
8).
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Figure 4.4.2 Progesterone was shown to up-regulate elafin mRNA in Hec-1A cells
in response to inflammatory stimuli (chapter 3). In the presence of stromal cells or
stromal derived media, the Hec-1A expression of elafin mRNA is also increased
(green arrows). However, this expression was inhibited (red) in the presence of the
stroma, suggesting the presence stromal factors with influence over the epithelial
expression of elafin. Also in chapter 3 it was shown that TGFfM inhibited the
inflammatory expression of elafin mRNA. Progesterone up-regulates stromal
expression of TGFp-1 and this may be one of the paracrine factors involved in the
epithelial expression of elafin. However, there are stromal derived factors in the
absence of progesterone that are responsible for the increase in elafin mRNA.
There are also other candidates including MMP-7 that are progesterone/stromal
mediated that may have a role.
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4.4.1 Future work
The preliminary data contained within this chapter demonstrates a likely role for
paracrine mediated factor(s) in the expression of elafin. The cytokine TGFP-1 is a
candidate factor for this stromal-epithelial interaction, and was shown to inhibit
elafin expression in the Hec-IA cell line and is documented to be upregulated in
response to progesterone. The analyses of stromal derived culture media for the
presence of TGFp-1 both in response to progesterone and/or the presence of
epithelial cells would help confirm this interaction. There are many commercial
ELISA kits available for the examination of TGFp-1 production and would be useful
in this case. Further studies involving the inhibition or blocking of TGFp-1
expression and the examination on the effects of elafin expression would also be
informative. It was also identified from the literature that MMP-7 is downregulated
via progesterone mediated stromal expression of TGFp-1 (Bruner, Rodgers et al.
1995). Furthermore, there is a possibility of a role for MMP-7 in the splicing of pre¬
formed antimicrobials in the endometrium. An analysis of the effect of MMP-7 upon
the pre-mature forms of antimicrobials such as the P-defensins and elafin would be
informative along with a measurement of expression levels in co-culture
experiments. The significance of MMP-7 expression is addressed through the
remainder of this thesis and discussed in chapters 5 to 8.
There have also been a number of inconsistencies observed with regard the hormonal
influence over the expression of some antimicrobials. In the endometrium it has
been shown that hBDl levels are maximal during the high progesterone mediated
stages of the menstrual cycle (Fleming, King et al. 2003). However, in vitro studies
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showed that hBDl mRNA was suppressed in the presence of progesterone, indicative
of an indirect or coincident effect. Thus, further work would examine the role of
stromal-epithelial interaction upon the expression of other natural antimicrobials
such as the P-defensins and identification of any factors or mechanisms.
Decidualised stromal cells in combined culture with the epithelial cell line upon the
expression of natural antimicrobials and the presence of different factors or
interactions would also be worth investigating. The use of decidualised stromal cells
may provide a mechanism for the further understanding of both the expression and
regulation of natural antimicrobials during pregnancy.
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Chapter 5:
A comparative analysis of elafin, SLPI, TGF(3-1 and MMP-7
mRNA expression in pregnant and non-pregnant
endometrium.
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Chapter 5: A comparative analysis of elafin, SLPI, TGFp-1 and MMP-7 mRNA
expression in pregnant and non-pregnant endometrium.
5.1 Introduction
The endometrium undergoes morphological changes in response to the interchanging
balance of a number of mediators. These changes are under the control of the steroid
hormones, oestradiol and progesterone. It has been shown that many of the factors
thought to be involved in the modulation of the immune defence of the female
reproductive tract are similarly affected by hormone levels (Wira and Fahey 2004;
Schaefer, Fahey et al. 2005; Wira, Fahey et al. 2005; Wira, Grant-Tschudy et al.
2005). Cytokines and natural antimicrobials are amongst the molecules which
undergo cyclical changes in expression. It has been previously shown that both
elafin and SLPI expression is differential across the menstrual cycle. SLPI has been
shown to be upregulated during the mid secretory stage of the menstrual cycle where
circulatory progesterone levels are maximal (King, Critchley et al. 2003). It has
further been demonstrated that in vitro treatment of the breast cancer cell line T47D
with progesterone gives rise to an increase in SLPI mRNA (King, Morgan et al.
2003). It has been shown that the endometrial epithelial cell line (Hec-IA), also
demonstrates an increase in SLPI when treated with progesterone, and that this can
be reversed with the addition of the progestin antagonist RU486 (mifepristone),
(chapter 3). Elafin has been shown to be expressed during the late secretory and
maximally during the menstrual phase when progesterone levels are low (King,
Critchley et al. 2003; King, Morgan et al. 2003). The data presented in chapter 3,
have shown elafin to be increased in response to progesterone treatment of Hec-IA
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cells. A further increase in elafin mRNA was observed when the cells were treated
with the progesterone receptor antagonist, RU486 (mifepristone), which was
suggestive of an increase in elafin being brought about by the act of progesterone
withdrawal (King, Morgan et al. 2003), and this observation is consistent with the
increase observed in late secretory endometrium. In chapter 4 it has been
demonstrated that the effect of progesterone on elafin mRNA expression is mediated
by paracrine factors, such as TGFp-1 and MMP-7. The addition of progesterone to
Hec-IA cells in the presence of endometrial stromal cells resulted in an inhibition of
expression in response to inflammatory mediators. Possible candidates for this
indirect effect of progesterone remain to be established. TGF[3-1 has been shown to
inhibit elafin expression (chapter 3). TGFp-1 has been shown to increase in the
presence of progesterone and is expressed mainly by the endometrial stromal cells
(Bruner, Rodgers et al. 1995). The data presented in this thesis are suggestive of an
association between MMP7 (matrilysin) and elafin (chapters 6-8). MMP-7 has also
been shown to be mediated by progesterone concentration and may act in a paracrine
fashion between the endometrial stromal and epithelial cells (Rodgers, Osteen et al.
1993; Osteen, Rodgers et al. 1994; Bruner, Rodgers et al. 1995; Osteen, Keller et al.
1999).
Thus, it was deemed necessary to re-examine the expression of these proteins in a
comparative fashion in primary endometrial explants in order to further explore the
significance of the cell culture data presented in Chapters 3 and 4.
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5.2 Materials and methods
5.2.1 Human uterine tissue collection
Endometrial (n=14; table 5.2.1.1) and decidual (n=5; 5.2.1.2) samples were collected
as detailed in chapter 2 (section 2.1). The endometrial samples provided for study in
this chapter were in the form of extracted and validated RNA cDNA from the
laboratory archive (Prof Critchley group; LREC 1994/6/17) and was prepared in a
similar manner to that described in section 2.3 (chapter 2). The decidual samples
(LREC 04/S1103/20), were prepared for RNA analysis as described in section 2.3.
Sample
No.
Age Parity Endometrial histological





1 42 2+0 Menstrual 167 1.6
2 39 1+0 Menstrual* 118 2.94
3 38 2+0 Menstrual* 151 4.31
4 25 1+0 Proliferative 895 2.5
5 41 3+3 Proliferative 842 7.1
6 32 1+0 Proliferative 953 3.7
7 39 2+0 Early Secretory 604 42.5
8 45 0+0 Early Secretory 680 106.25
9 44 0+1 Mid Secretory 276 42.1
10 40 3+0 Mid Secretory 490 22.9
11 44 2+0 602 14.7
12 44 2+0 183 5.4
13 42 2+0 129 5.7
14 44 3+0 423 5.19
Table 5.2.1.1. Details of the endometrial samples used when analysing the
expression of elafin, SLPI, MMP-7 and TGF(3-1 across the menstrual cycle. Three
of the samples were undetermined upon histological analysis and have been staged
according to the patients last menstrual period (LMP) and sex steroid levels at the
time of biopsy (*).
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Sample
No. Age Group Parity Gestation Procedure
1 33 2 3+3 10+5
Surgical Termination of
Pregnancy
2 28 2 0+0 10
Surgical Termination of
Pregnancy
3 22 2 1+1 8+6
Surgical Termination of
Pregnancy
4 24 2 0+0 10
Surgical Termination of
Pregnancy
5 29 2 1+3 10+6
Surgical Termination of
Pregnancy
Table 5.2.1.2. Details of first trimester decidual samples used when analysing the
expression of elafin, SLPI, MMP-7 and TGF(5-1. Group 2 contained samples of
decidua collected from women undergoing termination of pregnancy.
5.2.2 QRT-PCR
Elafin, SLPI, TGFP-1 and MMP-7 expression was determined using quantitative real
time PCR as detailed in chapter 2.
5.2.3 Statistical Analysis
The PCR results in this chapter were analysed by ANOVA for significant difference.





5.3.1 Elafin mRNA expression in endometrium
Elafin mRNA expression was maximal in the menstrual phase biopsies (figure
5.3.1.1; Menstrual/proliferative, menstrual/early secretory and menstrual/mid-
secretory P<0.001; menstrual/late secretory P<0.01).
5.3.2 SLPI mRNA expression in endometrium
SLPI mRNA levels were maximally increased in mid-secretory endometrium (figure
5.3.2.1; mid-secretory/proliferative P<0.01; mid-secretory/early secretory P<0.05).
SLPI mRNA was increased in late secretory phase endometrium (figure 5.3.2.1; late
secretory/proliferative and late secretory/early secretory P<0.05) and in menstrual
phase endometrium (figure 5.3.2.1; menstrual/proliferative and menstrual/early
secretory P<0.05).
5.3.3 MMP-7 mRNA expression in endometrium
MMP-7 mRNA levels were found to be maximal in menstrual endometrium (figure
5.3.3.1; menstrual/early secretory, menstrual/mid-secretory and menstrual/late
secretory P<0.01). In addition there was an increase in the level of MMP-7 mRNA
in proliferative phase endometrium (figure 5.3.3.1; not statistically significant)
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5.3.4 TGFp-1 mRNA expression in endometrium
TGF(3-1 mRNA expression was found to be present across the menstrual cycle and
did not demonstrate any significant variation in any of the menstrual phases.
5.3.5 Expression of elafin, SLPI, MMP-7 and TGF0-1 in decidua
First trimester decidual biopsies (n=5) were examined for the expression of elafin
(blue), SLPI (green), MMP-7 (yellow) and TGF(3-1 (purple) mRNA (figure 5.3.5.1).

























Elafin mRNA Expression in the Endometrium
Mens Prolif ES MS LS
Figure 5.3.1.1. Elafin mRNA expression within human endometrium across the
menstrual cycle (n= detailed within the x axis). Data are presented as relative
changes in mRNA expression relative to a control (negative control obtained from a
sample of early secretory endometrium), given a nominal value of 1, mean ± s.e.m.
Mens/prolif, Mens/ES and Mens/MS P<0.001; Mens/LS P<0.01.
Abbreviations: Mens, Menstrual phase; Prolif, proliferative phase; ES, early
secretory phase; MS, mid secretory phase; LS, late secretory phase.
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SLPI mRNA Expression in the Endometrium
i
Mens Prolif ES MS LS
Figure 5.3.2.1. SLPI mRNA expression within human endometrium across the
menstrual cycle (n= detailed within the x axis). Data are presented as relative
changes in mRNA expression relative to a control (negative control obtained from a
sample of early secretory endometrium), given a nominal value of 1, mean ± s.e.m.
Mens/prolif, Mens/ES and Mens/MS P<0.001.
Abbreviations: Mens, Menstrual phase; Prolif, proliferative phase; ES, early






















MMP7 mRNA Expression in the Endometrium
Mens Prolif ES MS LS
Figure 5.3.3.1. MMP-7 mRNA expression within human endometrium across the
menstrual cycle (n= detailed within the x axis). Data are presented as relative
changes in mRNA expression relative to a control (negative control obtained from a
sample of mid secretory endometrium), given a nominal value of 1, mean ± s.e.m.
Mens/ES, Mens/MS and Mens/LS P<0.001.
Abbreviations: Mens, Menstrual phase; Prolif, proliferative phase; ES, early
secretory phase; MS, mid secretory phase; LS, late secretory phase.
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TGF(J-1 mRNA Expression in the Endometrium
Mens Proli ES MS LS
Figure 5.3.4.1. TGFp-1 mRNA expression within human endometrium across the
menstrual cycle (n= detailed within the x axis). Data are presented as relative
changes in mRNA expression relative to a control (negative control obtained from a
sample of early secretory endometrium), given a nominal value of 1, mean ± s.e.m.
Abbreviations: Mens, Menstrual phase; Prolif, proliferative phase; ES, early
secretory phase; MS, mid secretory phase; LS, late secretory phase.
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Comparative Expression in First Trimester Decidua
Elafin SLPI MMP7 TGFp-1
Figure 5.3.5.1 Elafin (blue), SLPI (green), MMP-7 (yellow) and TGFP-1 (lilac)
mRNA expression in first trimester decidual biopsies (n=6). Data are presented as
relative changes in mRNA expression relative to a control (negative control obtained




The role of the steroid hormones in the mediation of the innate immune response of
the female reproductive tract has been previously documented (Critchley, Kelly et al.
2001; Kayisli, Guzeloglu-Kayisli et al. 2004; Herath, Fischer et al. 2006). This
interaction may be direct or indirect via intermediate factor(s). Progesterone and
oestradiol have been shown to be involved with the differential expression of
cytokines throughout the menstrual cycle (Polli, Bulletti et al. 1996; Yang, Chen et
al. 1996; Agarwal and Marshall 1999; Verthelyi and Klinman 2000; Chegini, Ma et
al. 2002; Roberts, Luo et al. 2005). This effect may result from a change in the
balance or equilibrium that exists between progesterone and oestradiol. However, it
has been proposed that the act of withdrawal of either steroid may also stimulate a
response. The natural antimicrobials have been previously shown to be regulated by
the cyclical changes of steroid hormone levels (Quayle, Porter et al. 1998; King,
Critchley et al. 2003; King, Fleming et al. 2003; King, Morgan et al. 2003). This
regulation is believed to provide the female reproductive tract with a broad level of
coverage, with the differential expression of the proteins across the menstrual cycle.
In the female reproductive tract it has been shown that elafin mRNA is increased in
late secretory endometrium coincident with the withdrawal of progesterone, and
maximally expressed in menstrual endometrium when circulating concentrations of
progesterone are low (King, Critchley et al. 2003; King, Morgan et al. 2003). The
endometrial samples collected across the menstrual cycle, investigated within this
chapter confirm these observations (figure 5.3.1.1). The withdrawal of progesterone
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has been suggested to be stimulatory to an inflammatory response, with the up-
regulation of pro-inflammatory mediators (Stites and Siiteri 1983; Critchley, Kelly et
al. 2001; King, Critchley et al. 2001). Thus, it may be this indirect response which
mediates the increase in elafin expression in late secretory endometrium. However,
it has also been shown that leukocytes which infiltrate the late
secretory/perimenstrual endometrium, also express elafin (King, Critchley et al.
2003). Thus, this may account for the raised levels of elafin mRNA. It is possible
that progesterone has an inhibitory role on factors which serve to inhibit elafin, and
that in the absence of progesterone this inhibition is ablated. It has been
demonstrated that the expression of TGFp-1 is increased in endometrial stromal cells
in response to progesterone (Polli, Bulletti et al. 1996; Lim, Odukoya et al. 1998).
Data described in the present thesis demonstrated that the in vitro treatment of an
epithelial cell line with TGFp-1, resulted in a decrease in elafin mRNA (chapter 3).
Although not statistically significant there does also appear to be an increase in the
level of TGFP-1 mRNA in the mid and late secretory endometrium in comparison
with proliferative and early secretory endometrium (figure 5.3.4.1). This is
consistent with an up regulation in the presence of progesterone and it is possible that
this in turn serves to have an inhibitory role over elafin.
SLPI mRNA levels are shown to be increased in mid and late secretory endometrium
(figure 5.3.2.1) and this is in support of previous descriptions of SLPI up-regulation
in response to progesterone (King, Morgan et al. 2003). It has also been shown in
this thesis that SLPI may have an inhibitory effect upon the expression of elafin
(chapter 8). Perhaps SLPI acts as an indirect mediator in the progesterone dependent
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decrease in elafin mRNA in vivo. However, the co-culture studies (chapter 4) are
suggestive of paracrine mediated factor(s), as the inhibition of elafin in the presence
of progesterone and stromal cells represents that observed in primary endometrial
samples. There is also an increase in SLPI mRNA in menstrual endometrium, which
was not expected based on previous work (King, Morgan et al. 2003). The present
study contained a smaller number of subjects, which may be an explanation for the
results obtained that differ with previous larger studies (King, Critchley et al. 2000;
Fleming, King et al. 2003; King, Critchley et al. 2003; King, Fleming et al. 2003).
It was identified in the present thesis that MMP-7 has an associative relationship with
elafin, and this has been investigated in endometrial biopsies obtained across the
menstrual cycle. It has been previously shown, that MMP-7 is expressed in late
secretory, menstrual and proliferative endometrium and has not been detected in
early or mid secretory endometrium (Rodgers, Osteen et al. 1993). The present study
has demonstrated that MMP-7 mRNA expression is increased in menstrual and
proliferative endometrium, coinciding with both reduced progesterone and increasing
oestradiol levels (figure 5.3.3.1). MMP-7 has been shown to be inhibited in the
presence of progesterone (Bruner, Rodgers et al. 1995; Osteen, Sierra-Rivera et al.
1997; Osteen, Keller et al. 1999), and in studies described within this thesis (chapters
6-8). The present study was undertaken to investigate MMP-7 as a possible
candidate for the processing of pre-elafin (trappin-2) into the mature form (elafin) or
alternatively may function to degrade elafin. Timecourse studies in cell culture have
shown a similar pattern of MMP-7 to that exhibited by elafin mRNA, and in an
apparent lag i.e. MMP-7 mRNA expression appears to follow that of elafin (figure
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8.1.1, chapter 8). In the endometrium, elafin is expressed in late secretory and in
menstrual phase samples - whilst MMP-7 is observed to be increased in the
menstrual and proliferative samples. This would be in support of the Tag
relationship' in expression. TGFp-1 reduces the expression of epithelial MMP-7,
and with higher circulatory levels of progesterone there is an increase in the level of
TGFp-1. Thus, this may represent an indirect effect of progesterone via TGFp-1.
Elafin, SLPI, MMP-7 and TGFP-1 have been shown to be expressed in first trimester
decidua. There is no significant difference observed between these proteins in the
decidual samples that were studied, however, there is almost 3-point greater
expression of SLPI mRNA. Progesterone levels are maintained in decidua, and it has
been previously shown that SLPI levels are increased during the first trimester of
pregnancy (King, Fleming et al. 2002; King, Critchley et al. 2003; King, Morgan et
al. 2003). Further investigation of the role and possible interaction of these
molecules is addressed elsewhere in the present thesis (Chapters 6-8).
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In summary, the investigations undertaken in the present chapter were in response
to observations throughout the current thesis that a relationship likely exists between
the expression of SLPI, elafin and MMP-7 mRNA. Furthermore, the role ofTGF|3-l
upon the expression of these molecules and as a possible mediator was examined.
The expression of elafin and SLPI in the endometrium has been previously shown to
be governed by the cyclical changes of the sex steroids across the menstrual cycle
(King, Critchley et al. 2003). However, the expression of elafin and SLPI in relation
to other innate immune mediators has not been considered previously. In chapter 6
and 7 of the current thesis an associative expression between both SLPI and elafin
with MMP-7 has been observed. Whilst in chapter 8 the direct addition of SLPI has
been shown to decrease the Hec-IA expression of both elafin and MMP-7 mRNA.
The observations and questions raised in this current chapter are summarised in
figure 5.4.1. In this chapter it is shown that MMP-7 mRNA is expressed with elafin
during the menstrual phase and is expressed in the proliferative phase immediately
following. This may be to allow the enzyme to degrade elafin or to process elafin
and it could also be entirely coincidental. The expression of elafin and MMP-7 in
the menstrual phase may suggest an involvement in the breakdown of the functional
layer, with anti-protease activity. Whilst the expression of MMP-7 during the
proliferative phase may indicate a role in the rebuilding of the functional layer and
may also suggest the breakdown of molecules such as elafin following the high
levels of expression during the menstrual phase. The demonstration that TGFp-1
expression is highest during the secretory phase may serve as evidence of the
presence of progesterone mediated inhibitors of elafin and MMP-7. It has also been
reported previously that endometrial stromal cells upregulate the expression of
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TGFP-1 in response to progesterone (Polli, Bulletti et al. 1996). The increased levels
of SLPI mRNA during the secretory phase may also inhibit the expression of elafin
and MMP-7 as was shown in chapter 8. The data contained within the current














Proliferative phase Secretory phase
High circulating
progesterone levels
(A) Functional layer (B) basal Layer (C) myometrium
Figure 5.4.1 Schematic summary of the differential expression of SLPI (green),
elafin (blue), MMP-7 (yellow) and TGFP-1 (purple) at different stages of the
menstrual cycle. During the menstrual phase, involving tissue breakdown (*) and
when circulating levels of progesterone are low, elafin and MMP-7 have been shown
to be highly expressed. During the proliferative phase, MMP-7 is expressed at
similar levels to those observed in the menstrual phase. In mid secretory phase
when circulating progesterone levels are high, SLPI is maximally expressed. The
highest level of TGF(3-1 is also observed in the secretory phase. TGF(3-1 and SLPI
have been shown to be upregulated by progesterone and inhibitory towards the
expression of elafin and MMP-7 mRNA.
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Chapter 6:
Natural antimicrobial expression in human Fallopian tube with
and without the presence of an ectopic pregnancy.
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Chapter 6: Natural Antimicrobial Expression in human Fallopian tube with and
without the presence of an ectopic pregnancy
6.1 Introduction
Ectopic pregnancy is when the gestational tissues are located out with the uterine
cavity. In the UK ectopic pregnancy remains a cause of maternal death (RCOG
2004; Corpa 2006). Tubular pregnancies result from the mechanical failure of the
fertilised oocyte being delivered to the uterus in a timely fashion. The precise
underlying causes of an ectopic pregnancy are poorly understood. It has been
proposed that damage to the Fallopian tube due to sexually transmitted infections
such as chlamydia and gonorrhoea, may be a cause of ectopic gestation (Ankum, Mol
et al. 1996; Job-Spira, Fernandez et al. 1999). Chlamydia has been a well
characterised causal agent of chronic inflammation leading to pelvic inflammatory
disease (PID) (Bouyer, Coste et al. 2003). The prevalence of ectopic pregnancy has
increased over the past two decades and this has been linked to the increase in PID
(Westrom, Joesoef et al. 1992; Bouyer, Coste et al. 2003). It has been reported that
women who present with an ectopic pregnancy are found to have high levels of
antibodies to chlamydia (Svensson, Mardh et al. 1985; Chow, Yonekura et al. 1990;
Kihlstrom, Lindgren et al. 1990; Odland, Anestad et al. 1993). There is a 2-fold
greater risk of an ectopic pregnancy in women with a current or past history infection
with chlamydia (Westrom, Joesoef et al. 1992). There is a 4-fold risk of an ectopic
pregnancy for woman with a tubal pathology such as salpingitis, which involves
damage to the endosalpingeal mucosa (Westrom, Joesoef et al. 1992). This damage
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may result in obstruction of the migrating embryo, giving rise to an ectopic
implantation (Job-Spira, Fernandez et al. 1999; Bouyer, Coste et al. 2003).
A number of molecular factors and proteins have also been implicated in the
regulation of implantation and irregularities in these factors may be involved in
ectopic pregnancy. The possible inflammatory role in the pathogenesis of an ectopic
pregnancy gives rise to an interest in the role of immune effectors such as natural
antimicrobials in both the normal and ectopic implantation.
Currently very little is known about the expression or role of natural antimicrobials
within the Fallopian tubes. Natural antimicrobial expression in the Fallopian tube
has been previously described for human defensin 5 (HD5), a member of the a-
defensins (Quayle, Porter et al. 1998), and SLPI (Ota, Shimoya et al. 2002). In
contrast the expression levels of natural antimicrobials in the pregnant and non¬
pregnant endometrium has been well described and data have been presented in an
earlier chapter in this thesis (chapter 5), (Quayle, Porter et al. 1998; King, Fleming et
al. 2002; King, Critchley et al. 2003; King, Critchley et al. 2003; King, Fleming et al.
2003; Wira, Fahey et al. 2005). The role of antimicrobials in the decidua of failed
pregnancies such as in the event of miscarriage or a tubular ectopic pregnancy has
not been described and will be addressed in the next chapter. The expression of
natural antimicrobials in the endometrium has also been shown to be differentially
expressed across the menstrual cycle in response to changes in circulating sex steroid
hormones (King, Fleming et al. 2003). This differential expression in response to
sex steroids, has been further supported with in vitro studies using cell lines from the
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cervix, breast (King, Morgan et al. 2003) and in an endometrial cell line (data
described in chapter 3).
This study aimed to investigate the expression of natural antimicrobials in the normal
Fallopian tube and in samples that were collected at the time of surgical management
of ectopic pregnancy. The expression patterns of natural antimicrobials in normal
Fallopian tube samples were compared with endometrial tissue samples that had been
accurately categorised according to menstrual cycle phase. The Fallopian tube
samples obtained from the surgical management of ectopic pregnancy were
investigated for differential natural antimicrobial expression and compared with
normal Fallopian tube biopsies. The emerging pattern that has been observed
between the expression patterns of SLPI, elafin and MMP-7 was further explored.
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6.2 Materials and Methods
6.2.1 Sample collection
Fallopian tube biopsies (n=10) were collected from fertile woman undergoing
hysterectomy procedures for benign indications (age 18-45 years). Fallopian tube
biopsies were utilised for investigations into the expression of natural antimicrobials.
Fallopian tube biopsies were classified according to phase of ovarian/menstrual cycle
(n=7) as detailed in table 6.2.1.1. The samples were dated at the time of biopsy using
serum levels of E2 and P4 (figure 6.2.1.1) and histological dating of the
corresponding endometrial samples.
Fallopian tube biopsies (n=9) were collected from women undergoing surgical
management of ectopic pregnancy (age 25-40 years). The details of these samples














1 37 2+0 Late secretory 392.18 3.06 Total abdominal
hysterectomy
2 41 2+0 Proliferative 1022.87 0.81 Total abdominal
hysterectomy
3 37 2+2 Proliferative 940.44 3.82 Total abdominal
hysterectomy
4 44 3+1 Proliferative 829.42 4.19 Total abdominal
hysterectomy
5 44 2+2 Proliferative 116.3 2.88 Sub-total
abdominal
hysterectomy
6 36 3+0 Proliferative 770.63 5.16 Total abdominal
hysterectomy
7 32 1+0 Mid secretory 549.91 88 Total abdominal
hysterectomy
Table 6.2.1.1 Details of the Fallopian tube samples used when analysing natural
antimicrobial expression across the menstrual cycle.
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Proliferative Mid Secretory Late Secretory Proliferative Mid Secretory Late Secretory
Figure 6.2.1.1 Graphical demonstration of serum oestradiol (A) and progesterone
(B) levels in peripheral blood obtained at the time of biopsy for the Fallopian tubes
investigated for cyclic expression of natural antimicrobials.
Tissue
Sample
Age Parity Gestation Procedure
1 30 0+0 6+2 Laparoscopic
salpingectomy
2 25 1+1 7+1 Laparoscopic
salpingectomy
3 40 1+0 8+3 Laparoscopic
salpingectomy
4 31 2+1 5+4 Laparoscopic
salpingectomy
5 28 2+2 5+3 Laparoscopic
salpingectomy
6 26 0+0 6+0 Laparoscopic
salpingectomy
7 26 1+0 6+6 Laparoscopic
salpingectomy
9 33 0+0 11+1 Laparoscopic
salpingectomy
Table 6.2.1.2 Details of the Fallopian tube samples obtained from women with an
ectopic gestation (tubal pregnancy).
6.2.2 RNA extraction and PCR
RNA was extracted from frozen biopsy samples (Fallopian) stored in RNA later
(Ambion), using the Qiagen proteinase K protocol and cDNA prepared, as detailed in
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section 2.3, chapter 2. Expression levels of SLPI, Elafin, MMP-7 and hBDl-4
mRNA were determined using quantitative real time PCR (as detailed in section
2.3.3, chapter 2).
6.2.3 Immunohistochemistry
Elafin and SLPI protein was localised in the Fallopian tube using the protocols
described in section 2.6, chapter 2.
6.2.4 Statistical Analysis
The PCR results in this chapter were analysed by ANOVA for significant difference.
Fisher's protected least significant difference (PLSD) was used to assign individual
differences (PRISM).
Statistical analysis was not carried out on cyclic Fallopian biopsies due to the low
number of clearly endometrially staged samples.
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6.3 Results
6.3.1 Differential expression of antimicrobials and MMP-7 in relation to the
stage of ovarian cycle as determined by histological dating of endometrial
biopsy and oestradiol and progesterone levels at time of endometrial and
Fallopian biopsy collection.
6.3.1.1 Summary of results for section 6.3.1
Relative increase in mRNA expression over mid-secretory endometrial
control
Proliferative (n=5) Mid Secretory (n=1) Late Secretory (n=1)
hBD1 12 9 21
hBD2 3 Not detected 240
hBD3 2 2 1.7
hBD4 15 5 1
SLPI 11 6 13
Elafin 3 10 43
MMP-7 2 18 19
Table 6.3.1.1 Summary of relative changes in mRNA expression of natural
antimicrobials and MMP-7 across the menstrual cycle in Fallopian tube biopsies
(staged using histopathology of matched endometrium and E&P levels as described
in section 2.1, chapter 2).
To examine the influence of ovarian cycle stage modulation of natural antimicrobial
expression in the Fallopian tube, biopsies were staged relative to the corresponding
ovarian cycle stage as determined by endometrial histological stage and serum
oestradiol and progesterone concentration at the time of biopsy.
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Fallopian tube expression of SLPI, elafin, MMP-7 and hBD4 (figure 6.3.1.1) are
influenced by ovarian cycle stage.
hBD4 mRNA levels are significantly increased in biopsy from Fallopian tube
collected during the follicular phase (n=5) relative to other cycle stages (P<0.001)
(relative to the control; mid-secretory endometrium; figure 6.3.1.1 (C)). A 4-point
increase in hBD4 mRNA was observed in Fallopian tube (n=l) when compared to
expression in a sample of mid-secretory endometrium.
MMP-7 mRNA levels (figure 6.3.1.1 (D)) are found to be elevated in Fallopian
biopsy samples obtained from the mid and late secretory phases (according to
endometrial dating and serum measurements of oestradiol and progesterone). MMP-
7 mRNA is significantly lower in proliferative phase samples (n=5; P<0.001) relative
to mid-secretory phase endometrium (control) and almost 18-point greater in the mid
and late secretory phase Fallopian tube biopsies (n=l for each).
Expression of elafin mRNA (figure 6.3.1.1 (E)) was observed to be highest in
Fallopian tube collected during the late secretory phase of the menstrual cycle (n=l)
(relative to mid secretory phase endometrium as control). The expression of elafin
mRNA appears to be affected by the oestradiol levels (A) for these samples. There is
lower mRNA expression of elafin in Fallopian tube samples collected during the
proliferative phase of the menstrual cycle (n=5) expression is comparable with the
decreased level of MMP-7 mRNA (6.3.1.1 (D) in the same Fallopian tube samples;
this is true also for the late secretory phase biopsy.
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SLPI mRNA (6.3.1.1 (F)) levels were higher (trend, no statistics) in Fallopian
biopsies from the proliferative (n=5) and late secretory phase (n=l) of the menstrual
cycle (relative to mid secretory phase endometrium as control), 11 and 13-point
respectively. There is a slightly higher level (4 point) of SLPI mRNA expression in
the Fallopian tube obtained from the mid-secretory phase.
hBDl mRNA (6.3.1.2 (A)) levels were found to be relatively higher in Fallopian
tube biopsies collected during the proliferative (n=5), mid-secretory (n=l) and late
secretory phase (n=l) of the menstrual cycle, (relative to mid-secretory phase
endometrium utilised as control). The greatest level of hBDl is observed in the
Fallopian tube sample during the late secretory phase (20-point).
hBD2 mRNA expression (6.3.1.2 (B)) was found to be relatively higher 230-point
(over mid-secretory phase endometrial control) in the Fallopian tube sample
collected from the late secretory phase. In contrast there is a less than a 2-point
induction in the Fallopian tube samples collected during the proliferative (n=5) and
mid-secretory phase of the menstrual cycle in comparison to the control.
Messenger RNA levels of hBD3 (6.3.1.2 (C)) are similar for the Fallopian tube
biopsies obtained during the proliferative (n=5), mid-secretory (n=l) and late
secretory (n=l) phases (relative to mid-secretory phase endometrium as control).
hBD3 mRNA levels are unaffected with respect to the phases of the menstrual cycle
that were investigated during this study.
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Elafin mRNA expression in the Fallopian tube SLPI mRNA expression in the Fallopian tube
Proliferative Mid Secretory Late Secretory
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Phase of the menstrual cycle
Figure 6.3.1.1 The serum levels of sex steroids at the time of Fallopian tube biopsy
were measured and presented in (A) oestradiol and (B) progesterone. Graphical
demonstration of the natural antimicrobials hBD4 (C), MMP-7 (D), elafin (E) and
SLPI (F) mRNA expression in the Fallopian tube. Data are presented as relative




















































Figure 6.3.1.2 Graphical demonstration of the natural antimicrobials hBD1 (A),
hBD2 (B) and hBD3 (C) mRNA expression in the Fallopian tube. Data are
presented as relative changes in mRNA expression relative to a control; given a
nominal value of 1, mean ± s.e.m.
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6.3.2 Expression of natural antimicrobials and the matrix metalloproteinase,
MMP-7 in Fallopian tube with an ectopic gestation.
6.3.2.1 Summary of results for section 6.3.2






hBD1 12 +/-3.01 11 +/- 4.48
hBD2 31 +/- 29 117 +/-41.3 (P<0.05)
hBD3 2.4 +/- 0.31 41 +/- 17.8
hBD4 9 +/- 5.31 31 +/- 16.3
SLPI 9 +/- 1.65 19+/-5.7
Elafin 10+/-3.58 38 +/- 12.9
MMP-7 8 +/- 2.23 186 +/-62.23
The natural antimicrobial peptides hBD2 - 4 (6.3.2.1 (A)) have an altered level of
mRNA expression in the Fallopian tube samples with an ectopic gestation compared
to expression in Fallopian tube without an ectopic gestation. Human p-defensin 1
mRNA (yellow) expression was unaffected by the presence of an ectopic gestation
(n=9) when compared to samples without an ectopic gestation (n=10). Human P-
defensin 2 (red) mRNA expression was significantly increased in Fallopian tube
samples with an ectopic gestation (figure 6.3.2.1 (A), red; P<0.05) when compared to
the non-ectopic group. The P-defensins, 3 and 4 displayed an increased tendacy in
mRNA expression in the Fallopian tube samples collected from subjects with an
ectopic pregnancy.
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The anti-protease molecules elafin, SLPI and MMP-7 (figure 6.3.2.1 (B)) were
observed to have increased mRNA expression in Fallopian tube samples collected
from subjects with an ectopic pregnancy. The ratio of expression for the respective
genes is altered with each showing a similar level of expression in subjects without
an ectopic expression. Fallopian tube samples with an ectopic gestation
demonstrated an increase in both elafin and MMP-7 mRNA expression, which was
greater than that observed for SLPI mRNA. The increased expression of elafin and
SLPI in the ectopic group is not statistically significant; the increase in MMP-7 is
significant (P<0.001).
The mRNA expression profiles of elafin, SLPI and MMP-7 in individual Fallopian
tube samples are represented individually in figure 6.3.2.2 (A) and (B). The
expression of elafin and MMP-7 is similar, with both increased or decreased relative
to SLPI in the Fallopian tube samples without an ectopic gestation (6.3.2.2 (A)). In
contrast this apparent ratio is altered in the Fallopian tube biopsies from women with
an ectopic pregnancy (6.3.2.2 (B)), demonstrating an increased level of MMP-7
mRNA, over that of both SLPI and elafin.
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Figure 6.3.2.1 Human p-defensin 1, 2 (P<0.05), 3 and 4 (A) and elafin, SLPI and
MMP-7 (P<0.001) (B) mRNA expression in Fallopian tube biopsies with (n=9) and
without (n=10) an ectopic gestation. Data are presented as relative changes in
mRNA expression relative to a control (mid-secretory endometrium); given a
nominal value of 1, mean ± s.e.m.
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Biopsy No.
Figure 6.3.2.2 Messenger RNA expression profiles of elafin, SLPI and MMP-7 in
individual Fallopian tube biopsies from subjects without (n=11; A) and with an
ectopic gestation (n=9; B). Data are presented as relative changes in mRNA
expression relative to a control, given a nominal value of 1, mean ± s.e.m is
representative of duplicate sample wells. Note that the y axis is presented on
different scales.
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6.3.3 Immunohistochemical localisation of SLPI and Elafin in human
Fallopian tube.
6.3.3.1 Localisation of SLPI and elafin in the Fallopian tube
Fallopian tube biopsies obtained from women undergoing surgery for benign
gynaecological conditions were investigated for the presence of SLPI and elafin
protein.
SLPI protein (figure 6.3.3.1) was found to be present in Fallopian tube samples
obtained from women in the mid-secretory phase of the menstrual cycle (determined
as described in section 2.1, chapter 2). This immunoreactivity was localised to the
epithelium (B, C and D; figure 6.3.3.1) and no staining could be observed within the
stromal regions. SLPI protein was found to be on the surface of the epithelial cells
and in some areas gave rise to a 'blebbing' appearance (D). The level of
immunoreactivity was not quantitatively determined.
Elafin protein (figure 6.3.3.2) was present in Fallopian tube biopsies collected from
women in the mid and late secretory phase of the menstrual cycle (determined as
described in section 2.1, chapter 2). In the mid-secretory phase biopsies (B),
immunostaining was restricted to the leukocyte population (indicated by an arrow;
B). There was no immunoreactivity observed in either the epithelial cells or stromal
regions. In late secretory Fallopian tube samples (C and D), immunoreactivity is
present in the epithelium and appears to be located in the cytoplasm.
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6.4 Discussion
6.4.1 Schematic summary of natural antimicrobial and MMP-7 mRNA
expression in endometrial tissue across the menstrual cycle.
Antimicrobial mRNA expression in endometrium
across the menstrual cycle
Secretory
Figure 6.3.1 Schematic diagram showing the distribution of natural antimicrobial
expression in endometrial tissue both in relation to the phase of the menstrual cycle
and the level of circulating sex steroids, oestrogen (black) and progesterone (red).
The diagram is based on reports in the literature (King, Critchley et al. 2003) and
work undertaken for this thesis (chapter 5).
Based upon our knowledge of NAP expression in the endometrium and the role of
the sex steroids in the regulation of natural antimicrobial expression, these
preliminary data suggest that the expression of these molecules may be similarly
modulated in the Fallopian tube. This is particularly evident in the expression of
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elafin and hBD4, where a pattern associated with the serum levels of steroids can be
observed. In the endometrium it has been previously reported that hBD4 is
predominantly and maximally expressed during the proliferative phase of the
menstrual cycle, when the levels of circulatory oestradiol are high. The data in this
thesis demonstrate that this may also be the case in the Fallopian tube, with the
greatest level of hBD4 observed in staged proliferative (follicular) samples and
corresponds with the serum concentration of oestradiol measured for the same
samples. It has also been shown that there is less hBD4 expression in the mid and
late secretory samples corresponding to decreased levels of oestradiol measured for
those samples. Further analysis of the proliferative (follicular) samples (n=5) for the
level of hBD4 mRNA and the serum oestradiol for each of the individual samples
(figure 6.4.1), appeared to demonstrate a direct association between expression and
oestradiol levels. The expression of hBD4 could be associated with a decline or
withdrawal in levels of circulatory oestradiol, in the samples investigated in this
thesis, the greatest level of expression is observed in the sample with the lowest
serum level of oestradiol - perhaps this sample is representative of the end of the
proliferative (follicular) phase of the menstrual cycle, and it is the withdrawal of the
hormones which stimulates the expression of hBD4. Further investigations using a
larger sample group would enable a clearer association between the level of serum
oestradiol at the time of biopsy and the expression of hBD4 mRNA. A consideration
into the the possible mediators and/or mechanisms that could be attributed to the
increase in this antimicrobial should be explored. It should be noted that to date
none of the other antimicrobials have been found to be upregulated during the
proliferative phase of the menstrual cycle for either the endometrium or the Fallopian
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tube as presented herein. The reasons for this remain unclear and merits further
investigation.








Figure 6.4.1 Comparative plot of hDB4 mRNA levels obtained for each Fallopian
tube sample and compared with the serum levels of E2 obtained at the time of
biopsy.
In the endometrium it has been show previously that elafin mRNA is upregulated
during the late secretory/peri-menstrual and maximally expressed during the
menstrual phase of the cycle this has been proposed to be in response to progesterone
withdrawal (King, Critchley et al. 2003; King, Critchley et al. 2003). In the present
thesis it was demonstrated that elafin mRNA was greatly increased in the late
secretory Fallopian tube biopsy. Fallopian tube biopsy samples which had been
accurately staged and identified as being menstrual (as described in section 2.1,
chapter 2) were unavailable at the time of writing. However, preliminary data was
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obtained from pre-staged Fallopian tube biopsy samples. The level of elafin
expression was consistent with that which might be expected from the menstrual
phase and subsequently matched information obtained from the patients last
menstrual period (LMP).
It has also been observed that there may be an inverse relationship between elafin
mRNA expression and serum oestradiol levels. Increased levels of oestradiol
appears to correspond with decreased levels of elafin mRNA in the samples that we
investigated (n=7). The expression of elafin mRNA is highest in the Fallopian tube
collected during the late secretory (luteal) phase and with lower levels of serum
progesterone. There is a low serum progesterone level in the samples obtained from
the proliferative phase; however, there is a high oestradiol level. Thus, it may be
possible that oestradiol has an inhibitory effect upon the expression of elafin or
mediators/mechanisms required for the expression of elafin.
SLPI has been shown to be upregulated by progesterone in vitro in the breast cell line
and within this thesis the endometrial epithelial cell line Hec-IA. In the
endometrium SLPI has been reported previously and confirmed within this thesis
(chapter 5) to be maximally expressed during the mid-secretory phase of the
menstrual cycle, when circulatory progesterone levels are high. However, in the
Fallopian tube biopsies investigated there was an increased level of SLPI in those
collected during the proliferative (follicular) phase and late secretory (luteal) phase
and was greater than the level of SLPI observed in the mid-secretory phase (luteal)
biopsy. However, the numbers are too small to allow for any conclusive statements.
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It has also been observed that the expression of SLPI in the Fallopian tube samples
studied is opposite to the level of serum progesterone. There may be a difference
between the Fallopian tube and the endometrium in the expected level of SLPI
expression. An alternative is that it may suggest that the local levels of sex steroids
within the Fallopian tube may not be representative of that detected in the peripheral
blood samples. There is no precedence that endometrial cycle stage is necessarily in
synchrony with the Fallopian tube or indeed that the Fallopian tube responds in
relation to the stages of the ovarian cycle.
In order to further discover the proposed role of MMP-7 in the expression of elafin
and or SLPI, this too was investigated in the menstrual staged Fallopian tube samples
in order to elucidate any similarities in the patterns of expression. MMP-7 has been
previously described to be maximally expressed during the menstrual and
proliferative phase in the endometrium (Rodgers, Osteen et al. 1993; Rodgers,
Matrisian et al. 1994) and was demonstrated within this thesis (chapter 5). However,
the analysis of MMP-7 mRNA expression demonstrates maximal expression in the
mid and late secretory (luteal) phase Fallopian tube biopsies, with relative reduced
levels in those collected during the follicular (proliferative) phase. It could be
proposed that if there is a direct or indirect relationship between the expressions of
MMP-7 with elafin and/or SLPI there may be a Tag'. In the endometrium MMP-7
expression is shown to be increased in the menstrual phase along with elafin,
however, increased MMP-7 expression has also been observed in the proliferative
phase, whilst elafin is not expressed. In the Fallopian tube it appears that the
maximal expression of both MMP-7 and elafin is coupled in the biopsies collected in
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the late secretory (luteal) phase. Whereas a smaller increase in the levels of elafin
mRNA are observed in the mid secretory (luteal) phase along with high levels of
MMP-7. In contrast both demonstrate low expression levels in the proliferative
phase Fallopian tube biopsies. It may also be interesting to note that this coincides
with an increased level of SLPI in the proliferative (follicular) phase samples.
Analysis of the mRNA levels of the P-defensins in the stage determined Fallopian
tube biopsies have also demonstrated differential expression. Human p-defensin 1 is
shown to be expressed at a similar level in the proliferative (follicular) and mid
secretory (luteal) phase biopsies, whilst the late secretory (luteal) phase sample
demonstrates almost a doubled level of hBDl mRNA. Previously, it has been shown
that hBD 1 is constitutively expressed through all phases of the cycle in endometrium
(Fleming, King et al. 2003; King, Critchley et al. 2003); it has also been proposed to
have a constant level of expression in other mucosal regions (Pazgier, Hoover et al.
2006). The low group numbers currently presented prevent conclusive analysis.
However, the expression of hBDl in the Fallopian tube in relation to the menstrual
cycle has not previously been described. In contrast hBD2 was found to be highly
expressed only in the late secretory (luteal) sample, low levels of hBD2 mRNA are
observed in the proliferative (follicular) phase, but, was undetected in the mid
secretory (luteal) biopsy. Human P-defensin 2 has been described as being
maximally expressed during the menstrual phase in endometrium (Fleming, King et
al. 2003; King, Critchley et al. 2003), it has further been demonstrated that hBD2
expression is inhibited in the presence of progesterone (Fleming, King et al. 2003),
(chapter 3). The serum level of progesterone for the late secretory (luteal) sample is
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low which may also support these observations for the Fallopian tube. Human p-
defensin 3 mRNA is observed at a similar but relatively low level for all Fallopian
tube biopsy samples, hBD3 in the endometrium was reported to be greatest in the late
secretory phase and this is thought to be in response to an increase in cytokines and
the influx of IFNy secreting neutrophils (King, Fleming et al. 2003).
It is likely that the expression of natural antimicrobials in the Fallopian tube is
differential according to the stage of the ovarian cycle at the time of collection.
Fallopian tube biopsies were collected across the ovarian cycle from women
undergoing surgery for benign gynaecological procedures and were compared with
the Fallopian tube samples collected from women with an ectopic pregnancy. The
mRNA expression levels of the human p-defensins are altered between the two
groups with the exception of hBDl which is unchanged. Human P-defensin 2
mRNA is significantly (P<0.05) greater in the Fallopian tube of woman with an
ectopic pregnancy, which may indicate the potential for this defensin to be further
investigated as a diagnostic marker for this condition. It may also offer further
opportunities from our understanding of the conditions required for hBD2 expression
and allow for the elucidation of other candidates and/or mechanisms. However,
hBD2 is also an inflammatory mediator and it is not possible with the current study
to differentiate between a causal or effective role in ectopic pregnancy. Human p-
defensins 3 & 4 are also increased in the Fallopian tube of women with an ectopic
pregnancy, further indicating a role for these molecules in an ectopic gestation and
further study is merited.
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The investigation into the expression of elafin, SLPI and MMP-7 in Fallopian tube
were also undertaken. An increase in mRNA levels was seen for all three molecules
in the group of subjects with ectopic pregnancy, with MMP-7 being significant
(P<0.001). SLPI mRNA was only slightly elevated, whilst elafin was 30-point
greater in Fallopian tube with an ectopic gestation. The MMPs have been identified
as having a number of roles in innate immunity including the processing of cytokines
(Gearing, Beckett et al. 1995; Opdenakker, Van den Steen et al. 2001), and defensins
into their active forms (Ayabe, Satchell et al. 2002; Shirafuji, Tanabe et al. 2003;
Weeks, Tanabe et al. 2006). They are also involved in the chemotaxis and
movement of leukocytes through regions of inflammation (Murphy and Gavrilovic
1999; Vaday, Hershkoviz et al. 2000; Vaday, Franitza et al. 2001). Thus, it is
possible that MMP-7 has a role in relation to the expression of natural antimicrobials
or in the modulation of an inflammatory response towards an ectopic gestation. A
role has been suggested for the MMPs in the post infection scarring and pathology
associated with Chlamydia. The TNFa mediated upregulation and subsequent
monocyte infiltration increases the level of damage to the extracellular matrix (ECM)
and deposition of collagen (Ault, Kelly et al. 2002). The involvement of elafin (van
Bergen, Andriessen et al. 1996) and SLPI (Angelov, Moutsopoulos et al. 2004) in
wound repair may explain any association between these molecules in the Fallopian
tube with an ectopic gestation.
The analysis of the samples within the Fallopian tube both with and without an
ectopic gestation revealed interesting differences in the ratio of elafin, SLPI and
MMP-7 mRNA expression. In the control group (no ectopic), the expression of
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elafin and MMP-7 appear to be increased together over SLPI (*n=6), or both
decreased in relation to SLPI (*n=4). Further, to this observation it can also be seen
that these two expression ratio/relationships are represented almost 60:40 - in that
out of 11 samples, 6 show increased elafin and MMP-7, and 4 show the converse
decreased elafin and MMP7, increased SLPI. One sample (10) demonstrates similar
levels for each of the genes. Fallopian samples with an ectopic pregnancy did as
previously described show an increased level of mRNA for elafin, SLPI and MMP-7
in comparison with the Fallopian tube samples with no ectopic gestation. However,
the ratios are altered; the expression level of MMP-7 mRNA is the most increased in
the majority of the samples. As with the Fallopian tube samples without an ectopic
gestation, there is also an increased level of elafin along with MMP-7. The least
amount of change is observed with the level of SLPI mRNA and in contrast to the
samples without an ectopic gestation, only exceeds the level of elafin and SLPI
expression in one of the nine samples (figure 6.3.2.2 B [*]). This may be a
significant observation for the further understanding of the changes involved in
tubular ectopic pregnancy. However, whether this change is causal or consequential
would also need to be elucidated.
SLPI and elafin protein were detected in the Fallopian tube obtained from women
undergoing surgery for benign gynaecological conditions. Immunoreactivity for
SLPI was present in the epithelium of Fallopian tube sampled during the mid
secretory (luteal) phase. This was in agreement with the observation of increased
SLPI mRNA in mid-secretory (luteal) phase also. However, greater amounts of
SLPI mRNA were observed in the proliferative (follicular) and late secretory (luteal)
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phase samples (figure 6.3.1.1.F). A larger number of samples are required to be
investigated before any conclusive discussions are possible. Elafin immunoreactivity
was found to be localised to the leukocyte population in mid secretory (luteal) phase
biopsies. The epithelial cells of samples obtained from the late secretory (luteal)
phase were found to have staining for elafin. The highest level of elafin mRNA was
also found to be in the samples obtained from the late secretory (luteal) phase (figure
6.3.1.1 E). However, the amount of immunoreactivity was not quantitatively
measured and too few samples were examined due to time restrictions.
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In summary, these preliminary data suggest that the expression of natural
antimicrobials in the Fallopian tube is subjected to changes governed by the ovarian
cycle. This is similar to the observations of the differential expression of natural
antimicrobials in the endometrium across the menstrual cycle (King, Critchley et al.
2003). However, it seems likely that the expression of natural antimicrobials in the
Fallopian tube is asynchronous to that observed in the endometrium. The expression
of hBD4 in the Fallopian tube appears to be asscociated with circulating levels of
oestradiol. This may be significant when considered with the previous findings of
maximal expression in endometrium collected from the proliferative phase of the
menstrual cycle (King, Fleming et al. 2003).
The presence of an ectopic pregancy increased the level of most natural
antimicrobials and MMP-7 when compared to Fallopian tubes without an ectopic
gestation. The expression levels of SLPI, elafin and MMP-7 mRNA have been
shown to have an association with each other. The expression of SLPI was found to
be greater than both elafin and MMP-7 (n=4) or lower than both elafin and MMP-7
(n=6), (figure 6.4.2 A). Furthermore, this pattern of expression appears to be altered
in the presence of an ectopic gestation (figure 6.4.2 B). The expression of MMP-7
mRNA was greatly increased; similarly elafin was increased but remained below that
of MMP-7. Perhaps it is not the expression of these molecules but their ratio in
relation to one another that should be considered. Further analysis of the expression
pattern and possible association between SLPI, elafin and MMP-7 was also
undertaken with decidual groups (chapter 7), and via the treatment of Hec-IA cells
with SLPI and MMP-7 in chapter 8 of the current thesis.
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A Expression pattern of SLPI, elafin and MMP-7 mRNA in
individual Fallopian tube samples
n=11
Expression pattern of SLPI, elafin and MMP-7 mRNA in
individual Fallopian tube samples with an ectopic gestation
Figure 6.4.2 Schematic summary derived from the data presented in figure 6.2.5.2.
In Fallopian tube without an ectopic gestation (A), SLPI was found to be lower than
elafin and MMP-7 (n=6) or higher than elafin and MMP-7 (n=4). It was also
apparent that elafin was greater than MMP-7 (n=7). In Fallopian tube with an
ectopic gestation (B), the pattern(s) were altered. MMP-7 was found to be
expressed at a higher level elafin. Both MMP-7 and elafin were found to be greater
than SLPI in 8 out of the 9 samples investigated.
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Chapter 7:
Natural antimicrobial expression in first trimester decidua from
women with ectopic gestation and miscarriage.
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Chapter 7: Natural antimicrobial expression in first trimester decidua from
women with ectopic gestation and miscarriage.
7.1 Introduction
Successful human reproduction involves the implantation of a fertilised oocyte into
endometrial tissue, where sufficient nutrient support is available to allow for
development and maturity (Marx, Arck et al. 1999). In preparation for implantation
the human endometrium undergoes the process of decidualisation, involving both
functional and morphologically distinct changes in the tissue (Loke, King et al. 1995;
King 2000). In the event of an ectopic pregnancy, implantation occurs outwith the
endometrium. The epithelium of the Fallopian tube can not facilitate a successful
pregnancy and does not undergo decidualisation (Stewart-Akers, Krasnow et al.
1997). However, the uterine endometrium still undergoes the process of
decidualisation (Stewart-Akers, Krasnow et al. 1997). Thus, there have been studies
into the comparative differences between the decidua of a normal intra-uterine
pregnancy with that of an empty uterus arising from an ectopic gestation (Marx,
Arck et al. 1999).
Natural antimicrobials have been found to be associated with a number of mucosal
surfaces and serve to function as key members of the innate immune response.
Natural antimicrobials have been shown to be expressed throughout the female
reproductive tract (summarised in figure 1.6.1) which is suggestive of a pivotal role
for these molecules in immune regulation. In chapter 6 it was shown that the
presence of an ectopic gestation gave rise to an increase in the expression of natural
antimicrobial mRNA in the Fallopian tube. This was suggestive of a role for these
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molecules in the inflammatory response associated with an ectopic pregnancy. The
expression of natural antimicrobials during early pregnancy has been previously
described. SLPI has been shown to be more highly expressed than in cyclic
endometrium (maximal during the mid-secretory phase), (within this thesis; chapter
5) (King, Critchley et al. 2000); hBDl, hBD2 and granulysin have also been shown
to be expressed (Fleming, unpublished), (King, Critchley et al. 2003) and elafin,
within this thesis, chapter 5.
The expressions of natural antimicrobials in the decidua of pathologic situations such
as the failure in pregnancy resulting from an ectopic gestation or in miscarriage have
not been described previously.
243
7.2 Materials and Methods
7.2.1 Sample collection
First trimester decidua was obtained from patients undergoing surgical termination of
pregnancy (STOP; n=6); surgical management of miscarriage (n=5) and ectopic
gestation (n=10) and detailed in table 7.2.1.1. All samples were examined
histologically (H&E) to exclude the presence of trophoblast.
Tissue
Sample
Age Group Parity Gestation Procedure
1 35 1 1+2 10+6 Evacuation of Retained Products of Conception
2 31 1 1+0 10+6 Evacuation of Retained Products of Conception
3 34 1 0+0 12+6 Evacuation of Retained Products of Conception
4 30 1 0+0 14+1 Evacuation of Retained Products of Conception
5 28 1 1+1 11+1 Evacuation of Retained Products of Conception
6 28 1 0+0 9+6 Evacuation of Retained Products of Conception
1 33 2 3+3 10+5 Surgical Termination of Pregnancy
2 28 2 0+0 10 Surgical Termination of Pregnancy
3 22 2 1+1 8+6 Surgical Termination of Pregnancy
4 24 2 0+0 10 Surgical Termination of Pregnancy
5 29 2 1+3 10+6 Surgical Termination of Pregnancy
1 30 3 0+0 6+2 Diagnostic Laparoscopy
2 25 3 1+1 7+1 Diagnostic Laparoscopy
3 40 3 1+0 8+3 Diagnostic Laparoscopy
4 31 3 2+1 5+4 Diagnostic Laparoscopy
5 28 3 2+2 5+3 Diagnostic Laparoscopy
6 26 3 0+0 6+0 Diagnostic Laparoscopy
7 26 3 1+0 6+6 Diagnostic Laparoscopy
9 33 3 0+0 11+1 Diagnostic Laparoscopy
10 35 3 0+1 6+1 Diagnostic Laparoscopy
Table 7.2.1.1 Uterine decidua collected from women (age 22-40) undergoing
surgical management of miscarriage (n=6; Group 1), surgical termination of
pregnancy (n=5; Group 2) and the surgical management of ectopic pregnancy
(n=10; Group 3).
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7.2.2 RNA extraction and Q-RT-PCR
RNA was extracted from frozen biopsy samples stored in RNA later, using the
Qiagen proteinase K protocol and cDNA prepared, as detailed in chapter 2.
Expression levels of SLPI, Elafin, MMP-7 and hBDl-4 mRNA were determined
using quantitative real time PCR (as detailed in section 2.3.1).
7.2.3 Immunohistochemistry
Elafin and SLPI were localised in first trimester decidua (STOP, n=6; Miscarriage,
n=5; Ectopic, n=10), using the protocol detailed in chapter 2 (section 2.6).
7.2.4 Statistical Analysis
The PCR results in this chapter did not conform to normal distribution and were
subject to non-parametric statistical analysis. Fisher's protected least significant
difference (PLSD) was used to assign individual differences (PRISM).
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7.3 Results
7.3.1 Natural antimicrobial expression in human first trimester decidua
Decidua was obtained from women undergoing surgical management of ectopic
pregnancy (n=10), surgical management of miscarriage (n=5) and termination of
pregnancy during the first trimester (STOP; n=6).
Elafin mRNA (figure 7.3.l.l (A)) expression levels were increased in the uterine
decidua from subjects with an ectopic gestation, when compared with expression
levels in decidua where the gestation was uterine (not statistically significant).
Messenger RNA levels for elafin are also raised in the decidual samples obtained
from woman with miscarriage (n=5).
SLPI mRNA (figure 7.3.1.1 (B)) levels are increased in the decidua from subjects
with an ectopic gestation (not statistically significant) when compared to expression
in decidua of STOP or miscarriage. There was no difference in the mRNA
expression levels of SLPI in decidua from women with miscarriage or having a
STOP.
Messenger RNA for MMP-7 was significantly increased in decidua from women
with an ectopic pregnancy when compared to the expression in decidua from women
with either a miscarriage or STOP (figure 7.3.1.1 (C); P<0.01 (n=10)). There was no
difference in the level of MMP-7 mRNA in decidua between the STOP and
miscarriage subjects.
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In order to view the level of changes in mRNA for elafin, SLPI and MMP-7 in
relation to one another the data are plotted on the same scale figure 7.3.1.1 (D).
The mRNA expression profiles of elafin, SLPI and MMP-7 in individual decidual
samples are represented individually in figure 7.3.1.2 (A) ectopic gestation, (B)
STOP and (C) miscarriage. In the decidua from women with an ectopic gestation
(A), MMP-7 mRNA levels were increased substantially over the level of both SLPI
and elafin mRNA. Elafin mRNA was found to be increased over the levels of SLPI.
SLPI was found to be the highest expressed in the decidua obtained from women
with a STOP (B), with lower levels of elafin and MMP-7 mRNA observed. In
decidua from failed intrauterine pregnancy (C), SLPI mRNA was reduced and the
levels of elafin and MMP-7 increased. The patterns of expression of SLPI, elafin
and MMP-7 are altered between the decidual groups
Human P-defensins 1-4 mRNA (figure 7.3.1.3 (A)) levels are found to be altered in
the decidua from women with an ectopic pregnancy. The mRNA expression profiles
for all four of the defensins are presented on the same scale (A), and on separate
scales respective of their level of expression (B - E). Human P-defensin 1 (B)
mRNA levels are decreased in the decidua from women with an ectopic pregnancy
when compared with expression in decidua from women with miscarriage or STOP
(non-significant). In contrast the mRNA levels of hBD2, hBD3 (P<0.05 decidua
from ectopic gestation vs. STOP) and hBD4 all demonstrate an increase in
expression in decidua with an ectopic gestation. Human p-defensins 2 and 4 also
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exhibit an increase in decidua from subjects with a failed intrauterine pregnancy
(miscarriage).
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Elafin mRNA Expression in Decidua SLPI mRNA Expression in Decidua
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MMP7 mRNA Expression in Decidua
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Figure 7.3.1.1 Elafin (A; blue), SLPI (B; green), MMP-7 (C; yellow; P<0.01 decidua
from ectopic pregnancy vs. STOP) and all on the same scale (D). Data are
presented as point changes in mRNA expression relative to a control (comparator


































Figure 7.3.1.2 Expression profiles of elafin, SLPI and MMP-7 in decidua from
ectopic gestation (A; n=10); STOP (B; n=5) and miscarriage (C; n=4). Data are
presented as relative changes in mRNA expression relative to a comparator, given a
nominal value of 1.
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hBD2 mRNA Expression in Decidua
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Miscarriage (n«5)















Miscarriage (n*5) Miscarriage (n*5) STOP (n=€) Ectopic (n*10)
Figure 7.3.1.3 hBD1 (B; yellow ), hBD2 (C; red), hBD3 (D; orange; P<0.05 ectopic
vs. stop) and all on the same scale (A). Data are presented as relative changes in
mRNA expression relative to a control (comparator obtained from a sample of early
secretory endometrium), given a nominal value of 1, mean ± s.e.m.
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7.3.2 Immunohistochemical localisation of elafin and SLPI in first trimester
decidua.
Elafin protein was found to be present in the decidua obtained from women with an
ectopic gestation (D) and in women with miscarriage (C), (figure 7.3.2.1). This
immunoreactivity was observed in the epithelium with some diffuse staining in the
stroma. In STOP decidua (B); there was no immunoreactivity observed in the stroma
or epithelial cells. Some immunostaining was observed within the leukocyte
population within the blood vessels (*). There appeared to be more elafin present in
the decidua of miscarriage patients (C) and decidua from women with an ectopic
pregnancy (D) when compared to decidua from women undergoing surgical
termination of pregnancy (STOP). However, this was not quantitatively measured.
SLPI protein (figure 7.3.2.2) was present in all types of decidua, from women with
STOP (B), miscarriage (C) and with an ectopic gestation (D). In STOP (B) decidua
immunoreactivity was observed to be intense within the epithelium with some
diffuse immunostaining observed within the stroma. In decidua obtained from
miscarriage patients (C) there was substantial immunoreactivity in the epithelium
and throughout the stroma, however, the cytoplasm and nucleus of stromal cells did
not exhibit any immunostaining. In decidua obtained from women with an ectopic
pregnancy, there was intense SLPI protein immunoreactivity observed in the
glandular epithelium. The amount of SLPI protein appeared to be increased in the
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7.4 Discussion
The decidua obtained from women with surgical management of miscarriage,
termination of pregnancy and tubular ectopic pregnancies have been investigated for
the expression of natural antimicrobials and MMP-7. The decidua obtained from
women with miscarriage has been included as an 'abnormal' control in order to try
and elucidate the difference in the expression of these genes over what might be
expected from an inflammatory response and with the inclusion of first trimester
decidua (STOP) as 'normal' controls.
Elafin and MMP-7 mRNA levels were found to be increased in the decidua obtained
from women with an ectopic gestation when compared to the decidua from women
undergoing STOP and with miscarriage. The increase in elafin mRNA in the
decidua from ectopic pregnancy is 65-point greater than the decidua of women with
ongoing intra-uterine pregnancy, and 60-point greater than the decidua from women
with miscarriage patients. There may be a slight increase in the level of elafin and
MMP-7 mRNA in the decidua obtained from miscarriage. The data obtained from
the decidua of both ectopic gestation and STOP is similar to the data obtained from
the corresponding Fallopian tube biopsies presented in chapter 6.
There was no difference observed for the level of SLPI mRNA between the decidua
obtained from women with a STOP and women with miscarriage. However, there
was a marked increase in the level of SLPI mRNA in decidua from women with an
ectopic pregnancy; this was also seen in the Fallopian tube with an ectopic gestation
(chapter 6). SLPI mRNA has been previously shown to be present during the first
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trimester of pregnancy and is responsive to progesterone ((King, Critchley et al.
2000; Fleming, King et al. 2003; King, Morgan et al. 2003) and chapter 5).
The results obtained from the analysis of the decidua obtained from women with an
ectopic pregnancy appear to match the levels observed in the corresponding
Fallopian tube biopsies (chapter 6). Thus, it may be conceivable that the use of
endometrial biopsies could prove helpful in the early diagnosis of ectopic pregnancy.
Previous studies investigating the use of frozen Pipelle endometrial biopsies as a
means of diagnosis for an ectopic pregnancy have proved to be unsuccessful (Al-
Ramahi, Nimri et al. 2006). However, it has been shown herein that the use of
Pipelle endometrial biopsies with an analysis of the level of natural antimicrobials
and MMP-7, that an ectopic gestation may be distinguished from a normal intra¬
uterine pregnancy (STOP). However, the numbers need to be increased before
conclusive discussion and further clinical studies would be warranted. Furthermore,
it can be surmised that the increase in both natural antimicrobials and MMP-7 is also
distinguishable between an ectopic gestation and that of an inflammatory uterine
pregnancy (miscarriage). An intrauterine abortion (miscarriage) must also be
distinguished from an ectopic pregnancy and further methods for an accurate
differential diagnosis between these complications have been sought (Nyberg, Filly
et al. 1987; Mashburn 1999). A number of studies have disputed the reliability of
circulating progesterone levels in differentiating between an ectopic pregnancy and a
miscarriage (McCord, Muram et al. 1996; O'Leary, Nichols et al. 1996; Dart,
Ramanujam et al. 2002). Further work is required in order to fully understand the
role of natural antimicrobials and MMP-7 in gestational complications. The role of
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infection would need to be taken into account as the present study did not attempt to
discriminate between subjects with a history of infection or pelvic inflammatory
disease, which as well as being a risk factor for an ectopic pregnancy would also
upregulate expression of the natural antimicrobials. Thus, the present study also
does enable the determination between cause and effect as it is conceivable that the
increased presence of these molecules could have a causal role in ectopic pregnancy.
An increased level of MMP-7 for example, has been associated with excess damage
to the extracellular matrix (ECM). MMP-7 is upregulated in the event of injury or
infection (Lopez-Boado, Wilson et al. 2000; Lopez-Boado, Wilson et al. 2001).
MMP-7 is hypothesised to have a role in immune defence and thus, a role in the
regulation of the natural antimicrobials is possible. Unlike most of the other MMPs
there has yet to be a substrate identified for MMP-7 (Pal, Schmidt et al. 2006).
MMPs have also been associated with the pathogenesis of Chlamydia trachomatis, a
sexually transmitted infection. The long term implications of an infection with C.
trachomatis is the build up scar tissue for which the MMPs are thought to be
responsible (Pal, Schmidt et al. 2006). This scar formation in the Fallopian tube is
also believed to be a cause of ectopic pregnancy (Stamm 2001; Andersen, Ostergaard
et al. 2007). However, the histological examination of Fallopian tubes with a history
of infection with Chlamydia often shows no evidence of scarring (communication
from Dr Alistair Williams).
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The human (3-defensins have also been found to be differentially expressed in each of
the decidual groupings, with the exception of hBDl, the defensins are greatly
increased in decidua with an ectopic gestation. Human P-defensin 1 mRNA levels
are at a similar level in decidua with miscarriage and STOP. This suggests that
miscarriage does not involve an increase in the level of hBDl in comparison with
normal first trimester pregnancy. However, there is almost a 50% relative decrease
in the level of hBDl mRNA (not significant) in decidua from women with an ectopic
pregnancy compared to the STOP and miscarriage. The inhibition of hBDl
expression in decidua from ectopic gestation may be an indication of the presence of
inhibitory factors. Further investigation would be required to address questions such
as, what factors/mechanisms could be involved in this inhibition and is the decrease
in expression of this defensin representative of a causal or contributory role with
regard to an ectopic outcome? Human p-defensin 1 has been shown to be
constitutively expressed in the cycling endometrium and in the first trimester of
pregnancy (Fleming, King et al. 2003; King, Critchley et al. 2003). Furthermore, it
has been shown that unlike most of the other defensins, hBDl is only very slightly
upregulated in the presence of inflammatory stimuli (Bajaj-Elliott, Fedeli et al.
2002). There may be an unidentified role for hBDl in pregnancy and this decrease
in decidua obtained from women with an ectopic gestation may be indicative of a
change in conditions favourable to the expression of hBDl and indeed pregnancy.
Investigation of hBDl expression in the Fallopian tube with and without an ectopic
gestation demonstrated no change in the level of expression (chapter 6).
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Messenger mRNA levels for hBD2 are relatively increased in decidua from
miscarriage subjects and further increased in decidua from women with an ectopic
gestation when compared to decidua from women having a STOP (not significant).
Human p-defensin 2 is found to be expressed in a variety of different mucosal linings
such as the lung, and is inducible by inflammatory stimuli (Liu, Destoumieux et al.
2002; Sorensen, Cowland et al. 2003; Tsutsumi-Ishii and Nagaoka 2003) including
Hec-1 A endometrial epithelial cells (chapter 3). It has also been proposed that hBD2
may be inhibited directly or indirectly by progesterone (chapter 3; (Fleming, King et
al. 2003) and thus, elevation in early pregnancy would not be predicted. This could
be suggestive of a problem with progesterone levels or with progesterone mediated
factors, giving rise to increased levels of hBD2 in decidua of miscarriage and ectopic
gestation. Human P-defensin 2 mRNA also has a tendancy to be increased in
Fallopian tubes with an ectopic pregnancy when compared with Fallopian tubes
without an ectopic gestation (chapter 6).
The level of hBD3 are also increased in decidua from women with an ectopic
pregnancy and is almost 350-point greater than decidua from women having STOP
(figure 7.3.1.3 (D); P<0.05). In contrast the expression of hBD3 was unchanged
between the decidua from patient having STOP and with miscarriage subjects.
Human P-defensin 3 is maximally expressed during the secretory phase of the
menstrual cycle (King, Fleming et al. 2003). However, the treatment of primary or
cultured epithelial cell lines with progesterone did not evoke a change in expression
(King, Fleming et al. 2003). The increase in hBD3 mRNA in decidua from women
with an ectopic gestation may be an indicator of inflammation as hBD3 is associated
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with the attraction of macrophages (Yang, Chertov et al. 1999), and monocytes
(Garcia, Jaumann et al. 2001). In chapter 6, data were presented that demonstrated
that there was also an increase in the level of hBD3 mRNA in Fallopian tube biopsies
with an ectopic gestation (chapter 6; figure 6.2.5.1A).
There is a tendancy for an increase in the level of hBD4 in decidua from women with
miscarriage and a further increase in decidua from patients with an ectopic gestation
when compared to decidua from women having STOP (not significant). This
defensin has been previously described as being maximally expressed during the
proliferative phase of the endometrium and has not been reported to respond to
inflammatory cytokines or mimics of infection (King, Fleming et al. 2003). The
expression of this gene may be oestradiol mediated as shown both in primary
endometrial samples (King, Fleming et al. 2003) and in the Fallopian tube biopsies
presented in chapter 6. The expression of hBD4 in decidua from women with an
ectopic suggestion may therefore be representative of aberrant steroid levels. The
Fallopian tube biopsies with an ectopic gestation were also shown to have an
increased level of hBD4 mRNA (chapter 6; figure 6.2.5.1A). Once again it has been
demonstrated that an elevated level of hBD4 in decidua is representative of an
elevated level within the Fallopian tube with an ectopic gestation and thus, may be a
useful candidate for a diagnostic marker.
In the previous chapter it was demonstrated that a pattern of expression existed
between SLPI, elafin and MMP-7 (chapter 6; figure 6.2.5.2), in the Fallopian tube
with and without an ectopic gestation. Thus, the expression of these molecules
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within the decidua from subjects having STOP, miscarriage and surgical treatment of
ectopic pregnancy were similarly examined (figure 7.3.1.2). As with the data
presented in chapter 6 there is a suggestion of a possible relationship between SLPI,
elafin and MMP-7, and that this was disrupted in both decidua from women with
miscarriage and women with an ectopic gestation. The levels of elafin and MMP-7
mRNA levels were found to be greatly upregulated in decidua from women with an
ectopic gestation, and there was also a doubling in the level of SLPI mRNA. In
decidua from STOP (B) all except one of the biopsies exhibits an increased level of
SLPI and lower levels of elafin and MMP-7 and previous work has confirmed that
SLPI is present during the first trimester of pregnancy (King, Critchley et al. 2000).
The inhibition of both elafin (chapter 3) and MMP-7 (Bruner, Rodgers et al. 1995) in
the presence of progesterone has also been suggested previously and these molecules
are not thought to be expressed during the first trimester of pregnancy. Therefore it
may be that the increased expression of these molecules in decidua obtained from
women with miscarriage or with ectopic pregnancy are indications of some
aberration in progesterone mediated mechanisms. The decidua from women with
miscarriage demonstrates a similar level of SLPI mRNA expression when compared
to decidua from women with a STOP. However, as with the decidua with an ectopic
gestation, there was increased expression of both elafin and MMP-7 mRNA, but,
lower than in decidua with an ectopic gestation.
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7.4.1 Future work
The potential for natural antimicrobials and MMP-7 to act as diagnostic markers in
the decidua obtained from patient groups where a risk of an ectopic is indicated had
been supported with the data presented and merits further investigation. The
inclusion of data relating to subjects with current or past infection with sexually
transmitted infections, such as chlamydia, may help to further understand the
expression levels of natural antimicrobials and MMP-7. Further work is also
required in the localisation and the quantitative analysis of variable levels of protein
in tissue biopsies, which was not possible within this study due to time constraints.
An investigation into the role of MMP-7 in decidua of normal and abnormal early
pregnancy pathology is also merited and further consideration as to the interaction
with elafin, direct, indirect or coincidental. Some further investigation into the




An investigation into the potential relationship between SLPI,
elafin and MMP-7 in Hec-1A cells.
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Chapter 8: An investigation into the potential relationship between SLPI, elafin
and MMP-7 in Hec-1A cells.
8.1 Introduction
SLPI (secretory leukocyte protease inhibitor) and elafin are both members of the
serine antiprotease family (Sallenave 2000; Hiemstra 2002; Sallenave 2002). These
proteins have been identified as alarm proteinase inhibitors as they are rapidly
upregulated in the event of injury or infection. In response to inflammation serine
proteases are produced such as human neutrophil elastase (HNE) by immune cells
and are responsible for a number of inflammatory disorders and exert proteolytic
activity which can result in tissue degradation (Sallenave 2000; Hiemstra 2002;
Sallenave 2002). Thus, it is believed that the role of SLPI and elafin is to prevent the
over exuberance of the proteolytic response and to minimise tissue damage. The
balance between proteases and protease inhibitors is important to the maintenance of
tissue integrity (Sallenave 2000; Hiemstra 2002; Sallenave 2002). In addition to the
anti-protease activity of both, SLPI and elafin exhibit chemotactic and antimicrobial
activity, similar to that observed in the defensins (Hiemstra, Fernie-King et al. 2004).
As discussed throughout the current thesis both elafin and SLPI are upregulated by
inflammatory stimuli such as the pro-inflammatory cytokines, TNFa and IL-lp and
mimics of infection such as LPS. The regulation of elafin expression via
inflammatory stimuli has been reported to be mediated at the transcriptional level by
the transcription factor nuclear factor k B (NF-kB) (Bingle, Tetley et al. 2001) and
the transcription factor activating protein-1 (AP-1) (Zhang, Magit et al. 1997). SLPI
has been shown to act as an anti-inflammatory with the inhibition of HIV infection of
monocytes (McNeely, Shugars et al. 1997). SLPI has further been demonstrated to
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inhibit the LPS induced expression of MMP-9 and TNFa in monocytic cells (Jin,
Nathan et al. 1997; Zhang, DeWitt et al. 1997). In the rat lung, SLPI has been shown
to prevent activation of NF-kB in response to stimulation with IgG immune
complexes (Lentsch, Jordan et al. 1999). SLPI can mediate further anti¬
inflammatory action via the up-regulation of other anti-inflammatory molecules such
as IL-10, TGF-P and HGF (hepatocyte growth factor) (Kikuchi, Abe et al. 2000;
Sano, Shimizu et al. 2000).
SLPI and elafin have been identified as being multi-functional members of the
immune defence with other roles and interactions still to be fully elucidated. In this
thesis a number of questions were raised as result of investigations into the function
of these proteins in the context of the female reproductive tract and the current
chapter was written in response to these observations. Therefore the following
summary of the relevant findings contained within this thesis as a motivation to
further work was deemed necessary.
Chapter 3
In chapter 3, an examination into the differential timing of mRNA expression of
natural antimicrobials in the endometrial epithelial cell line Hec-IA, seemed to
suggest that both SLPI and elafin were expressed in a reciprocal pattern (figure
3.4.2.1). The maximal expression of SLPI mRNA coincided with a lower level of
elafin mRNA and vice versa. This occurred consistently between experiments and at
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different time points within the timecourse experiments discussed in chapter 3 of the
current thesis. This raised the possibility that there may be a mechanism of direct or
indirect interaction between these molecules.
Chapter 4
An investigation into the role of paracrine mediated factors in the expression of
elafin in the endometrium was undertaken in chapter 4. This was in response to the
differential expression levels of elafin in the presence of progesterone and this was
suggested to be as a result of a stromal mediated effect upon the epithelial cells. An
examination of the literature identified possible factors that could be responsible for
the mediation of epithelial elafin expression via the stroma in response to
progesterone. The main candidate was considered to be TGF|3-1, as this has been
shown to be upregulated by the stroma in response to progesterone (Bruner, Rodgers
et al. 1995) and within this thesis to inhibit elafin (figure 3.4.3.1 and 3.4.3.2) and has
been previously reported to inhibit the expression of SLPI (Jaumann, Elssner et al.
2000). It was also shown that TGFp-1 expression by the stroma may mediate
epithelial expression of MMP-7, thus, this was investigated further for a possible role
in the mediation of natural antimicrobial expression within the female reproductive
tract. Matrix metalloproteinase-7 has been similarly identified as an important
mediator of immune defense with an initial characterised role in injury and repair
(Lopez-Boado, Wilson et al. 2000). MMP-7 is constitutively expressed across a
number of mucosal surfaces and is up-regulated in response to injury or infection in
much the same manner as components of the innate immune defence (Lopez-Boado,
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Wilson et al. 2000). MMP-7 has been identified as being involved in the degradation
or processing of other proteins, such as elastin (Filippov, Caras et al. 2003). In the
murine paneth cells, MMP-7 has been shown to be responsible for the cleavage of
pro-defensins into the active form and that mice without MMP-7 demonstrated a
reduced capacity for bacterial clearance (Wilson, Ouellette et al. 1999; Ayabe,
Satchell et al. 2002). Elafin and the human P-defensins have also been found to exist
in a pre-mature form that can be spliced for activity or for different functionality
(Schalkwijk, Wiedow et al. 1999; Guyot, Zani et al. 2005; Pazgier, Hoover et al.
2006). However, there is little conclusive evidence for the factor(s) or mechanism(s)
involved and there are suggestions that such interactions may be site specific. Thus,
MMP-7 could be a possible candidate within the female reproductive tract and as
such was examined within the current thesis. The cDNA obtained in chapter 3 for
the analysis of antimicrobial expression across a timecourse was reanalysed for
MMP-7 mRNA expression and the pattern compared to elafin (figure 8.1.1). The
mRNA expression pattern of MMP-7 over time was similar to that obtained for
elafin, like elafin MMP-7 exhibits two major peaks of expression each with a
subsequent decline. However, the maximal expression peaks for MMP-7 occurs in a
'delayed' fashion. Elafin peaks at 8 hour and declines at 10 hour, whilst MMP-7
peaks at 10 hour and declines at 12 hour and similar was seen for subsequent time
points. This delay may be suggestive of a processing role for MMP-7 on the pre-
elafin molecule. Alternatively, MMP-7 may serve to degrade elafin to prevent an
over exuberant inflammatory response, perhaps the phasic expression of elafin is due




Figure 8.1.1 Elafin (dark blue) and MMP-7 (light blue) mRNA expression over time
plotted on two axes on different scales. The left axis is representative of elafin
levels and the right axis MMP-7. The data were obtained as described in chapter 3
figure 3.4.1.1, of the current thesis.
Comparison of elafin and MMP-7 mRNA in Hec-1A cells treated with TNFu + IL-ip
Chapter 5
The pattern of SLPI, elafin and MMP-7 mRNA expression in primary endometrial
biopsy material was re-examined in chapter 5 and is summarised below (figure
8.1.2). The data obtained seemed to lend further support to an 'antagonistic'
relationship between elafin and SLPI as their mRNA expression occurs at different
times during the menstrual cycle. It was also observed that MMP-7 was expressed
along with elafin during the menstrual phase and in the subsequent proliferative
phase, which may be representative of the delay observed during the timecourse in
figure 8.1.1.
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Schematic summary of SLPI, elafin and MMP-7 expression in the
endometrium across the menstrual cycle
Figure 8.1.2 Schematic summary of the data presented in chapter 5; figures 5.3.2.1
(elafin), 5.3.3.1 (SLPI) and 5.3.4.1 (MMP-7)
Chapter 6
In chapter 6 the expression of SLPI, elafin and MMP-7 was investigated in biopsy
(Fallopian tube) samples obtained from woman with and without an ectopic gestation
(figure 6.2.5.2). An interesting pattern of expression could be observed in the
individual samples without an ectopic gestation (figure 8.1.3). It was found that a
sample would demonstrate one of two possible expression patterns. In pattern one,
the expression of SLPI mRNA was found to be lower than the level of both MMP-7
and elafin and this was true of 6 of the 11 samples examined. In pattern two, the
expression of SLPI mRNA was found to be greater than both elafin and MMP-7
mRNA (4 out of 11). It was also observed that elafin expression was higher than
MMP-7 mRNA in the majority of the patient samples.
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In Fallopian tube biopsy samples collected from women with an ectopic gestation
there was an increase in both elafin and MMP-7 mRNA in 7 out of the 9 patients
sampled. There was only a small increase in the level of SLPI mRNA in the same
samples. These patient samples also exhibited a change in the expression between
elafin and MMP-7. The level of MMP-7 was found to be higher than the level of
elafin, which is the opposite of what was observed previously in patients without an
ectopic pregnancy.
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A Expression pattern of SLPI, elafin and MMP-7 mRNA in
individual Fallopian tube samples
n=11
Figure 8.1.3 A cartoon representation of the data presented in chapter 6 (figure
6.3.2.2) of the current thesis. The expression pattern of SLPI (green), elafin (blue)
and MMP-7 (yellow) in relation to one another within individual Fallopian tube
samples, which presented as one of the two outcomes depicted in 10 of the samples
examined (n=11). Pattern one with the level of SLPI mRNA lower than both elafin
and MMP-7 levels. Pattern two, the level of SLPI mRNA expression was higher
than the levels of elafin and MMP-7 mRNA.
Chapter 7
There were similar findings in chapter 7 when the expression of these three
molecules was investigated in decidua collected from women undergoing a surgical
termination of pregnancy. The pattern was predominantly as shown on the right
hand side (1) of the above cartoon (figure 8.1.3) with only one sample demonstrating
the pattern depicted on the left (2) (n=5).
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The observations throughout this thesis that there is a likely relationship exists
between SLPI, elafin and MMP-7 expression, has prompted the investigations
undertaken in the current chapter with the following aims.
• To investigate the effect of SLPI upon the expression of elafin and MMP-7
using the cultured cell line Hec-IA.
• To explore the effects of SLPI upon other innate immune effectors including
the P-defensins and cytokines.
• To examine any effect of MMP-7 upon the expression of elafin
• To investigate whether SLPI has a direct immunomodulatory role over elafin




The Hec-IA endometrial epithelial cells were cultured as described in 2.2.3. The
cells were seeded into 6 well plates prior to treatment. The treatments used in this
chapter are detailed in table 8.2.1.1.






Table 8.2.1.1 Details of treatments used within this chapter. Supplier information is
contained within appendix I.
8.2.2 Transfection (transient)
The plasmid DNA was prepared as detailed in section 2.5.1 and the constructs are
shown in figure 8.2.2.1. The transfection efficiency was optimised and the
appropriate ratio of reagent (FuGene HD) to DNA determined using the P-
galactosidase assay detailed in section 2.5.2.
The Hec-IA cells were grown to 70% confluence in 6-wells and transfected with 5
pg of CAT reporter vectors driven by the elafin promoter or the control promoter as
described in section 2.5.3. Cells were stimulated with TNFa (5 pg/ml) + IL-ip (5
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ng/ml), 8 hour after transfection and 20 hour before cell lysis. CAT production was
measured by ELISA (Chapter 2, section 2.4.3).
8.2.3 RNA extraction and Q-RT-PCR
Following treatment and incubation for the relevant time point, the RNA was
extracted from the cells and cDNA prepared as described in chapter 2, section 2.3.
Elafin mRNA levels were measured in these cDNA samples by quantitative PCR
(chapter 2, section 2.3). The sequence details of the primer-probe sets used are
detailed in table 2.3.3.1, materials and methods.
8.2.4 CAT ELISA
The sandwich ELISA quantitatively measures the amount of CAT enzyme
expression as mediated via the elafin promoter in response to treatment as detailed in
8.2.2. The ELISA was carried out according to the manufacturer and is described in
chapter 2, section 2.4.3).
8.2.5 Statistical analysis
The PCR results in this chapter were analysed by ANOVA for significant difference.
274
8.2.6 Acknowledgement
The transient transfections and the CAT ELISA assays were carried out with the
assistance of Dr Forbes Howie and Dr Moira Nicol of the University of Edinburgh,
Department of Clinical Biochemistry.
275
8.3 Results
8.3.1 The effect of SLPI upon Hec-1A mRNA expression of elafin and MMP-7
in response to treatment with inflammatory stimuli TNFa + IL-1p.
In order to further understand the effect of SLPI upon the mRNA expression of both
elafin and MMP-7, the protein (SLPI 5 ng/ml) was added to Hec-IA cells in culture
along with inflammatory stimuli (TNFa + IL-lp).
Elafin mRNA (figure 8.3.1.1) expression levels were decreased in response to
treatment with TNFa + IL-ip in the presence of SLPI up to 18 hour post treatment
(A) when compared to the expression in the absence of SLPI (n=3). Elafin mRNA
(B) was significantly (P<0.001) decreased in the presence of SLPI when time points
4, 8 and 12 hour were averaged for each n=l and a total of 5 times (n=5). There was
no notable effect observed from the treatment of Hec-IA cells with SLPI without
inflammatory stimuli (controls).
MMP-7 mRNA (figure 8.3.1.2) expression levels were also found to be significantly
decreased with the addition of SLPI (5 ng/ml) in Hec-IA cells treated with TNFa +
IL-lp (n=5; P<0.001). The addition of MMP-7 to untreated cells consistently
resulted in a lowering of the 'basal' levels of elafin mRNA when compared to cells
untreated and without MMP-7 (n=5).
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Elafin mRNA (Hec-1A) expression over
time
TNFa + IL-1p
SLPI 5 ng + TNFa + IL-1P
10
Time (hr)
Figure 8.3.1.1 The effect of SLPI protein (5 ng/ml) upon the expression of elafin in
response to inflammatory stimuli, TNFa + IL-1(3 The expression of elafin over time
(A) with (red) and without (blue) the presence of SLPI. Elafin mRNA presented as a
mean of data collected from 3 time points (4, 8 and 12 hour equivalent to n=1), is
significantly decreased (n= 5; P<0.001) in the presence of SLPI. All data are
compared to untreated Hec-1A cells from the relevant time point as control, given a













D SLPI 5 ng
Control TNFa + IL-1P
Figure 8.3.1.2 The effect of SLPI protein (5 ng/ml) upon the expression of MMP-7
in response to inflammatory stimuli, TNFa + IL-ip. MMP-7 mRNA presented as a
mean of data collected from 3 time points (4, 8 and 12 hour equivalent to n=1), is
significantly decreased (n= 5; P<0.001) in the presence of SLPI. All data are
compared to untreated Hec-1A cells from the relevant time point as control, given a
nominal value of 1, mean ± s.e.m.
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8.3.2 The effect of SLPI on SLPI, hBD2 and hBD3 mRNA expression in Hec-
1A cells treated with TNFa + IL-1p.
In order to examine whether the 'anti-inflammatory' nature of SLPI was general an
examination of the effect upon the expression of the P-defensins and that of SLPI in
Hec-IA cells stimulated with pro-inflammatory cytokines TNFa + IL-l p.
SLPI mRNA (figure 8.3.2.1 (A)) was observed to be increased in response to
treatment with SLPI protein (green), (5 ng/ml). This increase was significant in cells
with and without the concurrent treatment with TNFa + IL-ip, when compared to the
cells without the presence of SLPI (blue) (n=5; PO.OOl).
Messenger RNA expression of human P-defensin 2 (figure 8.3.2.1 (B)) was similarly
found to be significantly increased in the presence of SLPI protein in response to
treatment with TNFa + IL-1 p (P<0.001).
Human P-defensin 3 mRNA (figure 8.3.2.1 (C)) was found to be increased in
response to the presence of SLPI both with and without the treatment with TNFa +
IL-l p. There was no significance between the cells with and without TNFa + IL-1 p
in the presence of SLPI (green; TNFa + IL-1 p, green stripe). The expression of
hBD3 is significantly increased with SLPI alone relative to the untreated control. A
2-point increase in hBD3 mRNA was observed in cells treated with TNFa + IL-ip in
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TNF a +IL-1p
Figure 8.3.2.1 The effect of SLPI protein (5 ng/ml) on the mRNA expression of
SLPI (A), hBD2 (B) and hBD3 (C) in response to inflammatory stimuli, TNFa + IL-1(3.
Data was collected from 3 time points (4, 8 and 12 hour equivalent to n=1). All data
were compared to untreated Hec-1A cells from the relevant time point as control,
given a nominal value of 1, mean ± s.e.m.
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8.3.3 Hec-1A expression of cytokines, TNFa, IL-ip, IL-8 and IL-6 in the
presence of SLPI.
Further to the data obtained in section 8.3.1 which indicated that SLPI had an
inhibitory effect upon the expression of elafin and MMP-7, which was in contrast to
the data obtained in section 8.3.2 where SLPI was shown to increase the expression
of human p-defensins and SLPI mRNA. It was decided to examine the possibility of
indirect effects via the interaction with cytokines and thus the effect of SLPI protein
upon the Hec-IA expression of cytokines was examined.
The expression of TNFa mRNA, figure 8.3.3.1 (A), was significantly increased in
response to treatment with the pro-inflammatory cytokines TNFa + IL-ip in the
presence of SLPI (n=4; P<0.001) when compared to cells treated without SLPI.
There was a small increase in the level of TNFa mRNA in response to SLPI without
inflammatory stimuli when compared to cells in the absence of SLPI.
Messenger RNA expression of IL-ip, figure 8.3.3.1 (B), was increased in the
presence of SLPI and inflammatory stimuli (n=4; P<0.05) in comparison to treatment
with TNFa + IL-lp without SLPI.
In order to further establish the role of SLPI as a possible anti-inflammatory mediator
it was deemed necessary to explore the effect upon other key innate immune
effectors such as the pro-inflammatory cytokines IL-6 and IL-8.
281
In contrast to the observed increase of TNFa and IL-1(3 in the presence of SLPI an
examination of IL-8 and IL-6, cytokines which are also associated with pro¬
inflammatory signalling were found to be decreased by the addition of SLPI.
Interleukin - 8 mRNA, figure 8.3.3.2 (A), was significantly decreased (n=4;
PO.OOl), when treated with TNFa + IL-ip in the presence of SLPI when compared
to treatment without SLPI (25-point). However, a small increase in the level of IL-8
mRNA was observed in cells treated with SLPI alone.
The level of IL-6 mRNA, figure 8.3.3.2 (B), was also decreased in response to
treatment with TNFa + IL-1 p in the presence of SLPI (n=4; PO.OOl). A 50-point
reduction could be observed between cells treated with TNFa + IL-1P without SLPI
and those that were treated with the addition of SLPI.
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TNFa (A) and IL-1(3 (B) mRNA expression
Figure 8.3.3.1 The effect of SLPI protein (5 ng/ml) on the mRNA expression of
TNFa (A) and IL-1 (3 (B) in response to inflammatory stimuli, TNFa + IL-1(3 (n=4).
The mRNA levels of both TNFa and IL-1 p were increased in the presence of SLPI.
The un-stimulated control was also increased with the addition of SLPI. Data was
collected from 3 time points (4, 8 and 12 hour equivalent to n=1). All data were
compared to untreated Hec-1A cells (control) from the relevant time point as control,
given a nominal value of 1, mean ± s.e.m.
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IL- 8 (A) and IL-6 (B) mRNA expression
Figure 8.3.3.2 The effect of SLPI protein (5 ng/ml) on the mRNA expression of IL-8
(A) and IL-6 (B) in response to inflammatory stimuli, TNFa + IL-ip (n=4). The
mRNA levels of both IL-6 and IL-8 were decreased in the presence of SLPI. The
un-stimulated control was increased with the addition of SLPI. Data was collected
from 3 time points (4, 8 and 12 hour equivalent to n=1). All data were compared to
untreated Hec-1A cells (control) from the relevant time point as control, given a
nominal value of 1, mean ± s.e.m.
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8.3.4 The effect of MMP-7 upon the expression of elafin mRNA in Hec-1A
cells treated with inflammatory stimuli, TNFa + IL-1 p
In order to further understand the possible interactions between elafin and MMP-7
the treatment of Hec-IA cells with MMP-7 protein concurrently with inflammatory
stimuli, TNFa + IL-ip was undertaken.
Elafin mRNA, figure 8.3.4.1, was significantly increased in response to the addition
of MMP-7 (n=4; P<0.001). The expression of elafin mRNA was over 12-point
greater in cells treated with TNFa + IL-ip in the presence of MMP-7 over cells
treated in the absence of MMP-7 (blue).
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Elafin mRNA expression (Hec-1A cells)
251
TNFa + IL-ip MMP-7 + TNFa + IL-ip
Figure 8.3.4.1 The effect of MMP-7 protein (5 ng/ml) on the expression of elafin
mRNA (Hec-1A cells) in response to treatment with TNFa + IL-ip (n=4). Elafin
mRNA was 12-point greater in the presence of MMP-7 (green) than without MMP-7
(P<0.001). Data was collected from 3 time points (4, 8 and 12 hour equivalent to
n=1). All data were compared to untreated Hec-1A cells (control) from the relevant
time point as control, given a nominal value of 1, mean ± s.e.m.
8.3.5 SLPI on the elafin promoter
In order to investigate the possibility that SLPI protein exerts its inhibitory effect
upon elafin mRNA by direct interaction with the elafin promoter, Hec-1 A cells were
transiently transfected with pCAT reporter constructs (section 2.5, chapter 2). If
SLPI binds to the elafin promoter, then the expression of the CAT reporter protein
would be inhibited.
At the time of writing it has not been possible to obtain a sufficient level of cell
viability in order for the results to be reliable.
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Summary of results
1. SLPI protein inhibits the mRNA expression of elafin (figure 8.3.1.1) and
MMP-7 (figure 8.3.1.2), in Hec-IA cells. SLPI acting in an anti¬
inflammatory capacity.
2. SLPI protein increases the mRNA expression of SLPI, hBD2 and hBD3
(figure 8.3.2.1, A-C) in Hec-IA cells. These data suggest a pro-inflammatory
role for SLPI.
3. SLPI protein was found to increase the level of mRNA for the inflammatory
cytokines TNFa and IL-ip (figure 8.3.3.1 A and B). An increase in the
presence of these molecules would give rise to the increase observed in 2
above.
4. However, SLPI protein was shown to decrease the expression of IL-8 and IL-
6 mRNA, both of these cytokines are associated with pro-inflammatory roles.
5. Treatment of Hec-IA cells with MMP-7 protein increased the level of elafin
mRNA.
6. Attempts to identify an interaction between SLPI protein and the elafin
promoter were inconclusive due to poor cell viability.
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8.4 Discussion
Investigations that were undertaken in this thesis gave rise to a number of
observations surrounding the possible interaction(s) between the molecules SLP1,
elafin and MMP-7. Throughout the current thesis there were a number of results that
were consistently suggestive of a relationship between the aforementioned
molecules. In brief, the maximal expression of elafin and SLPI mRNA were found
to be different when measured at different time points. This expression pattern
appears to be reciprocal in fashion, with high elafin coinciding with lowered SLPI
and high SLPI coinciding with lowered elafin (chapter 3). It has further been
observed that the expression of SLPI and elafin occurs at different stages of the
menstrual cycle, both in chapter 5 of the present thesis and as published previously
(King, Morgan et al. 2003). This different expression pattern across the menstrual
cycle was proposed to be due to the changing levels of the sex steroids and
specifically progesterone (King, Morgan et al. 2003). SLPI has been shown to be
upregulated by progesterone (King, Morgan et al. 2003) and this was confirmed in
chapter 3 of the current thesis in the Hec-IA cell line. SLPI contains a progesterone
response element (PRE) which enables this direct progesterone mediated response;
thus, the maximal expression of SLPI is in mid-secretory endometrium. However,
elafin has been shown to be maximally expressed during the menstrual phase, when
circulating levels of progesterone are low (King, Critchley et al. 2003), chapter 5 of
the current thesis. In contrast to SLPI however, there are is no PRE, thus any
progesterone mediated effect is likely to be indirect (King, Morgan et al. 2003). The
expression of elafin during the menstrual phase led to the theory that progesterone
was likely to be inhibitory. Previous investigations using the breast cancer cell line
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T47D, concluded that there was no effect upon elafin expression in response to
treatment with progesterone in vitro (King, Morgan et al. 2003). However, in the
current thesis, treatment of the endometrial epithelial cell line, Hec-IA with
progesterone gave rise to an increase in expression of elafin (chapter 3). This led to
investigations into the possible mechanisms of indirect progesterone mediation.
Consideration was given to the fact that the treatment of Hec-IA cells with
inflammatory mediators such as TNFa + IL-lp, in the presence of progesterone, was
not an accurate representation of the endometrial environment. Primary endometrial
explants are composed of different cell types, thus, possible paracrine influences
upon the response to progesterone were investigated in chapter 4. In chapters 3 and
4 it was found that the expression of elafin was increased in the presence of
progesterone, however, the expression of elafin was inhibited in the presence of
stromal cells or stromal derived media in the presence of progesterone. Thus, the
role for stromal factors in the epithelial expression of elafin was confirmed and
further investigation of the literature identified MMP-7 as a possible stromal
mediated factor. All three molecules, SLPI, elafin and MMP-7 formed the focus
throughout the current thesis as a result. In chapters 6 and 7 it was shown that
primary biopsy samples of Fallopian tube and intrauterine decidua collected from
women in different groups had distinct patterns of expression for these genes. Thus,
it was deemed necessary to explore the possibility of a relationship or interaction
between these genes and in the time available a number of questions were addressed.




Figure 8.4.1 Summary of the effect of SLPI on the expression of the innate immune
effectors investigated in this chapter. Green represents an increase and red a
decrease. The molecules in blue are novel epithelial observations within the current
thesis; the effect of SLPI upon the expression of IL-1 (3 and TNFa has been reported
in murine leukocytes (Lentsch, Jordan et al. 1999). IL-8 levels have been shown to
be reduced in the lungs of cystic fibrosis patients in response to treatment with
aerosolised SLPI (McElvaney, Nakamura et al. 1992). The expression of TGFp was
not directly investigated in this instance and has previously been reported to be
upregulated by SLPI in murine macrophages (Sano, Shimizu et al. 2000).
The effect of SLPI protein upon the expression of elafin and MMP-7 was
investigated in the Hec-IA cell line when stimulated with TNFa + IL-1 p. SLPI was
shown to significantly inhibit the expression of both elafin (figure 8.3.1.1) and
MMP-7 mRNA expression (figure 8.3.1.2) in cells treated with inflammatory stimuli.
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This effect may explain the observed differences in the expression of these genes as
summarised in figure 8.1.3. Increased levels of SLPI may cause a decrease in the
level of elafin and MMP-7, whilst lowered levels of SLPI may give rise to an
increase in expression. In chapters 6 and 7 of the current thesis it was shown that
elafin and MMP-7 mRNA levels were either both increased over SLPI or both
decreased below the level of SLPI. To clarify, an instance where raised SLPI and
MMP-7 with lowered elafin or an example of raised elafin and SLPI with lowered
MMP-7 was not observed for any of the human Fallopian tube or decidua samples
examined. Thus, it is reasonable to predict that some kind of interrelationship exists
between these molecules, although the precise mechanism is beyond the scope of the
current thesis. Any effect of SLPI upon MMP-7 and/or elafin may be direct or
indirect. SLPI has been reported to be involved in the resolution of inflammation
and has also been described as having a role as an anti-inflammatory molecule, with
the precise mechanism still to be elucidated (Weldon, McGarry et al. 2007). The
interaction of SLPI with anti-inflammatory mediators such as the cytokines IL-10
and TGFp (Sano, Shimizu et al. 2000), may suggest an indirect means of action
upon the expression of elafin and MMP-7. SLPI has been shown to increase the
expression of TGFP, which in this thesis has been shown to inhibit elafin mRNA in
Hec-IA cells treated with inflammatory stimuli (chapter 3). The amount of IL-10
and TGFp expression should be measured as part of future studies into the role of
SLPI in Hec-IA culture experiments.
This effect of SLPI upon the expression of elafin and MMP-7 is in support of the
anti-inflammatory nature of SLPI that has been proposed. However, when the effect
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of SLPI was examined for other antimicrobials such as the human P-defensins (figure
8.3.2.1) the expression of hBD-2 and hBD-3 was found to be increased. It was also
shown that SLPI mRNA is increased in the presence of SLPI. Thus, this anti¬
inflammatory action would appear to not be a generalised effect and an examination
of the effects upon the pro-inflammatory cytokines TNFa and IL-ip (figure 8.3.3.1)
offered some explanation. The increase in the level of these cytokines would in turn
increase the expression of SLPI and the hBDs. The addition of SLPI with and
without inflammatory stimuli brought about an increase in the level of hBD-2 and
hBD-3. In order to investigate further whether the effect of SLPI upon hBDs is
indirectly mediated by the increase in pro-inflammatory cytokines an experiment to
block the expression ofTNFa and IL-ip would be useful.
It was found that SLPI was inhibitory in the expression of the cytokines IL-8 and IL-
6 (figure 8.3.3.2), which have been described as being inflammatory 'alarm'
effectors of innate immunity. SLPI has been previously shown to inhibit the
expression of IL-8 in LPS induced human monocyte-derived macrophages (Taggart,
Cryan et al. 2005) and to inhibit IL-6 in human monocytes (Greene, McElvaney et al.
2004). This would lend credence to the role of SLPI as an anti-inflammatory protein.
One of the main mechanisms proposed for SLPI functioning as an anti-inflammatory
mediator is via the interaction with the NF-kB pathway. It has been shown that the
presence of SLPI leads to decreased activation of NF-kB in the lungs and this was
associated with increased levels of the NF-kB inhibitor, IkBP (Lentsch, Jordan et al.
1999). It has also been suggested that SLPI exerts effect upon the expression of pro-
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inflammatory cytokines such as TNFa and IL-8, via direct competitive binding of the
NF-kB-binding sites in the promoter regions of these genes (Taggart, Cryan et al.
2005). The interaction of SLPI with the NF-kB pathway in the modulation of the
immune response, led to further consideration of a role for SLPI in the modulation of
elafin expression. Elafin has also been shown to be regulated at the transcriptional
level by NF-kB (Bingle, Tetley et al. 2001) in the epithelial cells of the lung.
However, it has also been proposed that the transcriptional activation of elafin is cell
specific, as in mammary epithelial cells it is the transcription factor activating
protein-1 (AP-1) that regulates activation (Zhang, Zou et al. 1995). Thus, it is
conceivable that the ability of SLPI to interact with transcription factors and the
expression of elafin being modulated by the presence of an NF-kB site within its
promoter is a good route of interaction between these two molecules at the
transcriptional level. The provision of plasmid constructs containing the elafin
promoter attached to a CAT reporter gene enabled some investigation into this
possibility.
However, despite repeated attempts, it has not been possible to maintain the viability
of cells subsequent to both the transfection and stimulation with IL-ip + TNFa. The
cells were successfully transfected with P-gal reporter constructs and cell viability
was maintained, thus, it was not thought to be the process of transfection affecting
the cells. The untreated controls where viable and this has led to the conclusion that
it is the subsequent treatment with pro-inflammatory cytokines that was affecting the
viability of the cells. Further work is under way to determine the optimal time post
transfection to stimulate the cells prior to lysis and protein measurement.
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Preliminary analysis of the possible relationship between MMP-7 and elafin was
undertaken and it was shown that the addition of MMP-7 to Hec-1 A cells concurrent
with inflammatory stimuli gives rise to an increase in the level of elafin mRNA
(figure 8.3.4.1). The apparent 'coupled' expression of both elafin and MMP-7 has
been demonstrated in the Fallopian tube (chapter 6) and in the endometrium
(chapters 5 & 7). Therefore it is possible that MMP-7 has a role in the regulation of
expression of elafin. As has been described previously elafin is transcribed as pre-
elafin (trappin-2), which is thought to undergo proteolytic cleavage in order to
release the elafin molecule (Guyot, Zani et al. 2005). The mechanism or factors
involved in the cleavage of pre-elafin into elafin has yet to be fully elucidated. The
proteolytic cleavage of pre-elafin by tryptase has been suggested by Guyot et al
(Guyot, Zani et al. 2005) in the lungs of patients with cystic fibrosis (CF). Guyot et
al. also undertook to investigate the metalloproteases as candidates for the processing
of pre-elafin and showed that there was no activity against either pre-elafin or elafin
(Guyot, Zani et al. 2005). However, their study was restricted to that of MMP-8 and
MMP-9 due to the abundance of these respective molecules in the lung and the
established proteolytic role of these enzymes. Thus, the possibility was considered
as part of this thesis, that the high level of MMP-7 expression within the female
reproductive tract and the observed associative expression with elafin, may implicate
such a role. The role of MMP-7 could be either with the release of the elafin
molecule via the cleavage of pre-elafin or it could also serve to degrade elafin. It is
also possible that elafin serves to degrade excess MMP-7, in order to modulate the
activity of this enzyme during mucosal repair.
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It is clear that the function of natural antimicrobials within the innate immune system
is still to be fully determined and further characterisation of their role within the
female reproductive tract would offer opportunities for a greater understanding of
this locally regulated defence system. The female reproductive tract is a unique
environment in which the cyclical injury and repair process, hosting of non-self
sperm and the semi-allogeneic foetus, which involves complex immune regulation.
Thus, there are also opportunities to explore the potential for the female reproductive
tract as a model system in order to fully understand and implement the findings in
other mucosal systems in an attempt to control inflammatory disorders.
8.4.1 Future work
The aim of this chapter was to address some of the questions that have been raised
through the course of this thesis. However, due to time constraints it was only
possible to address a few of the possibilities as presented. The effect of SLPI protein
on the expression of elafin, MMP-7 and the hBDs was explored and served to
suggest a role for the interaction between antimicrobial proteins. Thus, it would be
useful to identify the effect of other antimicrobials upon the expression of innate
immune effectors in a similar fashion to that presented for SLPI. In order to further
understand the interaction between elafin and SLPI, it is necessary to undertake
experiments involving the treatment of cells with recombinant elafin. The use of
anti-SLPI in culture experiments would also be useful to in determining the effects of
SLPI on the expression of elafin and other immune effectors.
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The effect of MMP-7 upon the expression of SLPI and the other natural
antimicrobials should be investigated in order to further determine any role for
MMP-7 in their modulation. The possibility of MMP-7 having a role in the
processing of pre-elafin and other antimicrobials within the female reproductive tract
also merits further investigation. Preliminary attempts at cleaving pre-elafin with
MMP-7 in collaboration with colleagues in the Centre for Inflammation Research
(Dr Paul Fitch, University of Edinburgh) have proved inconclusive and form part of
ongoing studies. The effect of elafin protein on that of MMP-7 should also be
investigated as it is possible that elafin is responsible for the degradation of the
metalloproteases.
The interaction between elafin, SLPI and MMP-7 is likely to be indirect through the
modulation of other innate immune effectors and via transcription pathways. Thus, a





9.1 Synopsis of Results
The aims of this thesis have been to characterise further the expression and
regulation of natural antimicrobials in the female reproductive tract. The
investigations were undertaken using the Hec-IA endometrial epithelial cell line,
stromal cells cultured from endometrial explants (primary cell culture) and tissue
collected from women undergoing gynaecological procedures: Fallopian tube,
endometrium and first trimester decidua. As a result of the investigations undertaken
in this thesis the role of other innate immune effectors was also considered. The
roles of MMP-7 and TGF(3-1 were investigated as it became apparent that these
proteins may have a role in the expression and/or modulation of natural
antimicrobials.
The data in this thesis have been presented in distinct chapters and discussed in depth
within the focus of each chapter and the context of the motivations that dictated the
investigations undertaken. However, as the work progressed it was apparent that
there was considerable overlap in both the observations and the questions raised as a
result of the data obtained. The purpose of this chapter is to provide an overall
synopsis of some of the main points for discussion of the thesis as a whole and to
allow discussion in a wider context.
The main points and data are presented in 5 schematic summaries and discussed
within the context of each of the summaries.
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9.1.1 Summary of results
Natural Antimicrobial Expression is Time Dependent
Chapter 3A
SLPI In response to TNFo * IL-1p hBDS in response to TNFa ♦ IL-1p
What factors could be involved with the sequential decrease in expression?
?TGFp-1
FGFp-1 inhibits mRNA expression of Elafin and SLPI
Chapter 3B
TGFp-1 + Inflammatory stimuli 1 ElafinHec-1A cells I . g|_p|?hBDs
TNFa ♦ IL-1|J ♦ TGfp-1
The treatment of the endometrial epithelial cell line, Hec-1 A with pro-inflammatory
cytokines, IL-ip + TNFa resulted in the time dependent expression of natural
antimicrobials. The phasic pattern of expression exhibited by the natural
antimicrobials is differential for each of the antimicrobials that were investigated.
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Peak expression levels were followed by a rapid decrease in the level of expression
and this led to considerations of factors involved in this decrease. The growth factor,
TGFp-1 was investigated as a candidate factor in the decrease in expression of
natural antimicrobials. This was in part motivated by reports in the literature that
SLPI is decreased in the presence of TGFp-1 (Jaumann, Elssner et al. 2000). It was
shown that TGFp-1 can also inhibit the expression of elafin and SLPI mRNA in the
Hec-IA cell line.
Future work would involve the exploration of the effect of TGFP-1 upon the
expression of other natural antimicrobials; preliminary data suggests that some of the
P-defensins may be similarly inhibited. It would also be useful to explore the relative
levels of TGFp-1 in the culture media of the time course experiments to determine
whether any fluctuation in expression could be attributed to the phasic decrease in
expression observed. A consideration of other factors that may bring about the
decreased expression of natural antimicrobials observed during time course
experiments would also be useful. Further consideration of other innate immune
effectors such as the anti-inflammatory cytokine, IL-10 is also necessary in order to
further understand the regulation of natural antimicrobials.
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a
The Effect nf Prngftstftrone on Epithelial, Elafin Expression is Stromal Mediated"!
It was previously shown that elafin is maximally expressed in endometrial samples
collected from the menstrual phase of the cycle when circulating levels of
progesterone are low (King, Critchley et al. 2003) and chapter 5). This was in
contrast to the data obtained from treatment of the Hec-IA cell line, where the
addition of progesterone increased the expression of elafin. The role of paracrine
mediated factors was investigated and the presence of stromal cells in the treatment
of epithelial cells with progesterone and inflammatory stimuli inhibited the
expression of elafin. Treatment of stromal and epithelial cells without the presence
of progesterone increased the epithelial expression of elafin over that for epithelial
cells alone. Suggesting that there is a role for stromal cells in the epithelial
expression of elafin and this merits further investigation in terms of the innate








Endometrial explant from menstrual phase"^ Elafin
(low circulating progesterone)
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stromal mediated and offered an explanation for the apparent differences in
expression between primary material and the cultured cell line. This is discussed
further in part 3 below.
Future work, the effect of stromal mediated factors upon the expression of other
natural antimicrobials such as SLPI and the hBDs is required. Human (3-defensin 2,
as with elafin has been similary shown to be maximally expressed in endometrial
samples collected during the menstrual phase (low circulating levels of progesterone)
(King, Critchley et al. 2003). In chapter 3 of the current thesis the treatment of Hec-
1A cells with TNFa + IL-ip in the presence of progesterone inhibited the expression
of hBD2 mRNA (Chapter 3B, figure 3.8.3.3). The use of a progesterone antagonist,
RU486, was also utilised in chapter 3. The addition of RU486 and progesterone to
Hec-IA cells gave rise to a further increase in the level of elafin mRNA over the
previous increase in the presence of progesterone (figure 3.8.3.2; chapter 3B).
Whilst hBD2 levels were increased in contrast to the previous inhibition observed in
the presence of progesterone alone (figure 3.8.3.3; chapter 3B). The use of anti-
progestins in the co-culture set-up would be useful in furthering the understanding of
the role of progesterone both directly and indirectly.
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IKK
Stromal Mediated Candidate Factors: TGFp and MMP-7
Chapter 4
Epithelial Cells
Following on from the identification of a role for the stroma in the epithelial
expression of elafin the factors and possible mechanisms of this mediation were
explored. Having already identified that TGFp-1 has an inhibitory effect upon the
expression of both elafin and SLPI, this was investigated further. Endometrial
stromal cells upregulate the expression of TGFP-1 in response to progesterone
(Bruner, Rodgers et al. 1995) and this in turn has been reported to mediate the
epithelial expression of MMP-7 (Bruner, Rodgers et al. 1995; Osteen, Keller et al.
1999). In this thesis it was shown that MMP-7 could increase the expression of
elafin mRNA. This may suggest that an increase in TGFp-1 from the stroma in
response to progesterone could result in the inhibition of elafin by both directly or
indirectly through the inhibition of MMP-7 as shown above.
303
Natural Antimicrobial Expression in the Female Reproductive Tract
Chapter 6 • Elafin
• SLPI
• HBD1-


























An examination of natural antimicrobial expression in the human Fallopian tube
confirmed the expression of SLPI, elafin and hBDl-4 at this site of the female
reproductive tract. Furthermore there was a preliminary indication that this
expression was hormonally regulated across the ovarian cycle as was observed
previously in the human endometrium (King, Critchley et al. 2003). Fallopian tube
biopsies collected from women with an ectopic gestation were also investigated for
the expression of natural antimicrobials. The presence of an ectopic gestation
increased the expression of SLPI, elafin and hBD2-4, whilst hBDl remained
unchanged. The increased expression of natural antimicrobials in the event of an
ectopic pregnancy could offer an insight into the inflammatory mechanisms
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involved. However, further work is required in order to establish the difference
between a causal and a consequential involvement for natural antimicrobials.
Further investigations were undertaken with biopsy samples obtained from the
decidua of women undergoing surgical management for ectopic pregnancy for the
expression of natural antimicrobials. This was compared with samples obtained
from women undergoing surgical management for miscarriage and for the
termination of a viable intrauterine pregnancy. With the exception of hBD-1, all
antimicrobials (hBD2-4, SLP1 and elafin) were found to be increased in the decidua
obtained from an ectopic gestation. It was further identified that there was a
differential level of expression when compared with samples obtained from
intrauterine failed early pregnancy (miscarriage) and from viable intrauterine
pregnancy (STOP). This differential pattern of expression may present opportunities
in establishing a method of diagnosis, where an ectopic pregnancy could be
distinguished from a miscarriage, by study of a decidual sample collected from the
uterine cavity.
In addition to an analysis of natural antimicrobial expression in the tissue resource
described above (4), the expression of MMP-7was also examined. An interesting
pattern of associative expression was observed between elafin, MMP-7 and SLPI and
this is discussed in the context ofother results in the next section.
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Relationship between SLPI, Elafin and MMP-7 expression
Chapter 3






The expression of natural antimicrobials has been described as being time dependent
and that the timing of SLPI and elafin expression is reciprocal, when elafin
expression was increased this corresponded with lowered expression of SLPI and
vice versa. This pattern of expression was thought to be an indication of possible
interaction between these two anti-proteases and was investigated further.
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The identification of MMP-7 as a possible paracrine mediator in chapter 4 and the
observation of a similar level of differential time dependent pattern of expression in
chapter 8 (figure 8.1.1) when compared to elafin, motivated further study. The
pattern of MMP-7 mRNA exhibited was similar to that observed for elafin, but with
a 2 hour lag in time. MMP-7 maximal peaks in expression were observed to occur
subsequent to the maximal peaks in expression of elafin. Elafin was observed to
peak after 8 hr and a 2nd greater peak occurred at 12 hr, whilst MMP-7 showed the
largest peak at 10 hr and a 2nd smaller peak at 14 hr. It may be that MMP-7 is
involved in the splicing of pre-elafin into elafin, or perhaps to remove elafin to
prevent too great an immune response.
A comparative examination of the expression of elafin, SLPI and MMP-7 also
appeared to reveal a specific pattern in biopsy samples obtained from the Fallopian
tube and early pregnancy decidua. In the samples investigated one of two expression
scenarios were consistently found to be demonstrated: Either increased SLPI greater
than that observed for both elafin and MMP-7 OR increased elafin and MMP-7
greater than for SLPI. Although the precise mechanism involved is unclear it does
appear that some kind of relationship between these three molecules exists and
further investigation may offer both explanation and opportunities for a greater
understanding.
Biopsy samples of the decidua and Fallopian tube obtained from women with an
ectopic gestation were found to have a significantly increased level of MMP-7
mRNA with a corresponding but lower increase in elafin and SLPI. The significance
of this elevated expression in MMP-7 and the apparent deviation from the pattern
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observed in normal tissue needs further investigation. An exploration into the cause
or effect of increased expression of MMP-7 is required.
An investigation into the role of SLPI upon the expression of other innate immune
effectors was commenced in chapter 8 of the current thesis. SLPI was found to
decrease the expression of both elafin and MMP-7, whilst increasing the expression
of defensins and the inflammatory cytokines TNFa and IL-ip. Further work is
required in order to understand the mechanism by which SLPI exerts these effects,
especially the relationship between elafin and SLPI.
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9.2 General Discussion
The work in this thesis was undertaken in order to further understanding of natural
antimicrobial expression and their interactions within the innate immune system of
the female reproductive tract. These studies also offer some answers but, inevitably
with research the thesis gave to rise to further questions. It is clear that the
expression of natural antimicrobials is rapid and short term, whilst the factors
involved in the upregulation are well understood those involved with the sudden and
rapid decline are not so clear. The importance of understanding the modulation of
natural antimicrobials is due to the translational opportunities that would arise from
the establishment of effective control (Bowdish, Davidson et al. 2006). The control
of expression would enable both the prevention of a destructive inflammatory
response and as well as increasing protection when required. Furthermore it should
be considered that there is an increasing concern with regard to microbial resistance
to our current synthetic repertoire of antibiotics (Wright 2007). Thus, there is a
growing interest in the development of natural products to fulfil the role in the
treatment of infections, and the natural antimicrobial peptides offer such possibilities
(McPhee and Flancock 2005).
Within the female reproductive tract it has been shown that the natural antimicrobials
are subject to hormonal regulation (King, Critchley et al. 2003) and this has also
been shown to be an important consideration with regard to the use of contraceptives
(Fleming, King et al. 2003). In this thesis it has been shown that elafin is likely to be
affected by progesterone in an indirect manner through interaction with other factors
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and cells. This requires to be further investigated for other natural antimicrobials and
in relation to the effect upon other cells and inflammatory mediators. The role of sex
hormones in the regulation of innate immune effectors is important in order to
understand the consequences of both systemic and local hormone levels upon
immune status.
The demonstration in chapter 3 that the natural antimicrobials were differentially
expressed in a time dependent manner and that different peptides were expressed at
different times suggested distinct roles and or interactions. There also seemed to be a
level of associative expression between some of the molecules, such as being
expressed together (same timepoint) or in opposition to one another. The potential
for synergistic action is a likely explanation for this pattern of expression and indeed
other groups have shown antimicrobials act in a synergistic manner, for example
SLPI in the lung (Singh, Tack et al. 2000). It has also been demonstrated that a
synergistic relationship exists between hBD2 and LL-37 (Dorschner, Lin et al. 2003).
The expression of natural antimicrobials in the human Fallopian tube was established
within this thesis. There was also a suggestion that this expression may be affected
by the ovarian cycle and this needs to be further investigated in order to fully
understand the role of natural antimicrobials within the Fallopian tube. The
expression of natural antimicrobials and the potential modulation of other immune
factors and the effect upon the mucosal and cellular environment may also reveal the
function of the immune response within the Fallopian tube. In the Fallopian tube
biopsies collected from women with an ectopic gestation it was shown that there was
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an increase in natural antimicrobial expression. There was also a large increase in
the level of MMP-7 which may suggest a role for this matrix metalloprotease protein
(MMP) in the event of an ectopic pregnancy. The role of MMPs in the human
Fallopian tube is poorly understood and their involvement in the repair of the extra
cellular matrix (ECM) raises the possibility of a role in implantation (Bai, Wang et
al. 2005). The high level of MMP-7 may indicate an increased risk of an ectopic
implantation, as high levels of MMP-7 would cause an increased immune response
and lead to scarring in the Fallopian tube. The role of MMP-7 within the female
reproductive tract requires to be investigated further. MMPs have been implicated in
the pathogenesis of Fallopian tube damage in response to infection (Ault, Kelly et al.
2002). The excessive degradation of the ECM and subsequent scarring of the
Fallopian tube would impede the progress of the conceptus. Flowever, the increased
expression of both natural antimicrobials and MMP-7 may also be likely as a result
of the inflammatory nature of an ectopic gestation and further work into the cause or
effect, and the roles of these molecules is merited.
The decidua from women with an ectopic gestation was also investigated and
compared alongside decidua biopsies obtained from the surgical management of
miscarriage and termination of first trimester pregnancy. The expression of natural
antimicrobials and MMP-7 in the decidua from an ectopic gestation was
representative of the data observed in corresponding Fallopian tube biopsies. As was
discussed in chapter 7 this raises the possibility of natural antimicrobials being
utilised as molecular markers or in the early diagnosis of an ectopic pregnancy
through sampling of uterine decidua.
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The data in this thesis have raised many questions and perhaps really only offers a
prelude to the possibilities for a greater understanding of the innate immune effectors
and involvement in the function of the reproductive tract.
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Appendix 1: General Materials
Tissue Collection and Culture Source
Pipelle suction curette Pipelle, Laboratoire CCD, France
RPMI 1640 medium Sigma, Poole, Dorset, UK
Neutral Buffered Formalin (NBF) See appendix 2
Complete RPMI See appendix 2
F supplement See appendix 2
Phosphate Buffered Saline (PBS) Sigma









Transwells Costar, High Wycombe, UK
Culture flasks and plates Costar, High Wycombe, UK
Cell Line Source
Hec-IA American Type Culture Collection,
Manassas, VA)
Treatments and supplements Source
Oestradiol Sigma
Basic fibroblast growth factor (bFGF) Peprotech
Progesterone Sigma
RU 486 (mifepristone) Sigma
Lipoteichoic acid (LTA) S. aureus Sigma
Lipopolysaccharide (LPS) E. coli Sigma
Interleukin-113 (IL-1 (5) Peprotech
Tumour Necrosis Factor a (TNFa) Peprotech
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Total RNA Isolation Reagent (TRIR) Abgene Limited, Epsom, UK
Chloroform BDH Laboratory Supplies, UK
Isopropanol Sigma-Aldrich Co. Ltd.
Ethanol Hayman Ltd., Essex, UK
RNA storage solution Ambion Inc, Austin, Texas, USA
Phase Lock Gel Eppendorfs Eppendorf AG, Hamberg, Germany
TE Buffer See appendix 2
RNA storage solution Ambion
RNeasy Mini Kit Qiagen, UK
RT-PCR Source
cDNA reagents PE Biosystems, Warrington, UK
Mineral Oil Sigma
PCR Master mix kit Applied Biosystems
18s primer/probe kit PE Biosystems, Warrington, UK
Primers and probes Biosource, Nivelles, Belgium
Immunohistochemistry Source
Acetone BDH Labotatory supplies
PBS See appendix 2
PBS + Tween See appendix 2
0.01 M Sodium Citrate See appendix 2
Hydrogen peroxide BDH Laboratory supplies
Goat serum Vector Laboratories, UK
Protein Block Vector Laboratories, UK
Avidin block Vector Laboratories, UK
Biotin block Vector Laboratories, UK
Avidin-biotin-peroxidase complex (ABC) Vector laboratories, UK
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Diaminobenzidine (DAB) Vector laboratories, UK
Harris' hematoxylin Pioneer Research Chemicals Ltd.
UK
Xylene BDH Laboratory Supplies
Pertex Cellpath pic, Hemel Hempsted, UK
ELISA Source
96 well plates Nunc Maxi-Sorp, Gibco, UK
Wash buffer See appendix 2
Carbonate buffer See appendix 2
Blocking solution See appendix 2
Streptavidin peroxidase Sigma
Substrate See appendix 2
2N Sulphuric acid Sigma
CAT ELISA kit Roche
SLP1 ELISA kit R&D Systems
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Appendix 2: Recipes for solutions
All chemicals listed were from Sigma and all dilutions were in distilled water unless
otherwise stated
Blocking solution
In 1 litre: 20g 2% polyvinylpyrrolidone
5g bovine serum albumin
1ml preservatives Boehringer Mannheim
1.9g EDTA (5 mmol/L)
6.1 g Tris (50 mmol/L)
B-galactosidase assay solutions
Wash buffer pH7.3 (1000 ml): 46 ml 0.5M-NaH2PO4
154 ml 0.5M-Na2HPO4
2 ml lM-magnesium chloride
10 ml 1% (w/v) deoxycholate
10 ml 2% (v/v) nonidet-P40
Final volume with ROP H20 to 1000 ml
Fix solution pH 7.3 (200 ml): 9.2 ml 0.5M-NaFI2PC>4
30.8 ml 0.5M-Na2HPO4
1.6 ml 25% (w/v) gluteraldehyde
10 ml 100 mM-EGTA; pH7.3
0.4 ml 1.0 M-magnesium chloride
Final volume 200 ml with ROP H20
X-gal stain (250 ml): 11.5 ml 0.5M-NaH2PO4
38.5 ml 0.5M-Na2HPO4
0.53 g Potassium ferrocyanide
0.41 g Potassium ferricyanide
2.5 ml 1% (w/v) deoxycholate
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2.5 ml 2% (v/v) nonidet-P40
0.5 ml lM-magnesium chloride
Final volume 250 ml with ROP H2O
Complete medium (cRPMI)







In 1 litre: 9g NaCl (150mmol/L)
12.lg Tris (lOOmmol/L)







lml tetramethyl benzidine : 1ml urea-hydrogen peroxidase : 10ml sodium acetate
5g/l urea-hydrogen peroxidase (0.5% in 50mM sodium acetate, pH6)
3g/l tetramethyl benzidine in dimethylformamide
in 100mmol/l sodium acetate, pH6
1 OOmM sodium acetate









Neutral buffered formalin (NBF)




Phosphate buffered saline (PBS)
In 1 litre: 5 PBS tablets
pH 7.4 - 7.6
PBS + Tween
In 1 litre: 5 PBS tablets
8g NaCl
lOOpl Tween-20




in dimethylformamide (DMF) / dimethylsulphoxide (DMSO) 1:1
diluted 1:1000 to use
0.1M Sodium citrate buffer
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In 1 litre: 29.4g Tri-sodium citrate
O.lg sodium azide
pH 6
Diluted 1:10 to use
TE Buffer
10mmol/l Tris pH8.0
lmmol/1 EDTA in DEPC water
Tris buffer
In 1 litre: 121.1 g Trizma base
pH 7.2
